Modified arenavirus particles expressing cancer-testis antigens as cancer immunotherapy
By using genetically modified sand virus particles carrying cancer-testis antigen fragments, tumor-specific T-cell responses in cancer immunotherapy are enhanced, solving the problem of poor efficacy of existing immunotherapies, achieving effective cancer treatment and reducing the immune risk to healthy tissues.
Patent Information
- Application Number
- CN202580027575.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-03-15
- Filing Date
- 2025-03-14
- Publication Date
- 2026-11-10
AI Technical Summary
Existing cancer treatments are ineffective at activating and enhancing immune responses, especially against uncontrolled cell proliferation, and traditional methods may pose immunopathological risks to healthy tissues.
Genetically modified arenavirus particles carrying nucleotide sequences encoding cancer-testis antigen (CTA) fragments, including PRAME, MAGE-A3, MAGE-A4, and MAGE-A6, were used to optimize the arenavirus genome structure through heterologous ORF fusion protein expression to enhance tumor-specific T-cell responses in immunotherapy.
It improves the effectiveness of immunotherapy for cancer, reduces the risk of immunopathological damage to healthy tissues, and is suitable for a wide range of patient populations, covering various cancer indications.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Cross-references to related applications
[0001] This patent application claims priority to U.S. Provisional Application No. 63 / 565,812, filed March 15, 2024, the contents of which are incorporated herein by reference in their entirety.
[0002] sequence list
[0003] This patent application includes an electronic sequence list submitted with it in XML file format, the entire contents of which are incorporated herein by reference. The sequence list XML file submitted with this patent application is named "13194-098-228_SEQLISTING.xml", created on February 25, 2025, and is 204,893 bytes in size. Technical Field
[0004] This disclosure relates to genetically modified arenaviruses suitable for treating neoplastic diseases such as cancer. The arenaviruses described herein may be suitable for treating neoplastic diseases and / or for use in immunotherapy. Specifically, this document provides methods and compositions for treating neoplastic diseases by administering a genetically modified arenavirus, wherein the arenavirus has been engineered to include a nucleotide sequence encoding one or more antigenic fragments of one or more cancer-testis antigens (CTAs), including members of the melanoma-associated antigen (MAGE) family and PRAME antigens preferentially expressed in melanoma. Specifically, this document provides a genetically modified arenavirus wherein the arenavirus has been engineered to include a nucleotide sequence encoding antigenic fragments and / or epitopes encoding PRAME, MAGE-A3, MAGE-A4, and MAGE-A6. Background Technology
[0005] There is an unmet medical need for the treatment of oncological diseases such as cancer. The emerging field of immunotherapy offers hope for the treatment of these life-threatening diseases. Therapeutic methods for activating and enhancing the immune response against uncontrolled cell proliferation, such as cancer, remain needed in this field. Summary of the Invention
[0006] Cancer-testis antigen (CTA) expression in healthy adults is primarily confined to germ cells, thereby reducing the risk of immunopathological changes in healthy tissues caused by autoantigen-reactive T cells. Furthermore, because CTA expression is confined to immune-exempt sites, peripheral tolerance to CTA is considered absent or significantly reduced compared to overexpressed tissue-specific cancer autoantigens, which can facilitate the induction of higher and more functional tumor-specific T cell responses through active immunization. Cancer cells often exhibit dysregulation of protein expression; for example, ectopic expression of CTA has been observed in tumor cells of various types of human cancers. However, CTA expression can vary significantly between patients within a single indication, and some CTAs may also be found in healthy tissues.
[0007] This disclosure is partly based on the finding that selected CTA expression based on isopyrvirus induces an effective immune response in vivo, thus allowing targeting of a broad patient population, covering a large number of patients across various indications.
[0008] This patent application relates to genetically modified arenaviruses suitable for treating neoplastic diseases such as cancer. In one aspect, this patent application relates to an arenavirus particle containing an arenavirus genome comprising:
[0009] a. A first heterologous open reading frame (ORF) encoding a first fusion protein containing two or more cancer-testis antigen (CTA) fragments; and
[0010] b. A second heterologous ORF encoding a second fusion protein containing two or more CTA fragments.
[0011] Wherein (i) at least one isovirus ORF is functionally inactivated or deleted; or (ii) at least one isovirus ORF or a fragment thereof is located at a position different from the wild-type position of at least one isovirus ORF or a fragment thereof.
[0012] In some embodiments, two or more CTA fragments of the first fusion protein and the second fusion protein are selected from the group consisting of: a fragment of a melanoma-preferred antigen (PRAME), a melanoma-associated antigen 3 (MAGE-A3) fragment, a melanoma-associated antigen 4 (MAGE-A4) fragment, and a melanoma-associated antigen 6 (MAGE-A6) fragment.
[0013] In some embodiments, the two or more CTA fragments of the first fusion protein comprise at least one PRAME fragment, at least one MAGE-A3 fragment, at least one MAGE-A4 fragment, and at least one MAGE-A6 fragment. In some embodiments, the at least one PRAME fragment of the first fusion protein is selected from the group consisting of: PRAME 3-13 (SEQ ID NO:29), PRAME 7-23 (SEQ ID NO: 30), PRAME 73-82 (SEQ ID NO: 31), PRAME 84-95 (SEQ ID NO: 32), PRAME 123-141 (SEQ ID NO: 33), PRAME 150-161 (SEQ ID NO: 34), PRAME 166-178 (SEQ ID NO: 35), PRAME 210-230 (SEQ ID NO: 36), PRAME 224-232 (SEQ ID NO: 37), PRAME 237-250 (SEQ ID NO: 38), PRAME 248-256 (SEQ ID NO: 39), PRAME 267-277 (SEQ ID NO: 40), PRAME 278-292 (SEQ ID NO: 41), PRAME 315-327 (SEQ ID NO: 42), PRAME 325-334 (SEQ ID NO: 43), PRAME 425-433 (SEQ ID NO: 44), PRAME 435-443 (SEQ ID NO: 45), PRAME 445-458 (SEQ ID NO: 46), PRAME 472-491 (SEQ ID NO: 47), PRAME 485-509 (SEQ ID NO: 48), and combinations thereof. In some embodiments, at least one MAGE-A3 fragment of the first fusion protein comprises MAGE-A3. 135-149 (SEQ ID NO: 66). In some embodiments, at least one MAGE-A4 fragment of the first fusion protein contains MAGE-A4. 112-121 (SEQ ID NO: 52) and / or MAGE-A4 286-305(SEQ ID NO: 63). In some embodiments, at least one MAGE-A6 fragment of the first fusion protein contains MAGE-A6. 167-184 (SEQ ID NO: 75).
[0014] In some embodiments, two or more CTA fragments of the first fusion protein contain PRAME. 3-13 (SEQ IDNO: 29), PRAME 7-23 (SEQ ID NO: 30), PRAME 73-82 (SEQ ID NO: 31), PRAME 84-95 (SEQ ID NO:32), PRAME 123-141 (SEQ ID NO: 33), PRAME 150-161 (SEQ ID NO: 34), PRAME 166-178 (SEQ ID NO:35), PRAME 210-230 (SEQ ID NO: 36), PRAME 224-232 (SEQ ID NO: 37), PRAME 237-250 (SEQ ID NO:38), PRAME 248-256 (SEQ ID NO: 39), PRAME 267-277 (SEQ ID NO: 40), PRAME 278-292 (SEQ ID NO:41), PRAME 315-327 (SEQ ID NO: 42), PRAME 325-334 (SEQ ID NO: 43), PRAME 425-433 (SEQ ID NO:44), PRAME 435-443 (SEQ ID NO: 45), PRAME 445-458 (SEQ ID NO: 46), PRAME 472-491 (SEQ ID NO:47), PRAME 485-509 (SEQ ID NO: 48), MAGE-A3 135-149 (SEQ ID NO: 66), MAGE-A4 112-121 (SEQ IDNO: 52), MAGE-A4 286-305 (SEQ ID NO: 63) and MAGE-A6 167-184 (SEQ ID NO: 75).
[0015] In some embodiments, the two or more CTA fragments of the second fusion protein comprise at least one MAGE-A3 fragment, at least one MAGE-A4 fragment, and at least one MAGE-A6 fragment. In some embodiments, the at least one MAGE-A3 fragment of the second fusion protein is selected from the group consisting of: MAGE-A3 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO: 70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO:69), MAGE-A3 192-202 (SEQ ID NO: 71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A3 160-171 (SEQ ID NO: 68), MAGE-A3 143-151 (SEQ ID NO: 67), and combinations thereof. In some embodiments, at least one MAGE-A4 fragment of the second fusion protein is selected from the group consisting of: MAGE-A4 136-155 (SEQ ID NO: 53), MAGE-A4 168-179 (SEQ ID NO: 55), MAGE-A4 190-199 (SEQ IDNO: 57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ ID NO: 64), MAGE-A4 175-183 (SEQ ID NO: 56), MAGE-A4 262-272 (SEQ ID NO: 61), MAGE-A4 222-246 (SEQ ID NO: 60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-218 (SEQ ID NO: 59), MAGE-A4 205-217 (SEQ ID NO:58), MAGE-A4 155-168 (SEQ ID NO: 54) or MAGE-A4 266-274 (SEQ ID NO: 62), MAGE-A4 73-83(SEQ ID NO: 49), and combinations thereof. In some embodiments, at least one MAGE-A6 fragment of the second fusion protein is selected from the group consisting of: MAGE-A6 196-204 (SEQ ID NO: 77), MAGE-A6 194-202 (SEQ ID NO: 76), MAGE-A6 231-241 (SEQ ID NO: 78), MAGE-A6 243-255 (SEQ ID NO: 79), and combinations thereof.
[0016] In some embodiments, two or more CTA fragments of the second fusion protein contain MAGE-A3. 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO: 70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ ID NO: 71), MAGE-A3 302-311 (SEQ ID NO:74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A3 160-171 (SEQ ID NO: 68), MAGE-A3 143-151 (SEQ IDNO: 67), MAGE-A4 136-155 (SEQ ID NO: 53), MAGE-A4 168-179 (SEQ ID NO: 55), MAGE-A4 190-199 (SEQ ID NO: 57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ ID NO: 64), MAGE-A4 175-183 (SEQ ID NO: 56), MAGE-A4 262-272 (SEQ ID NO: 61), MAGE-A4 222-246 (SEQ ID NO:60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-218 (SEQ ID NO: 59), MAGE-A4 155-168 (SEQID NO: 54) or MAGE-A4266-274 (SEQ ID NO: 62), MAGE-A4 73-83 (SEQ ID NO: 49), MAGE-A6 196-204 (SEQ ID NO: 77), MAGE-A6 194-202 (SEQ ID NO: 76), MAGE-A6 231-241 (SEQ ID NO: 78) and MAGE-A6 243-255 (SEQ ID NO: 79). In some embodiments, two or more CTA fragments of the second fusion protein contain MAGE-A3. 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO: 70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ ID NO: 71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A3 160-171 (SEQ ID NO: 68), MAGE-A3 143-151 (SEQ ID NO: 67), MAGE-A4 136-155 (SEQ ID NO: 53), MAGE-A4 168-179 (SEQ IDNO: 55), MAGE-A4 190-199 (SEQ ID NO: 57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ ID NO: 64), MAGE-A4 175-183 (SEQ ID NO: 56), MAGE-A4 262-272 (SEQ ID NO: 61), MAGE-A4 222-246 (SEQ ID NO: 60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-217 (SEQ ID NO:58), MAGE-A4 155-168 (SEQ ID NO: 54) or MAGE-A4 266-274 (SEQ ID NO: 62), MAGE-A473-83 (SEQ ID NO: 49), MAGE-A6 196-204 (SEQ ID NO: 77), MAGE-A6 194-202 (SEQ ID NO: 76), MAGE-A6 231-241 (SEQ ID NO: 78) and MAGE-A6 243-255 (SEQ ID NO: 79). In some embodiments, two or more CTA fragments of the second fusion protein contain MAGE-A3. 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ IDNO: 70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ ID NO: 71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A3 160-171 (SEQ ID NO: 68), MAGE-A3 143-151 (SEQ ID NO: 67), MAGE-A4 168-179 (SEQ ID NO:55), MAGE-A4 190-199 (SEQ ID NO: 57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ IDNO: 64), MAGE-A4 175-183 (SEQ ID NO: 56), MAGE-A4 262-272 (SEQ ID NO: 61), MAGE-A4 222-246 (SEQ ID NO: 60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-218 (SEQ ID NO: 59), MAGE-A4 155-168 (SEQ ID NO: 54) or MAGE-A4 266-274 (SEQ ID NO: 62), MAGE-A4 73-83 (SEQ ID NO:49), MAGE-A6 196-204 (SEQ ID NO: 77), MAGE-A6194-202 (SEQ ID NO: 76), MAGE-A6 231-241 (SEQ ID NO: 78) and MAGE-A6 243-255 (SEQ ID NO: 79). In some embodiments, two or more CTA fragments of the second fusion protein contain MAGE-A3. 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO: 70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ ID NO:71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A4 168-179 (SEQ IDNO: 55), MAGE-A4 190-199 (SEQ ID NO: 57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ ID NO: 64), MAGE-A4 175-183 (SEQ ID NO: 56), MAGE-A4 262-272 (SEQ ID NO: 61), MAGE-A4 222-246 (SEQ ID NO: 60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-218 (SEQ ID NO:59), MAGE-A4 155-168 (SEQ ID NO: 54) or MAGE-A4 266-274 (SEQ ID NO: 62), MAGE-A4 73-83 (SEQ ID NO: 49), MAGE-A6 196-204 (SEQ ID NO: 77), MAGE-A6 194-202 (SEQ ID NO: 76), MAGE-A6 231-241 (SEQ ID NO: 78) and MAGE-A6 243-255 (SEQ ID NO: 79).
[0017] In some embodiments, at least two of the two or more CTA fragments of the first fusion protein and / or the second fusion protein are linked by at least one adapter. In some embodiments, at least one adapter comprises the amino acid sequence AAY (SEQ ID NO: 80), ALL (SEQ ID NO: 81), SSL (SEQ ID NO: 82), or RKSY (SEQ ID NO: 83).
[0018] In some embodiments, the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 7, SEQ ID NO: 9, or SEQ ID NO: 11.
[0019] In some embodiments, the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, or SEQ ID NO: 26. In some embodiments, the second fusion protein comprises the amino acid sequence of SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, or SEQ ID NO: 26.
[0020] In some embodiments, the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 7, and the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 8. In some embodiments, the first fusion protein comprises the amino acid sequence of SEQ ID NO: 7, and the second fusion protein comprises the amino acid sequence of SEQ ID NO: 8.
[0021] In some embodiments, the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 9, and the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 10. In some embodiments, the first fusion protein comprises the amino acid sequence of SEQ ID NO: 9, and the second fusion protein comprises the amino acid sequence of SEQ ID NO: 10.
[0022] In some embodiments, the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 11, and the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 12. In some embodiments, the first fusion protein comprises the amino acid sequence of SEQ ID NO: 11, and the second fusion protein comprises the amino acid sequence of SEQ ID NO: 12.
[0023] In some embodiments, the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 7, and the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 23. In some embodiments, the first fusion protein comprises the amino acid sequence of SEQ ID NO: 7, and the second fusion protein comprises the amino acid sequence of SEQ ID NO: 23.
[0024] In some embodiments, the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 7, and the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 25. In some embodiments, the first fusion protein comprises the amino acid sequence of SEQ ID NO: 7, and the second fusion protein comprises the amino acid sequence of SEQ ID NO: 25.
[0025] In some embodiments, the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 9, and the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 24. In some embodiments, the first fusion protein comprises the amino acid sequence of SEQ ID NO: 9, and the second fusion protein comprises the amino acid sequence of SEQ ID NO: 24.
[0026] In some embodiments, the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 9, and the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 26. In some embodiments, the first fusion protein comprises the amino acid sequence of SEQ ID NO: 9, and the second fusion protein comprises the amino acid sequence of SEQ ID NO: 26.
[0027] In some embodiments, at least one isovirus ORF encodes the GP, NP, L, or Z protein of the isovirus particle. In some embodiments, at least one isovirus ORF is located at a position different from the wild-type position of at least one isovirus ORF.
[0028] In some implementations, the sand virus particle is three-segmented and capable of replication, comprising one L segment and two S segments, wherein one of the two S segments is selected from the group consisting of:
[0029] The aS segment, in which the ORF encoding the nucleoprotein (“NP”) is under the control of the 5' UTR of the arenavirus genome;
[0030] The bS segment, in which the ORF encoding matrix protein Z (“Z protein”) is under the control of the 5' UTR of the arenavirus genome;
[0031] The cS segment, in which the ORF encoding the RNA-dependent RNA polymerase L protein (“L protein”) is under the control of the 5' UTR of the arenavirus genome;
[0032] The dS segment, in which the ORF encoding the glycoprotein (“GP”) is under the control of the 3' UTR of the arenavirus genome;
[0033] The eS segment, in which the ORF encoding the L protein is controlled by the 3' UTR of the arenavirus genome; and
[0034] The fS segment, in which the ORF encoding the Z protein is under the control of the 3' UTR of the arenavirus genome.
[0035] In some implementations, the arenavirus genome includes:
[0036] a. The first S segment, which contains an ORF encoding an NP located under the control of the 3' UTR of the arenavirus genome, and a first heterologous ORF encoding a first fusion protein located under the control of the 5' UTR of the arenavirus genome;
[0037] b. The second S segment, which contains an ORF encoding GP located under the control of the 3' UTR of the arenavirus genome, and a second heterologous ORF encoding the second fusion protein located under the control of the 5' UTR of the arenavirus genome; and
[0038] cL segment.
[0039] In some implementations, the sand-like virus particles are derived from lymphocytic choriomeningitis virus (LCMV), Pichand virus, Tamiyami virus, or Tacalib virus.
[0040] In some implementations, the arenavirus genome includes:
[0041] (i) The first S segment, comprising the nucleotide sequence of SEQ ID NO: 1 under the control of the 5' UTR of the arenavirus genome, and the ORF encoding the arenavirus nucleoprotein (“NP”) under the control of the 3' UTR of the arenavirus genome; and
[0042] (ii) The second S segment, comprising the nucleotide sequence of SEQ ID NO: 2 under the control of the 5' UTR of the arenavirus genome, and the ORF encoding the arenavirus glycoprotein (“GP”) under the control of the 3' UTR of the arenavirus genome; and
[0043] (iii) L segment.
[0044] In some implementations, the arenavirus genome includes:
[0045] (i) The first S segment, comprising the nucleotide sequence of SEQ ID NO: 3 under the control of the 5' UTR of the arenavirus genome, and the ORF encoding the arenavirus nucleoprotein (“NP”) under the control of the 3' UTR of the arenavirus genome; and
[0046] (ii) The second S segment, comprising the nucleotide sequence of SEQ ID NO: 4 under the control of the 5' UTR of the arenavirus genome, and the ORF encoding the arenavirus glycoprotein (“GP”) under the control of the 3' UTR of the arenavirus genome; and
[0047] (iii) L segment.
[0048] In some implementations, the arenavirus genome includes:
[0049] (i) The first S segment, comprising the nucleotide sequence of SEQ ID NO: 5 under the control of the 5' UTR of the arenavirus genome, and the ORF encoding the arenavirus nucleoprotein (“NP”) under the control of the 3' UTR of the arenavirus genome; and
[0050] (ii) The second S segment, comprising the nucleotide sequence of SEQ ID NO: 6 under the control of the 5' UTR of the arenavirus genome, and the ORF encoding the arenavirus glycoprotein (“GP”) under the control of the 3' UTR of the arenavirus genome; and
[0051] (iii) L segment.
[0052] In some implementations, the arenavirus genome includes:
[0053] (i) the first S segment, which contains the nucleotide sequence of SEQ ID NO: 84; and
[0054] (ii) The second S segment, which contains the nucleotide sequence of SEQ ID NO: 85; and
[0055] (iii) L segment.
[0056] In some implementations, the arenavirus genome includes:
[0057] (i) the first S segment, which contains the nucleotide sequence of SEQ ID NO: 88; and
[0058] (ii) The second S segment, which contains the nucleotide sequence of SEQ ID NO: 89; and
[0059] (iii) L segment.
[0060] In some implementations, the arenavirus genome includes:
[0061] (i) the first S segment, which contains the nucleotide sequence of SEQ ID NO: 86; and
[0062] (ii) the second S segment, which contains the nucleotide sequence of SEQ ID NO: 87; and
[0063] (iii) L segment.
[0064] In some implementations, the arenavirus genome includes:
[0065] (i) the first S segment, which contains the nucleotide sequence of SEQ ID NO: 90; and
[0066] (ii) The second S segment, which contains the nucleotide sequence of SEQ ID NO: 91; and
[0067] (iii) L segment.
[0068] In some implementations, the arenavirus genome includes:
[0069] (i) The first S segment, comprising the nucleotide sequence of SEQ ID NO: 100 under the control of the 5' UTR of the arenavirus genome, and the ORF encoding the arenavirus nucleoprotein (“NP”) under the control of the 3' UTR of the arenavirus genome; and
[0070] (ii) The second S segment, comprising the nucleotide sequence of SEQ ID NO: 101 under the control of the 5' UTR of the arenavirus genome, and the ORF encoding the arenavirus glycoprotein (“GP”) under the control of the 3' UTR of the arenavirus genome; and
[0071] (iii) L segment.
[0072] In some implementations, the arenavirus genome includes:
[0073] (i) The first S segment, comprising the nucleotide sequence of SEQ ID NO: 102 under the control of the 5' UTR of the arenavirus genome, and the ORF encoding the arenavirus nucleoprotein (“NP”) under the control of the 3' UTR of the arenavirus genome; and
[0074] (ii) The second S segment, comprising the nucleotide sequence of SEQ ID NO: 103 under the control of the 5' UTR of the arenavirus genome, and the ORF encoding the arenavirus glycoprotein (“GP”) under the control of the 3' UTR of the arenavirus genome; and
[0075] (iii) L segment.
[0076] In some implementations, the arenavirus genome includes:
[0077] (i) The first S segment, comprising the nucleotide sequence of SEQ ID NO: 104 under the control of the 5' UTR of the arenavirus genome, and the ORF encoding the arenavirus nucleoprotein (“NP”) under the control of the 3' UTR of the arenavirus genome; and
[0078] (ii) The second S segment, comprising the nucleotide sequence of SEQ ID NO: 105 under the control of the 5' UTR of the arenavirus genome, and the ORF encoding the arenavirus glycoprotein (“GP”) under the control of the 3' UTR of the arenavirus genome; and
[0079] (iii) L segment.
[0080] In some implementations, the arenavirus genome includes:
[0081] (i) the first S segment, which contains the nucleotide sequence of SEQ ID NO: 92; and
[0082] (ii) The second S segment, which contains the nucleotide sequence of SEQ ID NO: 93; and
[0083] (iii) L segment.
[0084] In some implementations, the arenavirus genome includes:
[0085] (i) the first S segment, which contains the nucleotide sequence of SEQ ID NO: 96; and
[0086] (ii) The second S segment, which contains the nucleotide sequence of SEQ ID NO: 97; and
[0087] (iii) L segment.
[0088] In some implementations, the arenavirus genome includes:
[0089] (i) the first S segment, which contains the nucleotide sequence of SEQ ID NO: 94; and
[0090] (ii) The second S segment, which contains the nucleotide sequence of SEQ ID NO: 95; and
[0091] (iii) L segment.
[0092] In some implementations, the arenavirus genome includes:
[0093] (i) the first S segment, which contains the nucleotide sequence of SEQ ID NO: 98; and
[0094] (ii) The second S segment, which contains the nucleotide sequence of SEQ ID NO: 99; and
[0095] (iii) L segment.
[0096] Those skilled in the art will understand that the nucleotide sequence encoding the fusion protein disclosed herein can be a DNA sequence or its corresponding RNA sequence obtained by replacing each "T" in the DNA sequence with a "U". Therefore, in this disclosure, when a DNA sequence is described as encoding a fusion protein, those skilled in the art will understand that such disclosure also includes the corresponding RNA sequence used to encode the fusion protein. Furthermore, when a nucleotide sequence is described as part of an arenavirus genome, those skilled in the art will understand that if the described SEQ ID NO is a DNA sequence, then the described nucleotide sequence is an RNA sequence in which each "T" in the corresponding described SEQ ID NO is replaced with a "U".
[0097] In one aspect, this disclosure provides a pharmaceutical composition comprising the sand-like virus particles disclosed herein.
[0098] In one aspect, this disclosure provides multiple nucleic acids encoding the genome of the sand-like virus particles disclosed herein.
[0099] In one aspect, this disclosure provides a host cell comprising a variety of nucleic acids disclosed herein.
[0100] In one aspect, this disclosure provides a method for preparing the sand virus particles disclosed herein, wherein the method includes culturing host cells and harvesting the sand virus particles.
[0101] In one aspect, this disclosure provides a method for treating a neoplastic disease in a subject in need, wherein the method comprises administering to the subject a therapeutically effective amount of the sand-like virus particles disclosed herein or the pharmaceutical composition disclosed herein.
[0102] In some implementations, neoplastic diseases are selected from the group consisting of: adrenocortical carcinoma; urothelial carcinoma of the bladder; invasive breast carcinoma; cervical squamous cell carcinoma and cervical endometrial adenocarcinoma; cholangiocarcinoma; colonic adenocarcinoma; lymphoid neoplasms—diffuse large B-cell lymphoma; esophageal cancer; glioblastoma multiforme; head and neck squamous cell carcinoma; chromophobe renal carcinoma; clear cell renal carcinoma; papillary renal carcinoma; acute myeloid leukemia; low-grade glioma of the brain; hepatocellular carcinoma; lung adenocarcinoma; lung squamous cell carcinoma; mesothelioma; ovarian serous cystadenocarcinoma; pancreatic adenocarcinoma; pheochromocytoma and paraganglioma; prostate adenocarcinoma; rectal adenocarcinoma; sarcoma; cutaneous melanoma; gastric adenocarcinoma; testicular germ cell tumors; thyroid cancer; thymoma; endometrial cancer of the uterine corpus; uterine carcinosarcoma; and uveal melanoma.
[0103] In one aspect, this disclosure provides a fusion protein comprising two or more CTA fragments.
[0104] In some implementations, two or more CTA fragments are selected from the group consisting of: a melanoma-preferred antigen (PRAME) fragment, a melanoma-associated antigen 3 (MAGE-A3) fragment, a melanoma-associated antigen 4 (MAGE-A4) fragment, and a melanoma-associated antigen 6 (MAGE-A6) fragment.
[0105] In some embodiments, the two or more CTA fragments comprise at least one PRAME fragment, at least one MAGE-A3 fragment, at least one MAGE-A4 fragment, and at least one MAGE-A6 fragment. In some embodiments, the at least one PRAME fragment is selected from the group consisting of: PRAME 3-13 (SEQ ID NO: 29), PRAME 7-23 (SEQ ID NO:30), PRAME 73-82 (SEQ ID NO: 31), PRAME 84-95 (SEQ ID NO: 32), PRAME 123-141 (SEQ ID NO:33), PRAME 150-161 (SEQ ID NO: 34), PRAME 166-178 (SEQ ID NO: 35), PRAME 210-230 (SEQ ID NO:36), PRAME 224-232 (SEQ ID NO: 37), PRAME 237-250 (SEQ ID NO: 38), PRAME 248-256 (SEQ ID NO:39), PRAME 267-277 (SEQ ID NO: 40), PRAME 278-292 (SEQ ID NO: 41), PRAME 315-327 (SEQ ID NO:42), PRAME 325-334 (SEQ ID NO: 43), PRAME 425-433 (SEQ ID NO: 44), PRAME 435-443 (SEQ ID NO:45), PRAME 445-458 (SEQ ID NO: 46), PRAME 472-491 (SEQ ID NO: 47), PRAME 485-509 (SEQ ID NO:48), and combinations thereof. In some embodiments, at least one MAGE-A3 fragment contains MAGE-A3. 135-149(SEQ ID NO: 66). In some embodiments, at least one MAGE-A4 fragment contains MAGE-A4. 112-121 (SEQ ID NO:52) and / or MAGE-A4 286-305 (SEQ ID NO: 63). In some embodiments, at least one MAGE-A6 fragment contains MAGE-A6. 167-184 (SEQ ID NO: 75).
[0106] In some implementations, two or more CTA fragments contain PRAME. 3-13 (SEQ ID NO: 29), PRAME 7-23 (SEQ ID NO: 30), PRAME 73-82 (SEQ ID NO: 31), PRAME 84-95 (SEQ ID NO: 32), PRAME 123-141 (SEQ ID NO: 33), PRAME 150-161 (SEQ ID NO: 34), PRAME 166-178 (SEQ ID NO: 35), PRAME 210-230 (SEQ ID NO: 36), PRAME 224-232 (SEQ ID NO: 37), PRAME 237-250 (SEQ ID NO: 38), PRAME 248-256 (SEQ ID NO: 39), PRAME 267-277 (SEQ ID NO: 40), PRAME 278-292 (SEQ ID NO: 41), PRAME 315-327 (SEQ ID NO: 42), PRAME 325-334 (SEQ ID NO: 43), PRAME 425-433 (SEQ ID NO: 44), PRAME 435-443 (SEQ ID NO: 45), PRAME 445-458 (SEQ ID NO: 46), PRAME 472-491 (SEQ ID NO: 47), PRAME 485-509 (SEQ ID NO: 48), MAGE-A3 135-149 (SEQ ID NO: 66), MAGE-A4 112-121 (SEQ ID NO:52), MAGE-A4 286-305(SEQ ID NO: 63) and MAGE-A6 167-184 (SEQ ID NO: 75).
[0107] In some embodiments, the fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 7, SEQ ID NO: 9, or SEQ ID NO: 11.
[0108] In some embodiments, the two or more CTA fragments comprise at least one MAGE-A3 fragment, at least one MAGE-A4 fragment, and at least one MAGE-A6 fragment. In some embodiments, the at least one MAGE-A3 fragment is selected from the group consisting of: MAGE-A3 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO: 70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ ID NO:71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A3 160-171 (SEQ ID NO: 68), MAGE-A3 143-151 (SEQ ID NO: 67), and combinations thereof. In some embodiments, at least one MAGE-A4 fragment is selected from the group consisting of: MAGE-A4 136-155 (SEQ ID NO: 53), MAGE-A4 168-179 (SEQ ID NO: 55), MAGE-A4 190-199 (SEQ ID NO: 57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ ID NO: 64), MAGE-A4 175-183 (SEQ ID NO: 56), MAGE-A4 262-272 (SEQ ID NO: 61), MAGE-A4 222-246 (SEQ ID NO: 60), MAGE-A4109-117 (SEQ ID NO: 51), MAGE-A4 205-218 (SEQ ID NO:59), MAGE-A4 205-217 (SEQ ID NO: 58), MAGE-A4 155-168 (SEQ ID NO: 54) or MAGE-A4 266-274 (SEQ ID NO: 62), MAGE-A4 73-83 (SEQ ID NO: 49), and combinations thereof. In some embodiments, at least one MAGE-A6 fragment is selected from the group consisting of: MAGE-A6 196-204 (SEQ ID NO: 77), MAGE-A6 194-202 (SEQ ID NO: 76), MAGE-A6 231-241 (SEQ ID NO: 78), MAGE-A6 243-255 (SEQ ID NO: 79), and combinations thereof.
[0109] In some implementations, two or more CTA fragments contain MAGE-A3. 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO: 70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ ID NO: 71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A3 160-171 (SEQ ID NO: 68), MAGE-A3 143-151 (SEQ ID NO: 67), MAGE-A4 136-155 (SEQ ID NO: 53), MAGE-A4 168-179 (SEQ ID NO: 55), MAGE-A4 190-199 (SEQ ID NO:57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ ID NO: 64), MAGE-A4 175-183 (SEQ IDNO: 56), MAGE-A4 262-272(SEQ ID NO: 61), MAGE-A4 222-246 (SEQ ID NO: 60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-218 (SEQ ID NO: 59), MAGE-A4 155-168 (SEQ ID NO: 54) or MAGE-A4 266-274 (SEQ ID NO: 62), MAGE-A4 73-83 (SEQ ID NO: 49), MAGE-A6 196-204 (SEQ ID NO: 77), MAGE-A6 194-202 (SEQ ID NO: 76), MAGE-A6 231-241 (SEQ ID NO: 78) and MAGE-A6 243-255 (SEQ ID NO: 79). In some embodiments, two or more CTA fragments contain MAGE-A3. 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO: 70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ ID NO: 71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A3 160-171 (SEQ ID NO: 68), MAGE-A3 143-151 (SEQ ID NO: 67), MAGE-A4 136-155 (SEQ ID NO: 53), MAGE-A4 168-179 (SEQ ID NO: 55), MAGE-A4 190-199 (SEQ ID NO:57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ ID NO: 64), MAGE-A4 175-183 (SEQ IDNO: 56), MAGE-A4 262-272 (SEQ ID NO: 61), MAGE-A4 222-246(SEQ ID NO: 60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-217 (SEQ ID NO: 58), MAGE-A4 155-168 (SEQ ID NO: 54) or MAGE-A4 266-274 (SEQ ID NO: 62), MAGE-A4 73-83 (SEQ ID NO: 49), MAGE-A6 196-204 (SEQ ID NO: 77), MAGE-A6 194-202 (SEQ ID NO: 76), MAGE-A6 231-241 (SEQ ID NO: 78) and MAGE-A6 243-255 (SEQ ID NO: 79). In some embodiments, two or more CTA fragments contain MAGE-A3. 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO: 70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ ID NO: 71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A3 160-171 (SEQ ID NO: 68), MAGE-A3 143-151 (SEQ ID NO: 67), MAGE-A4 168-179 (SEQ ID NO: 55), MAGE-A4 190-199 (SEQ ID NO: 57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ ID NO: 64), MAGE-A4 175-183 (SEQ ID NO: 56), MAGE-A4 262-272 (SEQ IDNO: 61), MAGE-A4 222-246 (SEQ ID NO: 60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-218(SEQ ID NO: 59), MAGE-A4 155-168 (SEQ ID NO: 54) or MAGE-A4 266-274 (SEQ ID NO: 62), MAGE-A4 73-83 (SEQ ID NO: 49), MAGE-A6 196-204 (SEQ ID NO: 77), MAGE-A6 194-202 (SEQ ID NO: 76), MAGE-A6 231-241 (SEQ ID NO: 78) and MAGE-A6 243-255 (SEQ ID NO: 79). In some embodiments, two or more CTA fragments contain MAGE-A3. 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO: 70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ IDNO: 71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A4 168-179 (SEQ ID NO: 55), MAGE-A4 190-199 (SEQ ID NO: 57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ ID NO: 64), MAGE-A4 175-183 (SEQ ID NO: 56), MAGE-A4 262-272 (SEQ ID NO:61), MAGE-A4 222-246 (SEQ ID NO: 60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-218 (SEQ ID NO: 59), MAGE-A4 155-168 (SEQ ID NO: 54) or MAGE-A4 266-274 (SEQ ID NO: 62), MAGE-A4 73-83 (SEQ ID NO: 49), MAGE-A6 196-204(SEQ ID NO: 77), MAGE-A6 194-202 (SEQ ID NO: 76), MAGE-A6 231-241 (SEQ ID NO: 78) and MAGE-A6 243-255 (SEQ ID NO: 79).
[0110] In some embodiments, the fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, or SEQ ID NO: 26. In some embodiments, the fusion protein comprises the amino acid sequence of SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, or SEQ ID NO: 26.
[0111] In some embodiments, at least two of the two or more CTA fragments of the fusion protein are linked by at least one adapter. In some embodiments, at least one adapter comprises the amino acid sequence AAY (SEQ ID NO: 80), ALL (SEQ ID NO: 81), SSL (SEQ ID NO: 82), or RKSY (SEQ ID NO: 83).
[0112] 3.1 Exemplary Implementation Plan
[0113] Exemplary embodiments of this disclosure are provided in the following paragraphs:
[0114] 1. A sand-borne virus particle, said sand-borne virus particle comprising a sand-borne virus genome, said sand-borne virus genome comprising:
[0115] a. A first heterologous open reading frame (ORF) encoding a first fusion protein comprising two or more cancer-testis antigen (CTA) fragments; and
[0116] b. A second heterologous ORF encoding a second fusion protein containing two or more CTA fragments.
[0117] Wherein (i) at least one isovirus ORF is functionally inactivated or deleted, or (ii) at least one isovirus ORF or a fragment thereof is located at a position different from the wild-type position of the at least one isovirus ORF or a fragment thereof.
[0118] 2. The sand-borne virus particle according to embodiment 1, wherein the two or more CTA fragments of the first fusion protein and the second fusion protein are selected from the group consisting of: a fragment of a melanoma-preferred antigen (PRAME), a melanoma-associated antigen 3 (MAGE-A3) fragment, a melanoma-associated antigen 4 (MAGE-A4) fragment, and a melanoma-associated antigen 6 (MAGE-A6) fragment.
[0119] 3. The sand-like virus particle according to embodiment 2, wherein the two or more CTA fragments of the first fusion protein comprise at least one PRAME fragment, at least one MAGE-A3 fragment, at least one MAGE-A4 fragment, and at least one MAGE-A6 fragment.
[0120] 4. The sand-like virus particle according to embodiment 3, wherein the at least one PRAME fragment is selected from the group consisting of: PRAME 3-13 (SEQ ID NO: 29), PRAME 7-23 (SEQ ID NO: 30), PRAME 73-82 (SEQ IDNO: 31), PRAME 84-95 (SEQ ID NO: 32), PRAME 123-141 (SEQ ID NO: 33), PRAME 150-161 (SEQ IDNO: 34), PRAME 166-178 (SEQ ID NO: 35), PRAME 210-230 (SEQ ID NO: 36), PRAME 224-232 (SEQ IDNO: 37), PRAME 237-250 (SEQ ID NO: 38), PRAME 248-256 (SEQ ID NO: 39), PRAME 267-277 (SEQ IDNO: 40), PRAME 278-292 (SEQ ID NO: 41), PRAME 315-327 (SEQ ID NO: 42), PRAME 325-334 (SEQ IDNO: 43), PRAME 425-433 (SEQ ID NO: 44), PRAME 435-443 (SEQ ID NO: 45), PRAME 445-458 (SEQ IDNO: 46), PRAME 472-491 (SEQ ID NO: 47), PRAME485-509 (SEQ ID NO: 48), and combinations thereof.
[0121] 5. The sand-like virus particle according to embodiment 3 or 4, wherein the at least one MAGE-A3 fragment comprises MAGE-A3. 135-149 (SEQ ID NO: 66).
[0122] 6. The sand-like virus particle according to any one of embodiments 3 to 5, wherein the at least one MAGE-A4 fragment comprises MAGE-A4. 112-121 (SEQ ID NO: 52) and / or MAGE-A4 286-305 (SEQ ID NO: 63).
[0123] 7. The sand-like virus particle according to any one of embodiments 3 to 6, wherein the at least one MAGE-A6 fragment comprises MAGE-A6. 167-184 (SEQ ID NO: 75).
[0124] 8. A sand-like virus particle according to any one of embodiments 3 to 7, wherein the two or more CTA fragments of the first fusion protein comprise PRAME. 3-13 (SEQ ID NO: 29), PRAME 7-23 (SEQ ID NO: 30), PRAME 73-82 (SEQ ID NO: 31), PRAME 84-95 (SEQ ID NO: 32), PRAME 123-141 (SEQ ID NO: 33), PRAME 150-161 (SEQ ID NO: 34), PRAME 166-178 (SEQ ID NO: 35), PRAME 210-230 (SEQ ID NO: 36), PRAME 224-232 (SEQ ID NO: 37), PRAME 237-250 (SEQ ID NO: 38), PRAME 248-256 (SEQ ID NO: 39), PRAME 267-277 (SEQ ID NO: 40), PRAME 278-292 (SEQ ID NO: 41), PRAME 315-327 (SEQ ID NO: 42), PRAME 325-334 (SEQ ID NO: 43), PRAME 425-433(SEQ ID NO: 44), PRAME 435-443 (SEQ ID NO: 45), PRAME 445-458 (SEQ ID NO: 46), PRAME 472-491 (SEQ ID NO: 47), PRAME 485-509 (SEQ ID NO: 48), MAGE-A3 135-149 (SEQ ID NO: 66), MAGE-A4 112-121 (SEQ ID NO: 52), MAGE-A4 286-305 (SEQ IDNO: 63) and MAGE-A6 167-184 (SEQ ID NO: 75).
[0125] 9. The sand-like virus particle according to any one of embodiments 2 to 8, wherein the two or more CTA fragments of the second fusion protein comprise at least one MAGE-A3 fragment, at least one MAGE-A4 fragment, and at least one MAGE-A6 fragment.
[0126] 10. The sand-borne virus particle according to embodiment 9, wherein the at least one MAGE-A3 fragment is selected from the group consisting of: MAGE-A3 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO: 70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ ID NO:71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A3 160-171 (SEQ ID NO: 68), MAGE-A3 143-151 (SEQ ID NO: 67), and combinations thereof.
[0127] 11. The sand-like virus particle according to embodiment 9 or 10, wherein the at least one MAGE-A4 fragment is selected from the group consisting of: MAGE-A4 136-155 (SEQ ID NO: 53), MAGE-A4 168-179 (SEQ ID NO: 55), MAGE-A4 190-199(SEQ ID NO: 57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ ID NO:64), MAGE-A4 175-183 (SEQ ID NO: 56), MAGE-A4 262-272 (SEQ ID NO: 61), MAGE-A4 222-246 (SEQ ID NO: 60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-218 (SEQ ID NO: 59), MAGE-A4 205-217 (SEQ ID NO: 58), MAGE-A4 155-168 (SEQ ID NO: 54), MAGE-A4 266-274 (SEQ ID NO:62), MAGE-A4 73-83 (SEQ ID NO: 49), and combinations thereof.
[0128] 12. The sand-like virus particle according to any one of embodiments 9 to 11, wherein the at least one MAGE-A6 fragment is selected from the group consisting of: MAGE-A6 196-204 (SEQ ID NO: 77), MAGE-A6 194-202 (SEQ ID NO:76), MAGE-A6 231-241 (SEQ ID NO: 78), MAGE-A6 243-255 (SEQ ID NO: 79), and combinations thereof.
[0129] 13. The sand-like virus particle according to any one of embodiments 9 to 12, wherein the two or more CTA fragments of the second fusion protein comprise MAGE-A3. 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO:70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ ID NO: 71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A3 160-171(SEQ ID NO: 68), MAGE-A3 143-151 (SEQ ID NO: 67), MAGE-A4 136-155 (SEQ ID NO: 53), MAGE-A4 168-179 (SEQ ID NO: 55), MAGE-A4 190-199 (SEQ ID NO: 57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ ID NO: 64), MAGE-A4 175-183 (SEQ ID NO: 56), MAGE-A4 262-272 (SEQ IDNO: 61), MAGE-A4 222-246 (SEQ ID NO: 60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-218 (SEQ ID NO: 59), MAGE-A4 155-168 (SEQ ID NO: 54), MAGE-A4 266-274 (SEQ ID NO: 62), MAGE-A4 73-83 (SEQ ID NO: 49), MAGE-A6 196-204 (SEQ ID NO: 77), MAGE-A6 194-202 (SEQ ID NO: 76), MAGE-A6 231-241 (SEQ ID NO: 78) and MAGE-A6 243-255 (SEQ ID NO: 79).
[0130] 14. The sand-like virus particle according to any one of embodiments 9 to 12, wherein the two or more CTA fragments of the second fusion protein comprise MAGE-A3. 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO:70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ ID NO: 71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A3160-171 (SEQ ID NO: 68), MAGE-A3 143-151 (SEQ ID NO: 67), MAGE-A4 136-155 (SEQ ID NO: 53), MAGE-A4 168-179 (SEQ ID NO: 55), MAGE-A4 190-199 (SEQ ID NO: 57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ ID NO: 64), MAGE-A4 175-183 (SEQ ID NO: 56), MAGE-A4 262-272 (SEQ IDNO: 61), MAGE-A4 222-246 (SEQ ID NO: 60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-217 (SEQ ID NO: 58), MAGE-A4 155-168 (SEQ ID NO: 54), MAGE-A4 266-274 (SEQ ID NO: 62), MAGE-A4 73-83 (SEQ ID NO: 49), MAGE-A6 196-204 (SEQ ID NO: 77), MAGE-A6 194-202 (SEQ ID NO: 76), MAGE-A6 231-241 (SEQ ID NO: 78) and MAGE-A6 243-255 (SEQ ID NO: 79).
[0131] 15. The sand-like virus particle according to any one of embodiments 9 to 12, wherein the two or more CTA fragments of the second fusion protein comprise MAGE-A3. 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO:70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ ID NO: 71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81(SEQ ID NO: 65), MAGE-A3 160-171 (SEQ ID NO: 68), MAGE-A3 143-151 (SEQ ID NO: 67), MAGE-A4 168-179 (SEQ ID NO: 55), MAGE-A4 190-199 (SEQ ID NO: 57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ ID NO: 64), MAGE-A4 175-183 (SEQ ID NO: 56), MAGE-A4 262-272 (SEQ ID NO: 61), MAGE-A4 222-246 (SEQ IDNO: 60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-218 (SEQ ID NO: 59), MAGE-A4 155-168 (SEQ ID NO: 54), MAGE-A4 266-274 (SEQ ID NO: 62), MAGE-A4 73-83 (SEQ ID NO: 49), MAGE-A6 196-204 (SEQ ID NO: 77), MAGE-A6 194-202 (SEQ ID NO: 76), MAGE-A6 231-241 (SEQ ID NO: 78) and MAGE-A6 243-255 (SEQ ID NO: 79).
[0132] 16. The sand-like virus particle according to any one of embodiments 9 to 12, wherein the two or more CTA fragments of the second fusion protein comprise MAGE-A3. 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO:70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ ID NO: 71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A4168-179 (SEQ ID NO: 55), MAGE-A4 190-199 (SEQ ID NO: 57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ ID NO: 64), MAGE-A4 175-183 (SEQ ID NO: 56), MAGE-A4 262-272 (SEQ ID NO:61), MAGE-A4 222-246 (SEQ ID NO: 60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-218 (SEQ ID NO: 59), MAGE-A4 155-168 (SEQ ID NO: 54), MAGE-A4 266-274 (SEQ ID NO: 62), MAGE-A4 73-83 (SEQ ID NO: 49), MAGE-A6 196-204 (SEQ ID NO: 77), MAGE-A6 194-202 (SEQ ID NO: 76), MAGE-A6 231-241 (SEQ ID NO: 78) and MAGE-A6 243-255 (SEQ ID NO: 79).
[0133] 17. A sand-like virus particle according to any one of embodiments 1 to 16, wherein at least two of the two or more CTA fragments of the first fusion protein and / or the second fusion protein are connected by at least one adapter.
[0134] 18. The sand-like virus particle according to embodiment 17, wherein the at least one adapter comprises an amino acid sequence of AAY (SEQ ID NO: 80), ALL (SEQ ID NO: 81), SSL (SEQ ID NO: 82) or RKSY (SEQ ID NO: 83).
[0135] 19. The sand-like virus particle according to any one of embodiments 1 to 18, wherein the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 7, SEQ ID NO: 9 or SEQ ID NO: 11.
[0136] 20. A sand-like virus particle according to any one of embodiments 1 to 19, wherein the first fusion protein comprises the amino acid sequence of SEQ ID NO: 7, SEQ ID NO: 9 or SEQ ID NO: 11.
[0137] 21. The sand-like virus particle according to any one of embodiments 1 to 20, wherein the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25 or SEQ ID NO: 26.
[0138] 22. The sand-like virus particle according to any one of embodiments 1 to 21, wherein the second fusion protein comprises the amino acid sequence of SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25 or SEQ ID NO: 26.
[0139] 23. The sand-like virus particle according to any one of embodiments 1 to 13 and 17 to 22, wherein the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 7, and the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 8.
[0140] 24. The sand-borne virus particle according to embodiment 23, wherein the first fusion protein comprises the amino acid sequence of SEQ ID NO: 7, and the second fusion protein comprises the amino acid sequence of SEQ ID NO: 8.
[0141] 25. A sand-like virus particle according to any one of embodiments 1 to 13 and 17 to 22, wherein the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 9, and the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 10.
[0142] 26. The sand-borne virus particle according to embodiment 25, wherein the first fusion protein comprises the amino acid sequence of SEQ ID NO: 9, and the second fusion protein comprises the amino acid sequence of SEQ ID NO: 10.
[0143] 27. A sand-like virus particle according to any one of embodiments 1 to 12, 14 and 17 to 22, wherein the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 11, and the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 12.
[0144] 28. The sand-borne virus particle according to embodiment 27, wherein the first fusion protein comprises the amino acid sequence of SEQ ID NO: 11, and the second fusion protein comprises the amino acid sequence of SEQ ID NO: 12.
[0145] 29. A sand-like virus particle according to any one of embodiments 1 to 23, 15 and 17 to 22, wherein the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 7, and the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 12.
[0146] 30. The sand-borne virus particle according to embodiment 29, wherein the first fusion protein comprises the amino acid sequence of SEQ ID NO: 7, and the second fusion protein comprises the amino acid sequence of SEQ ID NO: 23.
[0147] 31. The sand-like virus particle according to any one of embodiments 1 to 12 and 16 to 22, wherein the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 7, and the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 25.
[0148] 32. The sand-borne virus particle according to embodiment 31, wherein the first fusion protein comprises the amino acid sequence of SEQ ID NO: 7, and the second fusion protein comprises the amino acid sequence of SEQ ID NO: 25.
[0149] 33. The sand-like virus particle according to any one of embodiments 1 to 24, 15 and 17 to 22, wherein the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 9, and the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 12.
[0150] 34. The sand-borne virus particle according to embodiment 33, wherein the first fusion protein comprises the amino acid sequence of SEQ ID NO: 9, and the second fusion protein comprises the amino acid sequence of SEQ ID NO: 24.
[0151] 35. The sand-like virus particle according to any one of embodiments 1 to 12 and 16 to 22, wherein the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 9, and the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 26.
[0152] 36. The sand-borne virus particle according to embodiment 35, wherein the first fusion protein comprises the amino acid sequence of SEQ ID NO: 9, and the second fusion protein comprises the amino acid sequence of SEQ ID NO: 26.
[0153] 37. A sand-like virus particle according to any one of embodiments 1 to 36, wherein the at least one sand-like virus ORF encodes the GP, NP, L, or Z protein of the sand-like virus particle.
[0154] 38. A sand-like virus particle according to any one of embodiments 1 to 37, wherein the at least one sand-like virus ORF is located at a position different from the wild-type position of the at least one sand-like virus ORF.
[0155] 39. A sand-like virus particle according to any one of embodiments 1 to 38, wherein the sand-like virus particle is three-segmented and has replication capability, and comprises an L segment and two S segments, wherein one of the two S segments is selected from the group consisting of:
[0156] The aS segment, in which the ORF encoding the nucleoprotein (“NP”) is under the control of the 5' UTR of the arenavirus genome;
[0157] The bS segment, in which the ORF encoding matrix protein Z (“Z protein”) is under the control of the 5' UTR of the arenavirus genome;
[0158] The cS segment, in which the ORF encoding the RNA-dependent RNA polymerase L protein (“L protein”) is under the control of the 5' UTR of the arenavirus genome;
[0159] The dS segment, in which the ORF encoding the glycoprotein (“GP”) is under the control of the 3' UTR of the arenavirus genome;
[0160] The eS segment, wherein the ORF encoding the L protein is under the control of the 3' UTR of the arenavirus genome; and
[0161] The fS segment, in which the ORF encoding the Z protein is under the control of the 3' UTR of the arenavirus genome.
[0162] 40. A sand-like virus particle according to any one of embodiments 1 to 39, wherein the sand-like virus genome comprises:
[0163] a. The first S segment, comprising an ORF encoding an NP located at the 3' UTR of the isopyrvirus genome and a first heterologous ORF encoding the first fusion protein located at the 5' UTR of the isopyrvirus genome;
[0164] b. The second S segment, comprising an ORF encoding GP located at the 3' UTR control position of the arenavirus genome, and a second heterologous ORF encoding the second fusion protein located at the 5' UTR control position of the arenavirus genome; and
[0165] cL segment.
[0166] 41. The sand-like virus particle according to any one of embodiments 1 to 40, wherein the sand-like virus particle is derived from lymphocytic choriomeningitis virus (LCMV), Pichind virus, Tammyami virus, or Tacalib virus.
[0167] 42. A sand-like virus particle according to any one of embodiments 1 to 13, 17 to 24 and 37 to 41, wherein the sand-like virus genome comprises:
[0168] a. The first S segment, comprising the nucleotide sequence of SEQ ID NO: 92; and
[0169] b. The second S segment, which contains the nucleotide sequence of SEQ ID NO: 93; and
[0170] cL segment.
[0171] 43. A sand-like virus particle according to any one of embodiments 1 to 13, 17 to 24 and 37 to 41, wherein the sand-like virus genome comprises:
[0172] a. The first S segment, comprising the nucleotide sequence of SEQ ID NO: 96; and
[0173] b. The second S segment, which contains the nucleotide sequence of SEQ ID NO: 97; and
[0174] cL segment.
[0175] 44. A sand-like virus particle according to any one of embodiments 1 to 13, 17 to 22, 25, 26 and 37 to 41, wherein the sand-like virus genome comprises:
[0176] a. The first S segment, comprising the nucleotide sequence of SEQ ID NO: 94; and
[0177] b. The second S segment, which contains the nucleotide sequence of SEQ ID NO: 95; and
[0178] cL segment.
[0179] 45. A sand-like virus particle according to any one of embodiments 1 to 13, 17 to 22, 25, 26 and 37 to 41, wherein the sand-like virus genome comprises:
[0180] a. The first S segment, comprising the nucleotide sequence of SEQ ID NO: 98; and
[0181] b. The second S segment, which contains the nucleotide sequence of SEQ ID NO: 99; and
[0182] cL segment.
[0183] 46. A pharmaceutical composition comprising sand-like virus particles according to any one of embodiments 1 to 45.
[0184] 47. Multiple nucleic acids, wherein the multiple nucleic acids encode the isovirus genome of an isovirus particle according to any one of embodiments 1 to 45.
[0185] 48. A host cell comprising a plurality of nucleic acids as described in embodiment 47.
[0186] 49. A method for preparing sand virus particles, wherein the method includes culturing host cells according to embodiment 48 and harvesting the sand virus particles.
[0187] 50. A method for treating a neoplastic disease in a subject in need, wherein the method comprises administering to the subject a therapeutically effective amount of any one of embodiments 1 to 45 of the sand-like virus particles or the pharmaceutical composition of embodiment 46.
[0188] 51. The method according to embodiment 50, wherein the neoplastic disease is selected from the group consisting of: adrenocortical carcinoma; urothelial carcinoma of the bladder; invasive breast carcinoma; cervical squamous cell carcinoma and cervical endometrial adenocarcinoma; cholangiocarcinoma; colonic adenocarcinoma; lymphoid tumors—diffuse large B-cell lymphoma; esophageal cancer; glioblastoma multiforme; head and neck squamous cell carcinoma; renal chromophobe carcinoma; renal clear cell carcinoma; renal papillary cell carcinoma; acute myeloid leukemia; low-grade glioma of the brain; hepatocellular carcinoma; lung adenocarcinoma; lung squamous cell carcinoma; mesothelioma; ovarian serous cystadenocarcinoma; pancreatic adenocarcinoma; pheochromocytoma and paraganglioma; prostate adenocarcinoma; rectal adenocarcinoma; sarcoma; cutaneous melanoma; gastric adenocarcinoma; testicular germ cell tumor; thyroid cancer; thymoma; uterine endometrial cancer; uterine carcinosarcoma; and uveal melanoma.
[0189] 52. A fusion protein comprising two or more CTA fragments.
[0190] 53. The fusion protein according to embodiment 52, wherein the two or more CTA fragments are selected from the group consisting of: a melanoma-preferred antigen (PRAME) fragment, a melanoma-associated antigen 3 (MAGE-A3) fragment, a melanoma-associated antigen 4 (MAGE-A4) fragment, and a melanoma-associated antigen 6 (MAGE-A6) fragment.
[0191] 54. The fusion protein according to embodiment 53, wherein the two or more CTA fragments comprise at least one PRAME fragment, at least one MAGE-A3 fragment, at least one MAGE-A4 fragment, and at least one MAGE-A6 fragment.
[0192] 55. The fusion protein according to embodiment 54, wherein the at least one PRAME fragment is selected from the group consisting of: PRAME 3-13 (SEQ ID NO: 29), PRAME 7-23 (SEQ ID NO: 30), PRAME 73-82 (SEQ ID NO:31), PRAME 84-95 (SEQ ID NO: 32), PRAME 123-141 (SEQ ID NO: 33), PRAME 150-161 (SEQ ID NO:34), PRAME 166-178 (SEQ ID NO: 35), PRAME 210-230 (SEQ ID NO: 36), PRAME 224-232 (SEQ ID NO:37), PRAME 237-250(SEQ ID NO: 38), PRAME 248-256 (SEQ ID NO: 39), PRAME 267-277 (SEQ ID NO:40), PRAME 278-292 (SEQ ID NO: 41), PRAME 315-327 (SEQ ID NO: 42), PRAME 325-334 (SEQ ID NO:43), PRAME 425-433 (SEQ ID NO: 44), PRAME 435-443 (SEQ ID NO: 45), PRAME 445-458 (SEQ ID NO:46), PRAME 472-491 (SEQ ID NO: 47), PRAME 485-509 (SEQ ID NO: 48), and combinations thereof.
[0193] 56. The fusion protein according to embodiment 54 or 55, wherein the at least one MAGE-A3 fragment comprises MAGE-A3 135-149 (SEQ ID NO: 66).
[0194] 57. The fusion protein according to any one of embodiments 54 to 56, wherein the at least one MAGE-A4 fragment comprises MAGE-A4. 112-121 (SEQ ID NO: 52) and / or MAGE-A4 286-305 (SEQ ID NO: 63).
[0195] 58. The fusion protein according to any one of embodiments 54 to 57, wherein the at least one MAGE-A6 fragment comprises MAGE-A6 167-184 (SEQ ID NO: 75).
[0196] 59. The fusion protein according to any one of embodiments 54 to 58, wherein the two or more CTA fragments comprise PRAME. 3-13 (SEQ ID NO: 29), PRAME 7-23 (SEQ ID NO: 30), PRAME 73-82 (SEQ ID NO:31), PRAME 84-95 (SEQ ID NO: 32), PRAME 123-141 (SEQ ID NO: 33), PRAME 150-161 (SEQ ID NO:34), PRAME166-178 (SEQ ID NO: 35), PRAME 210-230 (SEQ ID NO: 36), PRAME 224-232 (SEQ ID NO:37), PRAME 237-250 (SEQ ID NO: 38), PRAME 248-256 (SEQ ID NO: 39), PRAME 267-277 (SEQ ID NO:40), PRAME 278-292 (SEQ ID NO: 41), PRAME 315-327 (SEQ ID NO: 42), PRAME 325-334 (SEQ ID NO:43), PRAME 425-433 (SEQ ID NO: 44), PRAME 435-443 (SEQ ID NO: 45), PRAME 445-458 (SEQ ID NO:46), PRAME 472-491 (SEQ ID NO: 47), PRAME 485-509 (SEQ ID NO: 48), MAGE-A3 135-149 (SEQ IDNO: 66), MAGE-A4 112-121 (SEQ ID NO: 52), MAGE-A4 286-305 (SEQ ID NO: 63) and MAGE-A6 167-184 (SEQ ID NO: 75).
[0197] 60. The fusion protein according to any one of embodiments 54 to 59, wherein the fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 7, SEQ ID NO: 9 or SEQ ID NO: 11.
[0198] 61. The fusion protein according to any one of embodiments 54 to 60, wherein the fusion protein comprises the amino acid sequence of SEQ ID NO: 7, SEQ ID NO: 9 or SEQ ID NO: 11.
[0199] 62. The fusion protein according to embodiment 53, wherein the two or more CTA fragments comprise at least one MAGE-A3 fragment, at least one MAGE-A4 fragment, and at least one MAGE-A6 fragment.
[0200] 63. The fusion protein according to embodiment 62, wherein the at least one MAGE-A3 fragment is selected from the group consisting of: MAGE-A3 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO: 70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ ID NO:71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A3 160-171 (SEQ ID NO: 68), MAGE-A3 143-151 (SEQ ID NO: 67), and combinations thereof.
[0201] 64. The fusion protein according to embodiment 62 or 63, wherein the at least one MAGE-A4 fragment is selected from the group consisting of: MAGE-A4 136-155 (SEQ ID NO: 53), MAGE-A4 168-179 (SEQ ID NO: 55), MAGE-A4 190-199 (SEQ ID NO: 57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ ID NO: 64), MAGE-A4 175-183 (SEQ ID NO: 56), MAGE-A4 262-272 (SEQ ID NO: 61), MAGE-A4 222-246 (SEQ IDNO: 60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-218 (SEQ ID NO: 59), MAGE-A4 205-217 (SEQ ID NO: 58), MAGE-A4 155-168 (SEQ ID NO: 54), MAGE-A4 266-274 (SEQ ID NO: 62), MAGE-A4 73-83 (SEQ ID NO: 49), and combinations thereof.
[0202] 65. The fusion protein according to any one of embodiments 62 to 64, wherein the at least one MAGE-A6 fragment is selected from the group consisting of: MAGE-A6 196-204 (SEQ ID NO: 77), MAGE-A6 194-202 (SEQ ID NO:76), MAGE-A6 231-241 (SEQ ID NO: 78), MAGE-A6 243-255 (SEQ ID NO: 79), and combinations thereof.
[0203] 66. The fusion protein according to any one of embodiments 62 to 65, wherein the two or more CTA fragments comprise MAGE-A3. 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO: 70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ ID NO: 71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A3 160-171 (SEQ ID NO: 68), MAGE-A3 143-151 (SEQ ID NO: 67), MAGE-A4 136-155 (SEQ ID NO: 53), MAGE-A4 168-179 (SEQ IDNO: 55), MAGE-A4 190-199 (SEQ ID NO: 57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ ID NO: 64), MAGE-A4 175-183 (SEQ ID NO: 56), MAGE-A4 262-272 (SEQ ID NO: 61), MAGE-A4 222-246 (SEQ ID NO: 60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-218 (SEQ ID NO:59), MAGE-A4 155-168 (SEQ ID NO: 54), MAGE-A4266-274 (SEQ ID NO: 62), MAGE-A4 73-83 (SEQ IDNO: 49), MAGE-A6 196-204 (SEQ ID NO: 77), MAGE-A6 194-202 (SEQ ID NO: 76), MAGE-A6 231-241 (SEQ ID NO: 78) and MAGE-A6 243-255 (SEQ ID NO: 79).
[0204] 67. The fusion protein according to any one of embodiments 62 to 65, wherein the two or more CTA fragments comprise MAGE-A3. 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO: 70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ ID NO: 71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A3 160-171 (SEQ ID NO: 68), MAGE-A3 143-151 (SEQ ID NO: 67), MAGE-A4 136-155 (SEQ ID NO: 53), MAGE-A4 168-179 (SEQ IDNO: 55), MAGE-A4 190-199 (SEQ ID NO: 57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ ID NO: 64), MAGE-A4 175-183 (SEQ ID NO: 56), MAGE-A4 262-272 (SEQ ID NO: 61), MAGE-A4 222-246 (SEQ ID NO: 60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-217 (SEQ ID NO:58), MAGE-A4 155-168 (SEQ ID NO: 54), MAGE-A4266-274 (SEQ ID NO: 62), MAGE-A4 73-83 (SEQ IDNO: 49), MAGE-A6 196-204 (SEQ ID NO: 77), MAGE-A6 194-202 (SEQ ID NO: 76), MAGE-A6 231-241 (SEQ ID NO: 78) and MAGE-A6 243-255 (SEQ ID NO: 79).
[0205] 68. The fusion protein according to any one of embodiments 62 to 65, wherein the two or more CTA fragments comprise MAGE-A3. 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO: 70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ ID NO: 71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A3 160-171 (SEQ ID NO: 68), MAGE-A3 143-151 (SEQ ID NO: 67), MAGE-A4 168-179 (SEQ ID NO: 55), MAGE-A4 190-199 (SEQ IDNO: 57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ ID NO: 64), MAGE-A4 175-183 (SEQ ID NO: 56), MAGE-A4 262-272 (SEQ ID NO: 61), MAGE-A4 222-246 (SEQ ID NO: 60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-218 (SEQ ID NO: 59), MAGE-A4 155-168 (SEQ ID NO:54), MAGE-A4 266-274 (SEQ ID NO: 62), MAGE-A473-83 (SEQ ID NO: 49), MAGE-A6 196-204 (SEQ IDNO: 77), MAGE-A6 194-202 (SEQ ID NO: 76), MAGE-A6 231-241 (SEQ ID NO: 78) and MAGE-A6 243-255 (SEQ ID NO: 79).
[0206] 69. The fusion protein according to any one of embodiments 62 to 65, wherein the two or more CTA fragments comprise MAGE-A3. 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO: 70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ ID NO: 71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A4 168-179 (SEQ ID NO: 55), MAGE-A4 190-199 (SEQ ID NO: 57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ ID NO:64), MAGE-A4 175-183 (SEQ ID NO: 56), MAGE-A4 262-272 (SEQ ID NO: 61), MAGE-A4 222-246 (SEQ ID NO: 60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-218 (SEQ ID NO: 59), MAGE-A4 155-168 (SEQ ID NO: 54), MAGE-A4 266-274 (SEQ ID NO: 62), MAGE-A4 73-83 (SEQ ID NO: 49), MAGE-A6 196-204 (SEQ ID NO: 77), MAGE-A6 194-202 (SEQ ID NO: 76), MAGE-A6231-241 (SEQ IDNO: 78) and MAGE-A6 243-255 (SEQ ID NO: 79).
[0207] 70. The fusion protein according to any one of embodiments 62 to 69, wherein the fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25 or SEQ ID NO: 26.
[0208] 71. The fusion protein according to any one of embodiments 62 to 70, wherein the fusion protein comprises the amino acid sequence of SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25 or SEQ ID NO: 26.
[0209] 72. The fusion protein according to any one of embodiments 52 to 71, wherein at least two of the two or more CTA fragments of the fusion protein are connected by at least one adapter.
[0210] 73. The fusion protein according to embodiment 72, wherein the at least one linker comprises an amino acid sequence of AAY (SEQ ID NO: 80), ALL (SEQ ID NO: 81), SSL (SEQ ID NO: 82), or RKSY (SEQ ID NO: 83).
[0211] 3.2 Conventions and Abbreviations
[0212] Attached Figure Description
[0213] Figure 1 Schematic diagram of LCMV-CTA1 and PICV-CTA1 vectors.
[0214] Figure 2 Transgenic stability of LCMV-CTA1_H7 / CTA1_H8, LCMV-CTA1_H9 / CTA1_H10, PICV-CTA1_H7 / CTA1_H8 and PICV-CTA1_H9 / CTA1_H10 was analyzed by PCR at indicated passage levels (p1-p6).
[0215] Figures 3A to 3CIn C57BL / 6JRj mice ( Figure 3A ), for HLA-A 11:01 Transgenic mice ( Figure 3B ) and HLA-B 07:02 Transgenic mice ( Figure 3C The IFN-γ immune response was assessed 5 days after alternating dual-carrier treatment. Freshly isolated spleen cells from immunized animals were stimulated in vitro with the indicated overlapping peptide library (15-mers with 11 overlapping amino acids), and IFN-γ production was measured by ELISpot. For 1×10⁻⁶ cells... 6 Cells were counted, and responses were calculated after background subtraction. The values shown correspond to the values of the treatment group at each stimulus value minus (control mean + 3 × STD). Data for each animal are shown and plotted as box plots (median ± interquartile range) and whisker lines (minimum to maximum). Data derived from LCMV (LCMVNP) will be used. 396-404 A mixture of NP-based minimal epitopes of PICV (PICV NP38-45) and PICV (PICV NP38-45) was used as a control.
[0216] Figure 4A and Figure 4B Five days after alternating dual-vector therapy, HLA-B... 07:02 Transgenic mice ( Figure 4A ) and HLA-A 11:01 Transgenic mice ( Figure 4B HLA-restricted CD8+ T cell responses were demonstrated in this study. Freshly isolated or frozen spleen cells from immunized animals were stimulated in vitro with the indicated minimal epitope peptide, and IFN-γ production was measured by ELISpot. For 1×102 6 Individual cells were counted, and responses were calculated after background subtraction. The values shown correspond to the treatment group values minus (control mean + 3 × STD) for each stimulus. Data for each animal are displayed and plotted as box plots (median ± interquartile range) and whisker lines (minimum to maximum). Data were generated in each experiment and compared on the graphs. Statistical analysis was performed using two-way ANOVA with Tukey's post-hoc test. Detailed Implementation
[0217] This article provides fusion proteins (e.g., the fusion protein in Section 5.1) that comprise two or more CTA fragments selected from the group consisting of: a melanoma-preferred antigen (PRAME) fragment, a melanoma-associated antigen 3 (MAGE-A3) fragment, a melanoma-associated antigen 4 (MAGE-A4) fragment, and a melanoma-associated antigen 6 (MAGE-A6) fragment.
[0218] This disclosure also provides isovirus particles (e.g., the isovirus particles of Section 5.2) comprising an isovirus genome containing at least one heterologous ORF encoding at least one (e.g., two) fusion proteins disclosed herein. In some embodiments, the isovirus particle is engineered to contain an isovirus genome comprising (a) a first heterologous ORF encoding a first fusion protein comprising two or more CTA fragments; and (b) a second heterologous ORF encoding a second fusion protein comprising two or more CTA fragments, wherein (i) at least one isovirus ORF is functionally inactivated or deleted, or (ii) at least one isovirus ORF or a fragment thereof is located at a position different from the wild-type position of at least one isovirus ORF or a fragment thereof. In some embodiments, the two or more CTA fragments of the first and second fusion proteins are selected from the group consisting of preferred PRAME fragments, MAGE-A3 fragments, MAGE-A4 fragments, and MAGE-A6 fragments.
[0219] This disclosure also provides methods for treating neoplastic diseases in subjects of need (e.g., the method in Section 5.4), wherein the method comprises administering to the subject the arenavirus particles disclosed herein (e.g., the arenavirus particles in Section 5.2). In some embodiments, the method comprises administering to the subject a first arenavirus particle and a second arenavirus particle, wherein the first and second arenavirus particles encode the same fusion protein or different fusion proteins.
[0220] 5.1 Fusion Protein
[0221] In one aspect, this disclosure provides a fusion protein comprising two or more CTA fragments. In some embodiments, the fusion protein comprising two or more CTA fragments comprises two or more CTA epitopes.
[0222] In some embodiments, the fusion protein comprises two or more CTA fragments selected from the PRAME, MAGE-A3, MAGE-A4, and MAGE-A6 fragments. Exemplary amino acid sequences of the PRAME, MAGE-A3, MAGE-A4, and MAGE-A6 fragments disclosed herein are provided in Section 7.
[0223] In some embodiments, the fusion protein comprises at least one PRAME fragment, at least one MAGE-A3 fragment, at least one MAGE-A4 fragment, and at least one MAGE-A6 fragment.
[0224] In some implementations, at least one PRAME fragment is selected from the group consisting of: PRAME 3-13 PRAME 7-23 PRAME 73-82 PRAME 84-95 PRAME 123-141 PRAME 150-161 PRAME 166-178 PRAME 210-230 PRAME 224-232 PRAME 237-250 PRAME 248-256 PRAME 267-277 PRAME 278-292 PRAME 315-327 PRAME 325-334 PRAME 425-433 PRAME 435-443 PRAME 445-458 PRAME 472-491 PRAME 485-509 , and their combinations.
[0225] In some embodiments, at least one MAGE-A3 fragment contains MAGE-A3. 135-149 In some implementations, at least one MAGE-A3 fragment is selected from the group consisting of: MAGE-A3 243-255 MAGE-A3 171-184 MAGE-A3 284-296 MAGE-A3 167-176 MAGE-A3 192-202 MAGE-A3 302-311 MAGE-A3 70-81 MAGE-A3 160-171 MAGE-A3 143-151 , and their combinations.
[0226] In some implementations, at least one MAGE-A4 fragment contains MAGE-A4. 112-121 and / or MAGE-A4 286-305 In some implementations, at least one MAGE-A4 fragment is selected from the group consisting of: MAGE-A4 136-155 MAGE-A4 168-179 MAGE-A4 190-199 MAGE-A4 77-89 MAGE-A4 300-308 MAGE-A4 175-183MAGE-A4 262-272 MAGE-A4 222-246 MAGE-A4 109-117 MAGE-A4 205-218 MAGE-A4 205-217 MAGE-A4 155-168 Or MAGE-A4 266-274 MAGE-A4 73-83 , and their combinations.
[0227] In some implementations, at least one MAGE-A6 fragment contains MAGE-A6. 167-184 In some implementations, at least one MAGE-A6 fragment is selected from the group consisting of: MAGE-A6 196-204 MAGE-A6 194-202 MAGE-A6 231-241 MAGE-A6 243-255 , and their combinations.
[0228] In some implementations, the fusion protein contains PRAME 3-13 PRAME 7-23 PRAME 73-82 PRAME 84-95 PRAME 123-141 PRAME 150-161 PRAME 166-178 PRAME 210-230 PRAME 224-232 PRAME 237-250 PRAME 248-256 PRAME 267-277 PRAME 278-292 PRAME 315-327 PRAME 325-334 PRAME 425-433 PRAME 435-443 PRAME 445-458 PRAME 472-491 PRAME 485-509 MAGE-A3 135-149 MAGE-A4 112-121 MAGE-A4 286-305 and MAGE-A6 167-184 .
[0229] In some implementations, the fusion protein contains PRAME from the N-terminus to the C-terminus. 150-161 PRAME 472-491 PRAME 248-256 MAGE-A3 135-149PRAME 485-509 PRAME 123-141 PRAME 7-23 PRAME 210-230 PRAME 3-13 PRAME 278-292 PRAME 237-250 MAGE-A4 112-121 PRAME 224-232 PRAME 267-277 PRAME 166-178 PRAME 445-458 PRAME 73-82 PRAME 425-433 PRAME 325-334 PRAME 315-327 PRAME 84-95 MAGE-A6 167-184 PRAME 435-443 and MAGE-A4 286-305 In some implementations, the fusion protein contains PRAME in any possible order. 150-161 PRAME 472-491 PRAME 248-256 MAGE-A3 135-149 PRAME 485-509 PRAME 123-141 PRAME 7-23 PRAME 210-230 PRAME 3-13 PRAME 278-292 PRAME 237-250 MAGE-A4 112-121 PRAME 224-232 PRAME 267-277 PRAME 166-178 PRAME 445-458 PRAME 73-82 PRAME 425-433 PRAME 325-334 PRAME 315-327 PRAME 84-95 MAGE-A6 167-184 PRAME 435-443 and MAGE-A4 286-305 .
[0230] In some implementations, the fusion protein contains MAGE-A3 in any possible order. 243-255 MAGE-A3 171-184 MAGE-A3 284-296 MAGE-A3167-176 MAGE-A3 192-202 MAGE-A3 302-311 MAGE-A3 70-81 MAGE-A3 160-171 MAGE-A3 143-151 MAGE-A4 136-155 MAGE-A4 168-179 MAGE-A4 190-199 MAGE-A4 77-89 MAGE-A4 300-308 MAGE-A4 175-183 MAGE-A4 262-272 MAGE-A4 222-246 MAGE-A4 109-117 MAGE-A4 205-218 MAGE-A4 155-168 AruMAGE-A4 266-274 MAGE-A4 73-83 MAGE-A6 196-204 MAGE-A6 194-202 MAGE-A6 231-241 Japanese MAGE-A6 243-255 .
[0231] Currently, we are planning a small implementation of MAGE-A3, which includes any possible order of fusion protein. 243-255 MAGE-A3 171-184 MAGE-A3 284-296 MAGE-A3 167-176 MAGE-A3 192-202 MAGE-A3 302-311 MAGE-A3 70-81 MAGE-A3 160-171 MAGE-A3 143-151 MAGE-A4 136-155 MAGE-A4 168-179 MAGE-A4 190-199 MAGE-A4 77-89 MAGE-A4 300-308 MAGE-A4 175-183 MAGE-A4 262-272 MAGE-A4 222-246 MAGE-A4 109-117 MAGE-A4 205-217 MAGE-A4 155-168 AruMAGE-A4 266-274 MAGE-A4 73-83 MAGE-A6196-204 MAGE-A6 194-202 MAGE-A6 231-241 and MAGE-A6 243-255 .
[0232] In some implementations, the fusion protein contains MAGE-A3 in any possible order. 243-255 MAGE-A3 171-184 MAGE-A3 284-296 MAGE-A3 167-176 MAGE-A3 192-202 MAGE-A3 302-311 MAGE-A3 70-81 MAGE-A3 160-171 MAGE-A3 143-151 MAGE-A4 168-179 MAGE-A4 190-199 MAGE-A4 77-89 MAGE-A4 300-308 MAGE-A4 175-183 MAGE-A4 262-272 MAGE-A4 222-246 MAGE-A4 109-117 MAGE-A4 205-218 MAGE-A4 155-168 Or MAGE-A4 266-274 MAGE-A4 73-83 MAGE-A6 196-204 MAGE-A6 194-202 MAGE-A6 231-241 and MAGE-A6 243-255 .
[0233] In some implementations, the fusion protein contains MAGE-A3 in any possible order. 243-255 MAGE-A3 171-184 MAGE-A3 284-296 MAGE-A3 167-176 MAGE-A3 192-202 MAGE-A3 302-311 MAGE-A3 70-81 MAGE-A4 168-179 MAGE-A4 190-199 MAGE-A4 77-89 MAGE-A4 300-308 MAGE-A4 175-183 MAGE-A4 262-272 MAGE-A4 222-246 MAGE-A4109-117 MAGE-A4 205-218 MAGE-A4 155-168 Or MAGE-A4 266-274 MAGE-A4 73-83 MAGE-A6 196-204 MAGE-A6 194-202 MAGE-A6 231-241 and MAGE-A6 243-255 .
[0234] In some implementations, the fusion protein contains MAGE-A4 from the N-terminus to the C-terminus. 136-155 MAGE-A6 196-204 MAGE-A4 168-179 MAGE-A4 190-199 MAGE-A6 194-202 MAGE-A3 243-255 MAGE-A4 77-89 MAGE-A3 171-184 MAGE-A4 300-308 MAGE-A4 175-183 MAGE-A6 231-241 MAGE-A3 284-296 MAGE-A4 262-272 MAGE-A4 222-246 MAGE-A3 167-176 MAGE-A3 192-202 MAGE-A4 109-117 MAGE-A4 205-218 MAGE-A4 73-83 MAGE-A4 155-168 MAGE-A3 302-311 MAGE-A6 243-255 MAGE-A4 266-274 MAGE-A3 70-81 MAGE-A3 160-171 and MAGE-A3 143-151 In some implementations, the fusion protein contains MAGE-A4 in any possible order. 136-155 MAGE-A6 196-204 MAGE-A4 168-179 MAGE-A4 190-199 MAGE-A6 194-202 MAGE-A3 243-255 MAGE-A4 77-89 MAGE-A3 171-184 MAGE-A4 300-308 MAGE-A4175-183 MAGE-A6 231-241 MAGE-A3 284-296 MAGE-A4 262-272 MAGE-A4 222-246 MAGE-A3 167-176 MAGE-A3 192-202 MAGE-A4 109-117 MAGE-A4 205-218 MAGE-A4 73-83 MAGE-A4 155-168 MAGE-A3 302-311 MAGE-A6 243-255 MAGE-A4 266-274 MAGE-A3 70-81 MAGE-A3 160-171 and MAGE-A3 143-151。
[0235] In some embodiments, at least two of the two or more CTA fragments of the fusion protein are linked by at least one linker. In some embodiments, at least two of the two or more CTA fragments of the fusion protein are covalently linked together without any linker between the two CTA fragments. In some embodiments, the linker comprises the amino acid sequence AAY (SEQ ID NO: 80), ALL (SEQ ID NO: 81), SSL (SEQ ID NO: 82), or RKSY (SEQ ID NO: 83).
[0236] In some embodiments, the fusion protein is encoded by a nucleotide sequence comprising a nucleotide sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with the sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, or SEQ ID NO: 22. In some embodiments, the fusion protein is encoded by a nucleotide sequence comprising the nucleotide sequences of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, or SEQ ID NO: 22.
[0237] In some embodiments, the fusion protein is encoded by a nucleotide sequence comprising a nucleotide sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with the sequence of SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, or SEQ ID NO: 115. In some embodiments, the fusion protein is encoded by a nucleotide sequence comprising the nucleotide sequences of SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, or SEQ ID NO: 115.
[0238] In some embodiments, the fusion protein comprises an amino acid sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with the amino acid sequence of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, or SEQ ID NO: 26.
[0239] In some embodiments, the nucleotide sequence encoding the fusion protein is engineered to reduce or remove any CpG islands and TpA islands. In some embodiments, the removal of CpG and TpA islands comprises three cycles: (i) removing CpG in a first cycle; (ii) removing TpA in a second cycle; and (iii) removing CpG in a third cycle to remove any CpG newly introduced in the second cycle.
[0240] Those skilled in the art will understand that the nucleotide sequence encoding the fusion protein disclosed herein can be a DNA sequence or its corresponding RNA sequence obtained by replacing each "T" in the DNA sequence with a "U". Therefore, when a DNA sequence is described in this disclosure encoding a fusion protein, those skilled in the art will understand that such disclosure also includes the corresponding RNA sequence used to encode the fusion protein.
[0241] 5.2 Sand-like virus particles
[0242] This disclosure also provides a sand-virus particle containing a sand-virus genome that includes at least one heterologous ORF encoding at least one fusion protein disclosed herein (e.g., the fusion protein disclosed in Section 5.1). In some embodiments, the sand-virus particle contains a sand-virus genome that includes two heterologous ORFs, each of which encodes a fusion protein disclosed herein (e.g., the fusion protein disclosed in Section 5.1). In some embodiments, the two fusion proteins encoded by the two ORFs are different. In some embodiments, the two fusion proteins encoded by the two ORFs are the same.
[0243] In some embodiments, the sand-like virus particles that can be engineered for use in the methods and compositions herein include the constructs listed below. In some embodiments, the sand-like virus construct is a non-replicating sand-like virus construct as described in International Patent Application Publication WO2009 / 083210 (the entire contents of which are incorporated herein) and Section 5.2.1 of this disclosure. In some embodiments, the sand-like virus construct is a replicating or non-replicating three-segmented sand-like virus construct as described in International Patent Application Publications WO2016 / 075250 and WO2021 / 089853 (both the entire contents of which are incorporated herein) and Sections 5.2.2 and 5.2.3 of this disclosure.
[0244] Arenaviruses that can be used with the subject matter disclosed in this invention include Old World viruses, such as, for example, Lassa virus, Lymphocytic choriomeningitis virus (LCMV), Mobara virus, Mopeya virus, or Ipi virus, or New World viruses, such as, for example, Amapari virus, Flexal virus, Guanarito virus, Junin virus, Latino virus, Machupo virus, Oliveros virus, Paraná virus, Pichind virus, Piritar virus, Sabia virus, Tacalib virus, Tamiyami virus, Bear Canyon virus, Alpawayo virus (ALLV), and Whitewater Arroyo virus. Arenaviruses that can be used with the subject matter disclosed in this invention include, for example, arenaviruses, mammalian arenaviruses, Old World mammalian arenaviruses, New World mammalian arenaviruses, New World mammalian arenaviruses of branch A, New World mammalian arenaviruses of branch B, New World mammalian arenaviruses of branch C, and New World mammalian arenaviruses of branch D. Arenaviruses that can be used with the subject matter disclosed in this invention include mammalian arenaviruses, including but not limited to: Alpawayovirus, Alashanvirus, Juninvirus, Bear Canyonvirus, Sabiavirus, Pichind virus, Chapare virus, Lijiang virus, Kupishi virus, Flexal virus, Guero virus, Guanarito virus, Epivirus, Lassa virus, Latino virus, Lefu River virus, Luyo virus, Luna virus, Luli virus, Renke virus, and lymphocytic choroid plexus meningitis. The following viruses are included: Machupo virus, Mariental virus, Merinowalk virus, Mobara virus, Mopeya virus, Morogoro virus, Okahandja virus, Oliveros virus, Paraná virus, Piritar virus, Apolé virus, Ryukyu virus, Amapari virus, Solvezi virus, Suri virus, Tacalib virus, Tamiyami virus, Wenzhou virus, Whitewater Arroyo virus, Great Brahitan virus, Katharina virus, Skinner tank virus, Tonto Creek virus, and Shapri virus. In some embodiments, the arenavirus used with the methods and compositions provided herein is lymphocytic choriomeningitis virus. In some embodiments, the arenavirus used with the methods and compositions provided herein is Pichind virus.
[0245] 5.2.1 Replication-defective sand-like virus particles
[0246] Exemplary replication-defective arenavirus particles are described, for example, in International Patent Application Publication WO2009 / 083210 (the entire contents of which are incorporated herein by reference). In some embodiments, this disclosure provides a replication-defective (e.g., underreplicated) arenavirus particle comprising an arenavirus genome, wherein the arenavirus genome contains a heterologous ORF encoding a fusion protein disclosed herein (e.g., the fusion protein disclosed in Section 5.1). In some embodiments, the replication-defective arenavirus particle comprises an arenavirus genome containing two heterologous ORFs, each of which encodes a fusion protein disclosed herein (e.g., the fusion protein disclosed in Section 5.1). In some embodiments, the fusion protein comprises two or more CTA fragments as described in Section 5.1.
[0247] In some embodiments, the replication-defective isovirus particles described herein are combined with the replicative isovirus particles described herein in the methods and compositions provided herein. In some embodiments, the replication-defective isovirus particles described herein are combined with the replicative isovirus particles described herein in the methods and compositions provided herein, wherein the replicative isovirus particles are directly injected into a tumor of a subject.
[0248] In some embodiments, this document provides a arenavirus particle in which the ORF encoding the GP, NP, Z, or L protein has been removed or functionally inactivated, such that the resulting virus cannot produce further infectious progeny virus particles. Arenavirus particles containing a genetically modified genome with one or more of these ORFs deleted or functionally inactivated can be produced in complementary cells (i.e., cells expressing the deleted or functionally inactivated arenavirus ORF). The genetic material of the resulting arenavirus particle can be transferred to a host cell after infecting a host cell, where the genetic material can be expressed and amplified.
[0249] In some embodiments, the heteronucleotide sequence contained in the arenavirus genome may be polycistronic, such that multiple polypeptides are ultimately produced from a single heteronucleotide sequence / transcript. This can be achieved, for example, using an internal ribosome entry site. In some embodiments, one such polypeptide may be a CTA fragment. In some embodiments, such a heteronucleotide sequence may encode a fusion protein comprising two or more CTA fragments (e.g., the fusion protein disclosed in Section 5.1).
[0250] In some embodiments, the ORF of the arenavirus is deleted or functionally inactivated, and replaced with a nucleotide sequence encoding a fusion protein comprising two or more CTA fragments (e.g., the fusion protein disclosed in Section 5.1). In one specific embodiment, the ORF encoding the arenavirus glycoprotein GP is deleted or functionally inactivated. In some embodiments, functional inactivation of the gene eliminates any translation product. In some embodiments, functional inactivation means allowing some genetic alterations to the translation, however the translation product is no longer functional and cannot replace the wild-type protein.
[0251] In some embodiments, at least one of the four arenavirus ORFs encoding the GP, NP, Z, and L proteins is removed and replaced with a nucleotide sequence encoding a fusion protein containing two or more CTA fragments (e.g., the fusion protein disclosed in Section 5.1). In a more specific embodiment, the ORF encoding the GP segment of the arenavirus genome is removed.
[0252] Therefore, in some embodiments, the sand-like virus particles provided herein contain genomic segments, wherein (i) the ORF encoding the GP, NP, Z, or L protein is removed; and (ii) the removed ORF is replaced with a nucleotide sequence encoding a fusion protein (e.g., the fusion protein disclosed in Section 5.1) containing two or more CTA fragments provided herein.
[0253] In some embodiments, growth in complementary cells and infectivity of sand virus particles are not affected by the nucleotide sequence encoding a fusion protein (e.g., the fusion protein disclosed in Section 5.1) that contains two or more CTA fragments provided herein.
[0254] In some embodiments, the sand-like virus particles described herein are suitable for use as vaccines, immunotherapies, or pharmaceutical compositions, and methods of using such sand-like virus particles to treat neoplastic diseases (e.g., cancer) are provided. A more detailed description of the methods of using the sand-like virus particles described herein is provided in Section 5.4 of this disclosure.
[0255] 5.2.2 Three-segmented sand-like virus particles with their ORF rearrangements
[0256] Exemplary three-segmented sand-like virus particles are described in, for example, international patent applications published WO 2016 / 075250 and WO2017 / 198726, the entire contents of which are incorporated herein by reference.
[0257] In some embodiments, a three-segmented isovirus particle having its ORF rearrangement and containing a nucleotide sequence encoding a fusion protein (e.g., the fusion protein disclosed in Section 5.1) comprising two or more CTA fragments provided herein can be used with the methods and compositions provided herein. In one aspect, a three-segmented isovirus particle is provided herein comprising one L segment and two S segments, or two L segments and one S segment. Methods of manufacture are described in Section 5.3.2. In some embodiments, replication of the three-segmented isovirus particle does not result in a replicating two-segmented isovirus particle. In other words, the three-segmented virus provided herein is genetically stable. More specifically, in some embodiments, two of these genomic segments (e.g., two S segments or two L segments, respectively) cannot recombine in a manner that produces a single viral segment that can replace the two parental segments. In some embodiments, intersegmental recombination of two of these genomic segments (e.g., two S segments or two L segments, respectively) merges the two arenavirus ORFs into only one, rather than two, separate segments, eliminating viral promoter activity. In a specific embodiment, the genome of the trisegmental arenavirus particle contains an arenavirus ORF located outside the wild-type position of the ORF, and a nucleotide sequence encoding a fusion protein (e.g., the fusion protein disclosed in Section 5.1) comprising two or more CTA fragments provided herein. In yet another specific embodiment, the genome of the trisegmental arenavirus particle contains all four arenavirus ORFs. Thus, in some embodiments, the trisegmental arenavirus particle is both replicative and infectious.
[0258] In some embodiments, the genome of this replicative and infectious trisegmental isovirus particle (Section 5.2.2) has two sites available for incorporating heteronucleotide sequences. These sites can be used to integrate heteronucleotide sequences, for example, as shown in Table 1 below. In some embodiments, each such heteronucleotide sequence can be transcribed into a single transcript. In some embodiments, each such heteronucleotide sequence encodes a polypeptide. In some embodiments, such heteronucleotide sequences can be polycistronic, such that multiple polypeptides are ultimately produced from a single heteronucleotide sequence / transcript. This can be achieved, for example, by using an internal ribosome entry site. In some embodiments, one such polypeptide can be a CTA fragment. In some embodiments, the heteronucleotide sequences at both available sites encode a fusion protein (e.g., the fusion protein disclosed in Section 5.1) containing two or more CTA fragments. In a specific embodiment, the heteronucleotide sequence at one of the two available positions encodes a first fusion protein (e.g., the fusion protein disclosed in Section 5.1) comprising two or more CTA fragments, and the heteronucleotide sequence at the other of the two available positions encodes a second fusion protein (e.g., the fusion protein disclosed in Section 5.1) comprising two or more CTA fragments. In some embodiments, the first and second fusion proteins are selected from the first and second fusion proteins described in Section 5.2.4.
[0259] In some embodiments, a three-segmented isanvirus particle (Section 5.2.2) having its ORF rearrangement containing a nucleotide sequence that does not encode a foreign antigen can be used with the methods and compositions provided herein. In a specific embodiment, the three-segmented isanvirus particle contains an ORF located outside the wild-type position of the ORF. In yet another specific embodiment, the three-segmented isanvirus particle contains ORFs from all four isanvirus species. Thus, in some embodiments, the three-segmented isanvirus particle is capable of replication and is infectious.
[0260] In some embodiments, the ORF encoding the GP, NP, Z, or L proteins of the three-segmented arenavirus particle described herein (Section 5.2.2) may be under the control of the arenavirus genome 3' UTR or the arenavirus genome 5' UTR. In a more specific embodiment, the arenavirus genome 3' UTR is the 3' UTR of the arenavirus S segment. In another specific embodiment, the arenavirus genome 3' UTR is the 3' UTR of the arenavirus L segment. In a more specific embodiment, the arenavirus genome 5' UTR is the 5' UTR of the arenavirus S segment. In other specific embodiments, the arenavirus genome 5' UTR is the 5' UTR of the arenavirus L segment.
[0261] In other embodiments, the ORF encoding the GP, NP, Z, or L proteins of the three-segmented arenavirus particles described herein (see Section 5.3.2 for manufacturing method) may be under the control of conserved terminal sequence elements of arenavirus (5'- and 3'-terminal 19-20-nt regions) (see, for example, Perez and de la Torre, 2003, J Virol.77(2): 1184–1194).
[0262] In some embodiments, the ORF encoding the GP, NP, Z, or L proteins of the three-segmented arenavirus particle (see Section 5.3.2 for manufacturing method) may be under the control of a 5' UTR promoter element (see, for example, Albariño et al., 2011, J Virol., 85(8):4020-4). In another embodiment, the ORF encoding the GP, NP, Z, or L proteins of the three-segmented arenavirus particle may be under the control of a 3' UTR promoter element (see, for example, Albariño et al., 2011, J Virol., 85(8):4020-4). In a more specific embodiment, the 5' UTR promoter element is an S-segment or L-segment 5' UTR promoter element. In another specific embodiment, the 3' UTR promoter element is an S-segment or L-segment 3' UTR promoter element.
[0263] In some embodiments, the ORF encoding the GP, NP, Z, or L proteins of the three-segmented arenavirus particle may be under the control of a truncated arenavirus 3' UTR or a truncated arenavirus 5' UTR (see, for example, Perez and de la Torre, 2003, J Virol. 77(2): 1184–1194; Albariño et al., 2011, J Virol., 85(8): 4020-4). In more specific embodiments, the truncated 3' UTR is derived from the 3' UTR of the arenavirus S segment or L segment. In more specific embodiments, the truncated 5' UTR is derived from the 5' UTR of the arenavirus S segment or L segment.
[0264] This document also provides a cDNA of a three-segmented arenavirus particle genome containing a nucleotide sequence encoding a fusion protein comprising two or more CTA fragments provided herein (e.g., the fusion protein disclosed in Section 5.1). In a more specific embodiment, this document provides various nucleic acids encoding the three-segmented arenavirus particle genome as shown in Table 1.
[0265] In some embodiments, the nucleic acid encoding the trisegmental arenavirus genome (see Section 5.2.2) is part of or incorporated into one or more DNA expression vectors. In one specific embodiment, the nucleic acid encoding the trisegmental arenavirus particle genome is part of or incorporated into one or more DNA expression vectors that facilitate the production of trisegmental arenavirus particles as described herein. In another embodiment, the cDNA described herein may be incorporated into a plasmid. Techniques for generating cDNA, as well as conventional and traditional techniques in molecular biology and DNA manipulation and production, including any cloning techniques known to those skilled in the art, may be used. Such techniques are well known and can be obtained by those skilled in the art from laboratory manuals such as Sambrook and Russell, Molecular Cloning: A laboratory Manual, 3rd edition, Cold Spring Harbor Laboratory N.Y. (2001).
[0266] This article provides cell lines, cultures, and methods for culturing cells transfected with the nucleic acids, vectors, and compositions provided herein.
[0267] In specific embodiments, the arenavirus particles described herein are attenuated. In one specific embodiment, the three-segmented arenavirus particles are attenuated such that the virus retains at least partial replicative capability and can replicate in vivo, but can only produce low viral loads, resulting in non-pathogenic subclinical infection levels. Such attenuated viruses can be used as immunogenic compositions.
[0268] In some implementations, the three-segmented isovirus particles have the same tropism as the two-segmented isovirus particles from which the three-segmented virus is derived.
[0269] This article also provides pharmaceutical compositions comprising three-segmented sand virus particles as described herein.
[0270] (a) A three-segmented isovirus particle containing one L segment and two S segments.
[0271] In one aspect, this document provides a three-segmented isovirus particle comprising one L segment and two S segments. In some embodiments, replication of the three-segmented isovirus particle comprising one L segment and two S segments does not result in a replicating two-segmented virus particle.
[0272] Specifically, the genome of a three-segmented arenavirus particle comprises an L segment and two S segments, wherein a nucleotide sequence encoding a fusion protein comprising two or more CTA fragments as provided herein is inserted at a position on each S segment. More specifically, one S segment encodes arenavirus NP and a first fusion protein comprising two or more CTA fragments (e.g., the fusion protein disclosed in Section 5.1 or Section 5.2.4). The other S segment encodes arenavirus GP and a second fusion protein comprising two or more CTA fragments (e.g., the fusion protein disclosed in Section 5.1 or Section 5.2.4). The L segment encodes arenavirus L and Z proteins. Each segment has a 5' UTR and a 3' UTR flanking it. In some embodiments, the first and second fusion proteins are selected from the first and second fusion proteins described in Section 5.2.4, or the fusion proteins described in Section 5.1.
[0273] More specifically, this article provides a sand-like virus comprising:
[0274] (i) A first S segment containing a nucleotide sequence encoding a fusion protein comprising two or more CTA fragments (e.g., the fusion protein disclosed in Section 5.1, such as the first fusion protein described in Section 5.2.4) under the control of the 5' UTR of the arenavirus genome, and an ORF encoding the arenavirus nucleoprotein (“NP”) under the control of the 3' UTR of the arenavirus genome; and
[0275] (ii) A second S segment comprising a nucleotide sequence encoding a fusion protein comprising two or more CTA fragments (e.g., the fusion protein disclosed in Section 5.1, such as the second fusion protein described in Section 5.2.4) under the control of the 5' UTR of the arenavirus genome, and an ORF encoding an arenavirus glycoprotein (“GP”) under the control of the 3' UTR of the arenavirus genome; and
[0276] (iii) L segment.
[0277] In some implementations, the intersegmental recombination of the two S segments of the three-segmented arenavirus particle provided herein merges the two arenavirus ORFs into one rather than two separate segments, resulting in a nonfunctional promoter (i.e., a genomic segment with the following structure: 5' UTR-----------5' UTR or 3' UTR------------3' UTR), wherein each UTR forming one end of the genome is an inverted repeat sequence at the other end of the same genome.
[0278] In some embodiments, the trisegmental isovirus particle comprising one L segment and two S segments has been engineered to carry an isovirus ORF located outside the wild-type position of the ORF and a nucleotide sequence encoding a fusion protein (e.g., the fusion protein disclosed in Section 5.1) comprising two or more CTA fragments provided herein. In other embodiments, the trisegmental isovirus particle comprising one L segment and two S segments has been engineered to carry two, three, four, five, or six isovirus ORFs located outside their respective wild-type positions. In a specific embodiment, the trisegmental isovirus particle comprising one L segment and two S segments contains complete complementarity to all four isovirus ORFs. Thus, in some embodiments, the trisegmental isovirus particle is an infectious and replicative trisegmental isovirus particle. In a specific embodiment, the two S segments of the trisegmental isovirus particle have been engineered to carry one of its ORFs outside the wild-type position. In more specific implementations, the two S segments contain complete complementarity to the S segment ORF. In some specific implementations, the L segment has been engineered to carry an ORF located outside the wild-type location, or the L segment may be a wild-type genome segment.
[0279] In some implementations, one of these two S segments can be:
[0280] (i) The S segment of the arenavirus, in which the ORF encoding the Z protein is under the control of the 5' UTR of the arenavirus genome;
[0281] (ii) The S segment of the arenavirus, in which the ORF encoding the L protein is under the control of the 5' UTR of the arenavirus genome;
[0282] (iii) The S segment of the arenavirus, in which the ORF encoding NP is under the control of the 5' UTR of the arenavirus genome;
[0283] (iv) The S segment of the arenavirus, in which the ORF encoding GP is under the control of the 3' UTR of the arenavirus genome;
[0284] (v) The isanoxic S segment, in which the ORF encoding the L protein is controlled by the 3' UTR of the isanoxic genome; or
[0285] (vi) The S segment of the isopyrvirus, in which the ORF encoding the Z protein is under the control of the 3' UTR of the isopyrvirus genome.
[0286] In some embodiments, a trisegmental isovirus particle containing one L segment and two S segments may contain duplicated isovirus ORFs (i.e., two wild-type ORFs encoding, for example, GP or NP). In specific embodiments, a trisegmental isovirus particle containing one L segment and two S segments may contain one duplicated ORF (e.g., (GP, GP)) or two duplicated ORFs (e.g., (GP, GP) and (NP, NP)).
[0287] Those skilled in the art will understand that when a nucleotide sequence is described as part of a sand virus genome, if the described SEQ ID NO is a DNA sequence, then the described nucleotide sequence is an RNA sequence in which each "T" in the corresponding described SEQ ID NO is replaced with a "U".
[0288] In some implementations, the arenavirus genome includes:
[0289] (i) The first S segment, comprising the nucleotide sequence of SEQ ID NO: 1 under the control of the 5' UTR of the arenavirus genome, and the ORF encoding the arenavirus nucleoprotein (“NP”) under the control of the 3' UTR of the arenavirus genome; and
[0290] (ii) The second S segment, comprising the nucleotide sequence of SEQ ID NO: 2 under the control of the 5' UTR of the arenavirus genome, and the ORF encoding the arenavirus glycoprotein (“GP”) under the control of the 3' UTR of the arenavirus genome; and
[0291] (iii) L segment.
[0292] In some implementations, the arenavirus genome includes:
[0293] (i) The first S segment, comprising the nucleotide sequence of SEQ ID NO: 3 under the control of the 5' UTR of the arenavirus genome, and the ORF encoding the arenavirus nucleoprotein (“NP”) under the control of the 3' UTR of the arenavirus genome; and
[0294] (ii) The second S segment, comprising the nucleotide sequence of SEQ ID NO: 4 under the control of the 5' UTR of the arenavirus genome, and the ORF encoding the arenavirus glycoprotein (“GP”) under the control of the 3' UTR of the arenavirus genome; and
[0295] (iii) L segment.
[0296] In some implementations, the arenavirus genome includes:
[0297] (i) The first S segment, comprising the nucleotide sequence of SEQ ID NO: 5 under the control of the 5' UTR of the arenavirus genome, and the ORF encoding the arenavirus nucleoprotein (“NP”) under the control of the 3' UTR of the arenavirus genome; and
[0298] (ii) The second S segment, comprising the nucleotide sequence of SEQ ID NO: 6 under the control of the 5' UTR of the arenavirus genome, and the ORF encoding the arenavirus glycoprotein (“GP”) under the control of the 3' UTR of the arenavirus genome; and
[0299] (iii) L segment.
[0300] In some implementations, the arenavirus genome includes:
[0301] (i) The first S segment, comprising the nucleotide sequence of SEQ ID NO: 100 under the control of the 5' UTR of the arenavirus genome, and the ORF encoding the arenavirus nucleoprotein (“NP”) under the control of the 3' UTR of the arenavirus genome; and
[0302] (ii) The second S segment, comprising the nucleotide sequence of SEQ ID NO: 101 under the control of the 5' UTR of the arenavirus genome, and the ORF encoding the arenavirus glycoprotein (“GP”) under the control of the 3' UTR of the arenavirus genome; and
[0303] (iii) L segment.
[0304] In some implementations, the arenavirus genome includes:
[0305] (i) The first S segment, comprising the nucleotide sequence of SEQ ID NO: 102 under the control of the 5' UTR of the arenavirus genome, and the ORF encoding the arenavirus nucleoprotein (“NP”) under the control of the 3' UTR of the arenavirus genome; and
[0306] (ii) The second S segment, comprising the nucleotide sequence of SEQ ID NO: 103 under the control of the 5' UTR of the arenavirus genome, and the ORF encoding the arenavirus glycoprotein (“GP”) under the control of the 3' UTR of the arenavirus genome; and
[0307] (iii) L segment.
[0308] In some implementations, the arenavirus genome includes:
[0309] (i) The first S segment, comprising the nucleotide sequence of SEQ ID NO: 104 under the control of the 5' UTR of the arenavirus genome, and the ORF encoding the arenavirus nucleoprotein (“NP”) under the control of the 3' UTR of the arenavirus genome; and
[0310] (ii) The second S segment, comprising the nucleotide sequence of SEQ ID NO: 105 under the control of the 5' UTR of the arenavirus genome, and the ORF encoding the arenavirus glycoprotein (“GP”) under the control of the 3' UTR of the arenavirus genome; and
[0311] (iii) L segment.
[0312] Table 1 below is a diagram of the genome organization of a trisegmental arenavirus particle containing one L segment and two S segments, wherein intersegmental recombination of the two S segments in the trisegmental arenavirus genome does not produce a replicating bisegmental virus particle and eliminates arenavirus promoter activity (i.e., the resulting recombinant S segment consists of two 3' UTRs instead of one 3' UTR and one 5' UTR).
[0313] Table 1 shows three-segmented arenavirus particles containing one L segment and two S segments.
[0314] Location 1 is under the control of the 5' UTR of the S segment of the sand virus; Location 2 is under the control of the 3' UTR of the S segment of the sand virus; Location 3 is under the control of the 5' UTR of the S segment of the sand virus; Location 4 is under the control of the 3' UTR of the S segment of the sand virus; Location 5 is under the control of the 5' UTR of the L segment of the sand virus; Location 6 is under the control of the 3' UTR of the L segment of the sand virus.
[0315] ORF indicates that the nucleotide sequence encoding a fusion protein containing two or more CTA fragments provided herein has been inserted.
[0316]
[0317] In some embodiments, the IGR between position one and position two can be an isopyrvirus S-segment or L-segment IGR; the IGR between position three and position four can be an isopyrvirus S-segment or L-segment IGR; and the IGR between position five and position six can be an isopyrvirus L-segment IGR. In one specific embodiment, the IGR between position one and position two can be an isopyrvirus S-segment IGR; the IGR between position three and position four can be an isopyrvirus S-segment IGR; and the IGR between position five and position six can be an isopyrvirus L-segment IGR. In some embodiments, other combinations are also possible. For example, a trisegmental isopyrvirus particle comprising one L-segment and two S-segments, wherein intersegmental recombination of the two S-segments in the trisegmental isopyrvirus genome does not produce a replicative bisegmental virus particle and eliminates isopyrvirus promoter activity (i.e., the resulting recombinant S-segment consists of two 5' UTRs instead of one 3' UTR and one 5' UTR).
[0318] In some embodiments, in a trisegmental arenavirus particle containing one L segment and two S segments, intersegmental recombination of the S and L segments restores a functional segment such that the two viral genes are located on only one segment, rather than on two separate segments. In other embodiments, in a trisegmental arenavirus particle containing one L segment and two S segments, intersegmental recombination of the S and L segments does not produce a replicating bisegmental virus particle.
[0319] In some implementations, those skilled in the art can construct a sand-like virus genome having the organization shown in Table 1 and as described herein, and then use the assays described in Section 5.6 to determine whether the three-segmented sand-like virus particles are genetically stable, i.e., do not produce replicating two-segmented virus particles as discussed herein.
[0320] 5.2.3 Splitting Sand-like Virus Vector Particles
[0321] Arenaviruses can also be engineered in accordance with the manner described in International Patent Application Publications WO 2021 / 089853 and WO 2022 / 238546 (the full text of which is incorporated herein by reference). This technique is also known as “split” vector technology. Similar to the three-segmented viruses described above, the techniques described in WO 2021 / 089853 and WO 2022 / 238546 can be used to generate three-segmented viruses having two open positions for heteronucleotide sequences. Such heteronucleotide sequences can encode polypeptides. In some embodiments, such heteronucleotide sequences can encode fusion proteins comprising two or more CTA fragments (e.g., the fusion proteins disclosed in Section 5.1).
[0322] In short, such "split" arenavirus particles are engineered so that the arenavirus ORF is separated across two or more mRNA transcripts. In some embodiments, this document provides an arenavirus genome or antigenome segment engineered to transcribe into one or more mRNA transcripts containing nucleotide sequences encoding functional fragments of arenavirus GP, NP, L, or Z proteins.
[0323] In some embodiments, the ORF encoding the arenavirus GP is separately delimited (or split) on two mRNA transcripts and at two locations on the arenavirus genome. For example, the arenavirus GP signal peptide or a functional fragment thereof may be expressed from a first mRNA transcript (e.g., a viral mRNA transcript), and the arenavirus GP1 and GP2 subunits may be expressed from a second mRNA transcript (e.g., a viral mRNA transcript). In some embodiments, the first mRNA transcript is under the control of the arenavirus 3' genomic UTR. In some embodiments, the second mRNA transcript also encodes a heterologous non-arenavirus signal peptide (such as the signal peptide of the vesicular stomatitis virus Indiana serotype glycoprotein). In some embodiments, the first mRNA transcript also contains a nucleotide sequence encoding a fusion protein comprising two or more CTA fragments (e.g., the fusion protein disclosed in Section 5.1).
[0324] In some implementations, the genome organization of such a "split" sand-like viral vector is as follows:
[0325] First S segment: The arenavirus GP1 and GP2 subunits are fused with a heterologous signal peptide and are under the control of the arenavirus genome 5'UTR; the arenavirus GP signal peptide is fused with a nucleotide sequence encoding a fusion protein containing two or more CTA fragments (e.g., the fusion protein disclosed in Section 5.1) and is under the control of the arenavirus genome 3'UTR.
[0326] The second S segment: a nucleotide sequence encoding a fusion protein containing two or more CTA fragments (e.g., the fusion protein disclosed in Section 5.1), under the control of the 5' UTR of the arenavirus genome, and an ORF encoding a nucleoprotein (“NP”), under the control of the 3' UTR of the arenavirus genome.
[0327] L segment: The arenavirus Z protein is controlled by the 5' UTR of the arenavirus genome; the arenavirus L protein is controlled by the 3' UTR of the arenavirus genome.
[0328] In some embodiments, the nucleotide sequence encoding a fusion protein containing two or more CTA fragments on the first S segment is different from the nucleotide sequence encoding a fusion protein containing two or more CTA fragments on the second S segment. In other embodiments, the nucleotide sequence encoding a fusion protein containing two or more CTA fragments on the first S segment is the same as the nucleotide sequence encoding a fusion protein containing two or more CTA fragments on the second S segment.
[0329] In some embodiments, the fusion protein encoding two or more CTA fragments on the first S segment is different from the fusion protein encoding two or more CTA fragments on the second S segment. In some embodiments, one of the two fusion proteins on the first S segment and the second S segment is a first fusion protein, and the other is a second fusion protein, and the first and second fusion proteins are selected from the first and second fusion proteins described in Section 5.2.4, or the fusion proteins described in Section 5.1. In some embodiments, the fusion protein encoding two or more CTA fragments on the first S segment is the same as the fusion protein encoding two or more CTA fragments on the second S segment.
[0330] 5.2.4 The first and second fusion proteins encoded by heterologous ORFs contained in the arenavirus genome
[0331] In some embodiments, the first fusion protein encoded by the first heterologous ORF disclosed herein is different from the second fusion protein encoded by the second heterologous ORF disclosed herein, wherein the arenavirus genome disclosed herein contains both the first heterologous ORF and the second heterologous ORF. In some embodiments, the first fusion protein encoded by the first heterologous ORF disclosed herein is the same as the second fusion protein encoded by the second heterologous ORF disclosed herein, wherein the arenavirus genome disclosed herein contains both the first heterologous ORF and the second heterologous ORF.
[0332] In some embodiments, the two or more CTA fragments of the first fusion protein comprise at least one PRAME fragment, at least one MAGE-A3 fragment, at least one MAGE-A4 fragment, and at least one MAGE-A6 fragment.
[0333] The amino acid sequences of the exemplary PRAME, MAGE-A3, MAGE-A4 and MAGE-A6 fragments disclosed herein are provided in Section 7.
[0334] In some embodiments, at least one PRAME fragment of the first fusion protein is selected from the group consisting of: PRAME 3-13 PRAME 7-23 PRAME73-82 PRAME 84-95 PRAME 123-141 PRAME 150-161 PRAME 166-178 PRAME 210-230 PRAME 224-232 PRAME 237-250 PRAME 248-256 PRAME 267-277 PRAME 278-292 PRAME 315-327 PRAME 325-334 PRAME 425-433 PRAME 435-443 PRAME 445-458 PRAME 472-491 PRAME 485-509 and combinations thereof. In some embodiments, at least one MAGE-A3 fragment of the first fusion protein contains MAGE-A3. 135-149 In some embodiments, at least one MAGE-A4 fragment of the first fusion protein contains MAGE-A4. 112-121 and / or MAGE-A4 286-305 In some embodiments, at least one MAGE-A6 fragment of the first fusion protein contains MAGE-A6. 167-184 .
[0335] In some embodiments, two or more CTA fragments of the first fusion protein contain PRAME. 3-13 PRAME 7-23 PRAME 73-82 PRAME 84-95 PRAME 123-141 PRAME 150-161 PRAME 166-178 PRAME 210-230 PRAME 224-232 PRAME 237-250 PRAME 248-256 PRAME 267-277 PRAME 278-292 PRAME 315-327 PRAME 325-334 PRAME 425-433 PRAME 435-443 PRAME 445-458 PRAME 472-491 PRAME 485-509 MAGE-A3 135-149 MAGE-A4 112-121MAGE-A4 286-305 and MAGE-A6 167-184 In some implementations, two or more CTA fragments are arranged in any order within the first fusion protein.
[0336] In some embodiments, the two or more CTA fragments of the second fusion protein comprise at least one MAGE-A3 fragment, at least one MAGE-A4 fragment, and at least one MAGE-A6 fragment. In some embodiments, the at least one MAGE-A3 fragment of the second fusion protein is selected from the group consisting of: MAGE-A3 243-255 MAGE-A3 171-184 MAGE-A3 284-296 MAGE-A3 167-176 MAGE-A3 192-202 MAGE-A3 302-311 MAGE-A3 70-81 MAGE-A3 160-171 MAGE-A3 143-151 And combinations thereof. In some embodiments, at least one MAGE-A4 fragment of the second fusion protein is selected from the group consisting of: MAGE-A4 136-155 MAGE-A4 168-179 MAGE-A4 190-199 MAGE-A4 77-89 MAGE-A4 300-308 MAGE-A4 175-183 MAGE-A4 262-272 MAGE-A4 222-246 MAGE-A4 109-117 MAGE-A4 205-218 MAGE-A4 205-217 MAGE-A4 155-168 Or MAGE-A4 266-274 MAGE-A4 73-83 And combinations thereof. In some embodiments, at least one MAGE-A6 fragment of the second fusion protein is selected from the group consisting of: MAGE-A6 196-204 MAGE-A6 194-202 MAGE-A6 231-241 MAGE-A6 243-255 , and their combinations.
[0337] In some embodiments, two or more CTA fragments of the second fusion protein contain MAGE-A3. 243-255 MAGE-A3 171-184 MAGE-A3284-296 MAGE-A3 167-176 MAGE-A3 192-202 MAGE-A3 302-311 MAGE-A3 70-81 MAGE-A3 160-171 MAGE-A3 143-151 MAGE-A4 136-155 MAGE-A4 168-179 MAGE-A4 190-199 MAGE-A4 77-89 MAGE-A4 300-308 MAGE-A4 175-183 MAGE-A4 262-272 MAGE-A4 222-246 MAGE-A4 109-117 MAGE-A4 205-218 MAGE-A4 155-168 AruMAGE-A4 266-274 MAGE-A4 73-83 MAGE-A6 196-204 MAGE-A6 194-202 MAGE-A6 231-241 Japanese MAGE-A6 243-255 . Currently, there is a plan to implement a second fusion protein containing two or more CTA single-stage MAGE-A3. 243-255 MAGE-A3 171-184 MAGE-A3 284-296 MAGE-A3 167-176 MAGE-A3 192-202 MAGE-A3 302-311 MAGE-A3 70-81 MAGE-A3 160-171 MAGE-A3 143-151 MAGE-A4 136-155 MAGE-A4 168-179 MAGE-A4 190-199 MAGE-A4 77-89 MAGE-A4 300-308 MAGE-A4 175-183 MAGE-A4 262-272 MAGE-A4 222-246 MAGE-A4 109-117 MAGE-A4 205-217 MAGE-A4 155-168 AruMAGE-A4 266-274 MAGE-A4 73-83 MAGE-A6196-204 MAGE-A6 194-202 MAGE-A6 231-241 and MAGE-A6 243-255 In some embodiments, two or more CTA fragments of the second fusion protein contain MAGE-A3. 243-255 MAGE-A3 171-184 MAGE-A3284296, MAGE-A3 167-176 MAGE-A3 192-202 MAGE-A3 302-311 MAGE-A3 70-81 MAGE-A3 160-171 MAGE-A3 143-151 MAGE-A4 168-179 MAGE-A4 190-199 MAGE-A4 77-89 MAGE-A4 300-308 MAGE-A4 175-183 MAGE-A4 262-272 MAGE-A4 222-246 MAGE-A4 109-117 MAGE-A4 205-218 MAGE-A4 155-168 Or MAGE-A4 266-274 MAGE-A4 73-83 MAGE-A6 196-204 MAGE-A6 194-202 MAGE-A6 231-241 and MAGE-A6 243-255 In some embodiments, two or more CTA fragments of the second fusion protein contain MAGE-A3. 243-255 MAGE-A3 171-184 MAGE-A3 284-296 MAGE-A3 167-176 MAGE-A3 192-202 MAGE-A3 302-311 MAGE-A3 70-81 MAGE-A4 168-179 MAGE-A4 190-199 MAGE-A4 77-89 MAGE-A4 300-308 MAGE-A4 175-183 MAGE-A4 262-272 MAGE-A4 222-246 MAGE-A4 109-117 MAGE-A4 205-218 MAGE-A4155-168 Or MAGE-A4 266-274 MAGE-A4 73-83 MAGE-A6 196-204 MAGE-A6 194-202 MAGE-A6 231-241 and MAGE-A6 243-255 In some implementations, two or more CTA fragments are arranged in any order in the second fusion protein.
[0338] In some embodiments, at least two of the two or more CTA fragments of the first fusion protein and / or the second fusion protein are linked by at least one adapter. In some embodiments, at least two of the two or more CTA fragments of the first fusion protein and / or the second fusion protein are covalently linked without using an adapter. In some embodiments, at least one adapter contains the amino acid sequence AAY (SEQ ID NO: 80), ALL (SEQ ID NO: 81), SSL (SEQ ID NO: 82), or RKSY (SEQ ID NO: 83).
[0339] In some embodiments, the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 7, SEQ ID NO: 9, or SEQ ID NO: 11.
[0340] In some embodiments, the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, or SEQ ID NO: 26. In some embodiments, the second fusion protein comprises the amino acid sequence of SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, or SEQ ID NO: 26.
[0341] In some embodiments, the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 7, and the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 8. In some embodiments, the first fusion protein comprises the amino acid sequence of SEQ ID NO: 7, and the second fusion protein comprises the amino acid sequence of SEQ ID NO: 8.
[0342] In some embodiments, the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 9, and the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 10. In some embodiments, the first fusion protein comprises the amino acid sequence of SEQ ID NO: 9, and the second fusion protein comprises the amino acid sequence of SEQ ID NO: 10.
[0343] In some embodiments, the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 11, and the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 12. In some embodiments, the first fusion protein comprises the amino acid sequence of SEQ ID NO: 11, and the second fusion protein comprises the amino acid sequence of SEQ ID NO: 12.
[0344] In some embodiments, the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 7, and the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 23. In some embodiments, the first fusion protein comprises the amino acid sequence of SEQ ID NO: 7, and the second fusion protein comprises the amino acid sequence of SEQ ID NO: 23.
[0345] In some embodiments, the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 7, and the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 25. In some embodiments, the first fusion protein comprises the amino acid sequence of SEQ ID NO: 7, and the second fusion protein comprises the amino acid sequence of SEQ ID NO: 25.
[0346] In some embodiments, the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 9, and the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 24. In some embodiments, the first fusion protein comprises the amino acid sequence of SEQ ID NO: 9, and the second fusion protein comprises the amino acid sequence of SEQ ID NO: 24.
[0347] In some embodiments, the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 9, and the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 26. In some embodiments, the first fusion protein comprises the amino acid sequence of SEQ ID NO: 9, and the second fusion protein comprises the amino acid sequence of SEQ ID NO: 26.
[0348] 5.3 Production of Sand-like Virus Particles
[0349] Generally, the sand-like virus particles used in the methods and compositions provided herein can be recombined using standard reverse genetics techniques, as described for LCMV (see Flatz et al., 2006, Proc Natl Acad SciUSA 103:4663-4668; Sanchez et al., 2006, Virology 350:370; Ortiz-Riano et al., 2013, JGen Virol.94:1175-88, these references are incorporated herein by reference). To generate the sand-like virus particles provided herein, these techniques can be applied as described below. The viral genome can be modified as described herein.
[0350] 5.3.1 Generation of Replication-Defective Sand-like Virus Particles
[0351] Sandworm particles engineered to contain a genome capable of amplifying and expressing their genetic information in infected cells but unable to produce further infectious progeny particles in normal, non-complementary cells, wherein a sandworm open reading frame is removed and replaced with a nucleotide sequence encoding a fusion protein containing two or more CTA fragments (e.g., the fusion protein disclosed in Section 5.1), can be recombined using any reverse genetics technique known to those skilled in the art.
[0352] In some embodiments, the method for generating infectious replication-defective arenavirus particles includes (i) transfecting cDNA of a first arenavirus genome segment into a complementary host cell (the complementary host cell expressing an open reading frame that is deleted or functionally inactivated in the genome segment); (ii) transfecting cDNA of a second arenavirus genome segment into the host cell; (iii) transfecting a plasmid expressing the minimal trans-acting factors NP and L of arenavirus into the host cell; (iv) maintaining the host cell under conditions suitable for virogenesis; and (v) harvesting the arenavirus particles. In some more specific embodiments, the cDNA is contained within a plasmid.
[0353] Once generated from cDNA, infectious replication-defective arenaviruses can multiply in complementary cells. Complementary cells are cells that provide functionality that has been eliminated from replication-defective arenaviruses through genomic modifications (e.g., if the ORF encoding the GP protein is missing or functionally inactivated, the complementary cell provides the GP protein).
[0354] Due to the removal or functional inactivation of one or more ORFs in the arenavirus vector (e.g., the deletion of glycoprotein GP in this example), the arenavirus vector can be generated and amplified in cells that trans-provide the missing viral gene (e.g., GP in this example). Such complementary cell lines, hereinafter referred to as C-cells, are generated by transfecting cell lines (such as BHK-21, HEK 293, VERO, or others) with one or more plasmids (complementary plasmids, referred to as C-plasmids) for expressing the viral gene of interest. The C-plasmid expresses the missing viral gene in the arenavirus vector to be generated under the control of one or more expression cassettes suitable for expression in mammalian cells (e.g., mammalian polymerase II promoters with polyadenylation signals, such as the EF1α promoter). In addition, the complementary plasmid has a mammalian selection marker, such as puromycin resistance, under the control of an expression cassette suitable for gene expression in mammalian cells (e.g., polymerase II expression cassettes as described above), or a viral gene transcript followed by an internal ribosome entry site (such as the internal ribosome entry site of encephalomyocytic virus), followed by a mammalian resistance marker. To be produced in Escherichia coli (E. coli), the plasmid also has bacterial selection markers, such as ampicillin resistance cassettes.
[0355] Usable cells (e.g., BHK-21, HEK 293, MC57G, or others) are maintained in culture and transfected with complementary plasmids using any common strategy (such as calcium phosphate, liposome-based protocols, or electroporation). After a few days, a suitable selector, such as puromycin, is added at a titrated concentration. Viable clones are isolated and subcloned according to standard procedures, and C-cell clones with high expression are identified by Western blotting or flow cytometry using antibodies against the viral proteins of interest. As an alternative to using stably transfected C-cells, transient transfection with normal cells can supplement the missing viral genes in each step below using C-cells. Additionally, helper viruses can be used to trans-conjugate the missing functions.
[0356] In some implementations, complementary host cells are maintained in culture and transfected with one or more plasmids. The plasmids encode segments of the arenavirus genome of the arenavirus particles to be produced, and are under the control of polymerase I promoters and terminators.
[0357] Plasmids that can be used to generate arenavirus particles may include: i) plasmids encoding the S genome segment, such as pol-I S, and ii) plasmids encoding the L genome segment, such as pol-I L. In some embodiments, plasmids encoding arenavirus polymerases that direct the intracellular synthesis of viral L and S segments may be incorporated into the transfection mixture. For example, plasmids encoding the L protein and / or plasmids encoding NP (pC-L and pC-NP, respectively) may be present. The L protein and NP are minimal trans-acting factors essential for viral RNA transcription and replication. Alternatively, the intracellular synthesis of viral L and S segments, along with NP and L protein, may be performed using an expression cassette having pol-I and pol-II promoters that read L and S segment cDNAs from two separate plasmids from opposite sides.
[0358] Typically, RNA polymerase I-driven expression cassettes, RNA polymerase II-driven cassettes, or T7 phage RNA polymerase-driven cassettes can be used, the latter preferably containing a 3'-terminal ribozyme for processing the primary transcript to produce the correct ends. In some embodiments, the plasmids encoding arenavirus genome segments can be identical; that is, the genome sequence and trans-acting factors can be transcribed from T7, polI, and polII promoters of a single plasmid.
[0359] In other embodiments, transcription of the arenavirus genome segment is performed using a bidirectional expression cassette (see, for example, Ortiz-Riaño et al., 2013, J Gen Virol., 94 (part 6): 1175–1188). In a more specific embodiment, the bidirectional expression cassette contains both a polymerase I promoter and a polymerase II promoter, which are read from opposite sides of the two ends of the inserted arenavirus genome segment.
[0360] In other embodiments, transcription of the cDNA of the arenavirus genome segment described herein includes a promoter. Specific examples of promoters include RNA polymerase I promoter, RNA polymerase II promoter, RNA polymerase III promoter, T7 promoter, SP6 promoter, or T3 promoter.
[0361] To recover the sand-like virus particles described herein, the following procedure is envisioned. Day 1: As described above, transfect complementary cells with a plasmid mixture. For this, any commonly used strategy can be employed, such as calcium phosphate, liposome-based protocols, or electroporation.
[0362] Three to five days later: Harvest the cell suspension (i.e., cells and culture medium). Arenavirus particles present in the culture medium are removed from the cells and debris by centrifugation, and the supernatant (i.e., the arenavirus vector preparation) is aliquoted and stored at 4°C, -20°C, or -80°C. The infection titer of the arenavirus vector preparation is assessed by immunofocal assay. Alternatively, transfected cells and supernatant may be passaged into larger containers three to five days post-transfection, and the vector may be harvested up to five days post-passage, as previously described.
[0363] 5.3.2 Production of three-segmented, replicating sand-like virus particles
[0364] Three-segmented sand-like virus particles containing a genomic segment of a viral ORF that has been engineered to carry a position other than the wild-type position of the ORF and also containing a nucleotide sequence encoding a fusion protein comprising two or more CTA fragments (e.g., the fusion protein disclosed in Section 5.1 or Section 5.2.4) can be recombined using reverse genetics techniques known in the art, for example, as described in Emonet et al., 2008, PNAS, 106(9):3473-3478; Popkin et al., 2011, J. Virol., 85(15):7928–7932, which are incorporated herein by reference. The vector systems described in Sections 5.2.2 and 5.2.3 can be generated using the methods described in this section.
[0365] In some embodiments, the method for generating three-segmented arenavirus particles includes (i) transfecting a host cell with cDNA of one arenavirus L segment and two arenavirus S segments, or two arenavirus L segments and one arenavirus S segment; (ii) transfecting the host cell with a plasmid expressing the minimal trans-acting factors NP and L proteins of arenavirus; (iii) maintaining the host cell under conditions suitable for virogenesis; and (iv) harvesting the arenavirus particles. In some more specific embodiments, the cDNA of the arenavirus S and L segments is contained in a plasmid.
[0366] Once generated from cDNA, the three-segmented arenavirus particles (i.e., those with infectious and replicative capabilities) can multiply. In some embodiments, the three-segmented arenavirus particles can multiply in any host cell that allows the virus to grow to a titer that permits the viral use as described herein. In one embodiment, the host cell allows the three-segmented arenavirus particles to grow to a titer equivalent to that determined for the corresponding wild type.
[0367] In some embodiments, the three-segmented isovirus particles can multiply within host cells. Specific examples of host cells that can be used include BHK-21, HEK 293, VERO, or others. In one specific embodiment, the three-segmented isovirus particles can multiply in a cell line.
[0368] In some implementations, the host cell is maintained in culture and transfected with one or more plasmids. The plasmid encodes a segment of the isovirus genome of the isovirus particle to be produced, under the control of a polymerase I promoter and terminator.
[0369] In a specific implementation, the host cell is maintained in culture and transfected with one or more plasmids. The plasmid encodes the viral protein to be produced under the control of one or more expression cassettes suitable for expression in mammalian cells (e.g., consisting of a polymerase II promoter and a terminator).
[0370] Plasmids that can be used to generate a trisegmental arenavirus containing one L segment and two S segments may include: i) two plasmids, each encoding an S genome segment, such as pol-I S; ii) a plasmid encoding an L genome segment, such as pol-I L. The plasmids required to generate a trisegmental arenavirus containing two L segments and one S segment are: i) two plasmids, each encoding an L genome segment, such as pol-L; ii) a plasmid encoding an S genome segment, such as pol-I S.
[0371] In some embodiments, plasmids encoding arenavirus polymerases that guide the intracellular synthesis of viral L and S segments can be incorporated into the transfection mixture. For example, plasmids encoding the L protein and NP (pC-L and pC-NP, respectively) can be used. The L protein and NP are minimal trans-acting factors essential for viral RNA transcription and replication. Alternatively, the intracellular synthesis of viral L and S segments, along with NP and the L protein, can be performed using an expression cassette having pol-I and pol-II promoters that read the L and S segment cDNAs of two separate plasmids from opposite sides.
[0372] In addition, the plasmid contains mammalian selection markers, such as puromycin resistance, which are controlled by an expression cassette suitable for gene expression in mammalian cells (e.g., a polymerase II expression cassette as described above), or by an internal ribosome entry site following the viral gene transcript (such as the internal ribosome entry site of encephalomyelitis virus), followed by a mammalian resistance marker. For production in *E. coli*, the plasmid also contains bacterial selection markers, such as an ampicillin resistance cassette.
[0373] Plasmid transfection of host cells can be performed using any commonly used strategy, such as calcium phosphate, liposome-based protocols, or electroporation.
[0374] Typically, RNA polymerase I-driven expression cassettes, RNA polymerase II-driven cassettes, or T7 phage RNA polymerase-driven cassettes can be used, the latter preferably containing a 3'-terminal ribozyme for processing the primary transcript to produce the correct ends. In some embodiments, the plasmids encoding arenavirus genome segments can be identical; that is, the genome sequence and trans-acting factors can be transcribed from T7, polI, and polII promoters of a single plasmid.
[0375] In other embodiments, transcription of the arenavirus genome segment is performed using a bidirectional expression cassette (see, for example, Ortiz-Riaño et al., 2013, J Gen Virol., 94 (part 6): 1175–1188). In a more specific embodiment, the bidirectional expression cassette contains both a polymerase I promoter and a polymerase II promoter, which are read from opposite sides of the two ends of the inserted arenavirus genome segment.
[0376] In other embodiments, transcription of the cDNA of the arenavirus genome segment described herein includes a promoter. Specific examples of promoters include RNA polymerase I promoter, RNA polymerase II promoter, RNA polymerase III promoter, T7 promoter, SP6 promoter, or T3 promoter.
[0377] To recover the three-segmented sand virus vector, the following procedure is envisioned. Day 1: Transfect cells with a plasmid mixture as described above. For this, any commonly used strategy can be used, such as calcium phosphate, liposome-based protocols, or electroporation.
[0378] Three to five days later: Harvest the cell suspension (i.e., cells and culture medium). Arenavirus particles present in the culture medium are removed from the cells and debris by centrifugation, and the supernatant (i.e., the arenavirus vector preparation) is aliquoted and stored at 4°C, -20°C, or -80°C. The infection titer of the arenavirus vector preparation is assessed by immunofocal assay. Alternatively, transfected cells and supernatant may be passaged into larger containers three to five days post-transfection, and the vector may be harvested up to five days post-passage, as previously described.
[0379] In some embodiments, expression of a nucleotide sequence encoding a fusion protein comprising two or more CTA fragments (e.g., the fusion protein disclosed in Section 5.1) is provided, wherein a plasmid encoding a genomic segment is modified to incorporate the nucleotide sequence encoding the fusion protein. The nucleotide sequence encoding the fusion protein may be incorporated into the plasmid using a restriction enzyme.
[0380] 5.4 Treatment methods
[0381] This document provides methods for preventing and / or treating neoplastic diseases in subjects of need, comprising administering to the subject a sand-like virus particle disclosed herein (e.g., the sand-like virus particle disclosed in Section 5.2) or a pharmaceutical composition containing the sand-like virus particle (e.g., the pharmaceutical composition in Section 5.5). In some embodiments, these methods result in reduced tumor growth. In some embodiments, these methods result in a lower recurrence rate.
[0382] In some embodiments, this document provides a method for treating a subject with a neoplastic disease, the method comprising (a) administering to the subject a first isovirus particle, wherein the first isovirus particle encodes a first fusion protein and a second fusion protein (e.g., the fusion proteins described in Sections 5.1 and 5.2.4), each of which fusion proteins comprises two or more CTA fragments; and (b) administering to the subject a second isovirus particle, wherein the second isovirus particle encodes the first fusion protein and the second fusion protein (e.g., the fusion proteins described in Sections 5.1 and 5.2.4), each of which fusion proteins comprises two or more CTA fragments. In some embodiments, (a) and (b) are repeated 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times. In some embodiments, the first and second isovirus particles are administered simultaneously. In other embodiments, the interval between (a) and (b) is 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, or 12 weeks. In other embodiments, the interval between (a) and (b) is 13, 14, 15, 16, 17, 18, 19, 20, 22, 23, or 24 weeks. In other embodiments, the interval between (a) and (b) is 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 weeks. Furthermore, during the repetition of (a) and (b), the interval may be the same as or different from the original cycle of (a) and (b). Therefore, the interval between (a) and (b) in the repetition can be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 weeks. In some embodiments, the first and second sand-like virus particles encode the same first fusion protein and the same second fusion protein. In some embodiments, the first and second sand-like virus particles encode the same first fusion protein but a different second fusion protein. In some embodiments, the first and second sand-like virus particles encode the same second fusion protein but a different first fusion protein. In some embodiments, the first and second sand-like virus particles encode different first and different second fusion proteins. In some embodiments, the first and second fusion proteins are selected from the first and second fusion proteins described in Section 5.2.4 or the fusion proteins described in Section 5.1.
[0383] In some embodiments, the first and second arenavirus particles originate from different arenaviruses (i.e., have different backbones) but encode the same first fusion protein and the same second fusion protein. In some embodiments, the first and second arenavirus particles originate from different arenaviruses (i.e., have different backbones) and encode the same first fusion protein but different second fusion proteins. In some embodiments, the first and second arenavirus particles originate from different arenaviruses (i.e., have different backbones) and encode the same second fusion protein but different first fusion proteins. In some embodiments, the first and second arenavirus particles originate from different arenaviruses (i.e., have different backbones) and encode different first fusion proteins and different second fusion proteins.
[0384] In some embodiments, this document provides a method for treating a subject with a neoplastic disease, the method comprising (a) administering to the subject a first isovirus particle, wherein the first isovirus particle is capable of replication and encodes a first fusion protein and a second fusion protein, each of the fusion proteins comprising two or more CTA fragments; and (b) administering to the subject a second isovirus particle, wherein the second isovirus particle encodes the first fusion protein and the second fusion protein, each of the fusion proteins comprising two or more CTA fragments.
[0385] In some embodiments, the first sand-like virus particle is three-segmented (Section 5.2.2). In a specific embodiment, the first sand-like virus particle is capable of replication. In a specific embodiment, the second sand-like virus particle is replication-deficient. In a specific embodiment, the second sand-like virus particle is capable of replication. In some embodiments, the second sand-like virus particle is three-segmented. In a specific embodiment, the second sand-like virus particle is three-segmented and capable of replication. In a specific embodiment, both the first and second sand-like virus particles are three-segmented and capable of replication.
[0386] In some embodiments, this document provides a method for treating a subject with a neoplastic disease, the method comprising administering a sand-like virus particle containing a sand-like virus genome, the sand-like virus genome containing a first heterologous ORF encoding a first fusion protein comprising two or more CTA fragments, and a second heterologous ORF encoding a second fusion protein comprising two or more CTA fragments, wherein the neoplastic disease is adrenocortical carcinoma; bladder urothelial carcinoma; invasive breast carcinoma; cervical squamous cell carcinoma and cervical endometrial adenocarcinoma; cholangiocarcinoma; colonic adenocarcinoma; lymphoma; or other neoplastic diseases. Tumors such as: diffuse large B-cell lymphoma; esophageal cancer; glioblastoma multiforme; squamous cell carcinoma of the head and neck; chromophobe renal cell carcinoma; clear cell renal cell carcinoma; papillary renal cell carcinoma; acute myeloid leukemia; low-grade glioma of the brain; hepatocellular carcinoma; lung adenocarcinoma; lung squamous cell carcinoma; mesothelioma; ovarian serous cystadenocarcinoma; pancreatic adenocarcinoma; pheochromocytoma and paraganglioma; prostate adenocarcinoma; rectal adenocarcinoma; sarcoma; cutaneous melanoma; gastric adenocarcinoma; testicular germ cell tumor; thyroid cancer; thymoma; endometrial cancer of the uterine body; uterine carcinosarcoma; or uveal melanoma.
[0387] Successful treatment for cancer patients can be assessed as prolonged expected survival, induction of anti-tumor immune responses, or improvement of cancer-specific characteristics. Examples of cancer features that can be improved include tumor size (e.g., T0, Tis, or T1-4), metastatic status (e.g., M0, M1), number of observable tumors, lymph node involvement (e.g., N0, N1-4, Nx), grade (i.e., grade 1, 2, 3, or 4), stage (e.g., stage 0, I, II, III, or IV), presence or concentration of certain markers on cells or in body fluids (e.g., AFP, B2M, β-HCG, BTA, CA 15-3, CA 27.29, CA 125, CA 72.4, CA 19-9, calcitonin, CEA, chromogranin A, EGFR, hormone receptor, HER2, HCG, immunoglobulins, NSE, NMP22, PSA, PAP, PSMA, S-100, TA-90, and thyroglobulin), and / or associated pathology (e.g., ascites or edema) or symptoms (e.g., cachexia, fever, anorexia, or pain). If the improvement can be measured in percentage, it can be at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% (e.g., survival rate, or tumor volume or linear size).
[0388] In another embodiment, a isovirus particle comprising the following isovirus genome is administered to a subject via intratumoral injection: a first heterologous ORF encoding a first fusion protein comprising two or more CTA fragments; and a second heterologous ORF encoding a second fusion protein comprising two or more CTA fragments as provided herein. In another embodiment, a isovirus particle comprising the following isovirus genome is administered to a subject via intravenous injection: a first heterologous ORF encoding a first fusion protein comprising two or more CTA fragments; and a second heterologous ORF encoding a second fusion protein comprising two or more CTA fragments as provided herein. Methods of intratumoral administration of immunotherapy are known in the art, for example, as described in WO2018 / 185307, the contents of which are incorporated herein by reference in their entirety.
[0389] In another embodiment, a isopyrvirus particle or a composition thereof comprising the following isopyrvirus genome, administered to a subject with risk factors: a first heterologous ORF encoding a first fusion protein comprising two or more CTA fragments; and a second heterologous ORF encoding a second fusion protein comprising two or more CTA fragments provided herein. Exemplary risk factors include aging, tobacco use, sun exposure, radiation exposure, chemical exposure, family history, alcohol consumption, poor diet, lack of physical activity, or being overweight.
[0390] In another embodiment, a subject suffering from one or more types of cancer is administered an isopyrvirus particle or a composition thereof comprising the following isopyrvirus genome: a first heterologous ORF encoding a first fusion protein comprising two or more CTA fragments; and a second heterologous ORF encoding a second fusion protein comprising two or more CTA fragments provided herein. In other embodiments, any type of oncological disease (such as cancer) that is sensitive to treatment using the compositions described herein can be used as a target.
[0391] In another embodiment, administration to a subject of isavirus particles or compositions thereof comprising the following isavirus genome to confer cell-mediated immunity (CMI) against tumor cells or tumors (such as cancer cells or tumors): the isavirus genome comprising a first heterologous ORF encoding a first fusion protein comprising two or more CTA fragments; and a second heterologous ORF encoding a second fusion protein comprising two or more CTA fragments provided herein. Not bound by theory, in another embodiment, isavirus particles or compositions thereof comprising the following isavirus genome to infect host antigen-presenting cells (APCs) (e.g., macrophages) and express antigens of interest therein for direct presentation of antigens on major histocompatibility complex (MHC) classes I and II: the isavirus genome comprising a first heterologous ORF encoding a first fusion protein comprising two or more CTA fragments; and a second heterologous ORF encoding a second fusion protein comprising two or more CTA fragments provided herein. In another embodiment, administration to a subject of isopyrvirus particles or compositions thereof comprising the following isopyrvirus genome induces a high-intensity cancer-specific CD4+ and CD8+ T cell response co-produced by multifunctional IFN-γ and TNF-α (IFN-γ produced by CD4+ and CD8+ T cells, and TNF-α produced by CD4+ T cells) to treat neoplastic diseases, wherein the isopyrvirus genome comprises: a first heterologous ORF encoding a first fusion protein comprising two or more CTA fragments; and a second heterologous ORF encoding a second fusion protein comprising two or more CTA fragments provided herein.
[0392] In another embodiment, administration of isavirus particles or compositions thereof comprising the isavirus genome comprising: a first heterologous ORF encoding a first fusion protein comprising two or more CTA fragments; and a second heterologous ORF encoding a second fusion protein comprising two or more CTA fragments provided herein. Non-limiting examples of such outcomes are overall survival, progression-free survival, time to progression, time to treatment failure, event-free survival, time to next treatment, overall response rate, and duration of response. An increase or improvement in one or more clinical outcomes compared to patients or patient groups with the same neoplastic disease who have not received such treatment may be at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more.
[0393] Changes in cell-mediated immune (CMI) responses against tumor cells or tumors (including cancer cells or tumors) induced by administration of arenavirus particles or compositions thereof containing the following arenavirus genome in subjects can be measured by any assay known to those skilled in the art, wherein the arenavirus genome comprises: a first heterologous ORF encoding a first fusion protein comprising two or more CTA fragments; and a second heterologous ORF encoding a second fusion protein comprising two or more CTA fragments provided herein, any of the above assays including but not limited to flow cytometry (see, for example, Perfetto SP et al., Nat Rev Immun. 2004; 4(8):648-55), lymphocyte proliferation assays (see, for example, Bonilla FA et al., Ann Allergy Asthma Immunol. 2008; 101:101-4; and Hicks MJ et al., Am J Clin Pathol. 1983; 80:159-63), and assays measuring lymphocyte activation, including measuring changes in surface marker expression after activation of T lymphocyte cytokines (see, for example, Caruso A. et al., Cytometry. 1997; 27:71-6), ELISPOT assay (see, for example, Czerkinsky CC et al., J Immunol Methods. 1983; 65:109-121; and Hutchings PR et al., J Immunol Methods. 1989; 120:1-8), or natural killer cell cytotoxicity assay (see, for example, Bonilla FA et al., Ann Allergy Asthma Immunol. May 2005; 94(5 Supplement 1): S1-63).
[0394] In some embodiments, the treatments provided herein may be further combined with chemotherapeutic agents. Chemotherapy agents include alkylating agents (e.g., cyclophosphamide), platinum-based agents, antimetabolites, topoisomerase inhibitors, cytotoxic antibiotics, intercalating agents, mitotic inhibitors, taxanes, or combinations of two or more of these. In some embodiments, the alkylating agent is nitrogen mustard, nitrosourea, alkyl sulfonates, non-classical alkylating agents, or triazine. In some implementations, the chemotherapeutic agents include one or more of the following: cyclophosphamide, thiotepa, nitrogen mustard (chloromethylamine / sinic acid), uramustine, melphalan, chlorambucil, ifosfamide, chlornazamine, chophosphatamide, estradiol, neoempichine, phenylestradiol, prednimustine, trafosamide, uracil mustard, bendamustine, busulfan, inprospirin, meperazine, carmustine, lomustine, chlorureamycin, formustine, nimustine, ramustine, streptozotocin, cisplatin, carboplatin, nedaplatin, oxaliplatin, saplatin, triplatin tetranitrate, procarbazine, hexamethylmelamine, dacarbazine, mitozodamine, temozolomide Azoxystrobin, Paclitaxel, Docetaxel, Vincristine, Vincristine, Vinorelbine, Cabazitaxel, Actinomycin D, Kazimidic Acid, Danonemycin, Acridine, Doxorubicin, Daunorubicin, Epirubicin, Mitoxantrone, Idarubicin, Pirarubicin, Benzodopa, Carboquinone, Metodopa, Uredopa, Hexamethylmelamine, Triethylene melamine, Triethylene ethylphosphamide, Triethylene thiophosphamide, Tris(hydroxymethyl)melamine, Blattasine, Blattasine, Camptothecin, Topotecan, Lichenstatin, Calitamine, CC-1065, Adolexin, Carcelyl, Bicelyl, Cryptocorymidine, Sea Haretoxin, Pyromycin, KW-2189 CB1-TM1, Asparaginin, Lycordiidine, Sacodine, Spongibutine, Clophosphonate, Espemycin, Neocarcinogen Chromosome, Aclarubicin, Atrazomycin, Diazoserine, Bleomycin, Actinomycin C, Carrubicin, Erythromycin, Carcinogen, Chromomycin, Detoxin, 6-Diazon-5-oxo-L-Leucine, Isorubicin, Idarubicin, Masemycin, Mitomycin, Mycophenolic Acid, Nogamycin, Oligomycin, Pelomycin, Porphyromycin, Purulentamycin, Quelamycin, Rodobicin, Streptomycin, Streptozotocin, Tuberculin, Ubenimex, Netostatin, Zolarubicin, Methotrexate Acids, 5-fluorouracil (5-FU), dinothoridine, pteroxetine, trimethyltroxazone, fludarabine, 6-mercaptopurine, thioimidapurine, thioguanine, ancitabine, azacitidine, 6-azauridine, carmoflurane, cytarabine, dideoxyuridine, deoxyfluorouridine, enoxabin, fluorouridine, carotestosterone, drotalonone propionate, epithalandrolone, mepitistein, testrolide, mitotane, trelostan, leucovorin, glucuronolactone, aldehydephosphoramide glycoside, aminolevulinic acid, enuracil, bestabucil, bisperazine, edaraxazone, difamethamide, colchicine, diazinon, efornithine, ellipticrocortine, etogluconateGallium nitrate, hydroxyurea, lentinan, chlordamine, maytansine, anserine, mitoxantridine, mupidamo, nitroglycerin, pentostatin, phenacetin, pirarubicin, loxoantrone, podophyllic acid, 2-ethylhydrazine, PSK polysaccharide complex, razorbenzan, crizosyl alcohol, spirogermanium, Alternaria alternata ketone acid, triamine, 2,2',2''-trichlorotriethylamine; T-2 toxin, verrucosporin A. Rolimonin A and serpentin, urethane, vindesin, mannitol mustard, dibromomannitol, dibromoeutherol, piperobromane, gasitocin, cytarabine (“Ara-C”), etoposide (VP-16), vinorelbine, nifedipine, teniposide, edaraxal, aztreon, capecitabine, ibandronic acid, irinotecan (e.g., CPT-11), topoisomerase inhibitor RFS 2000, difluoromethylornithine (DMFO), retinoic acid, capecitabine, procamycin, gemcitabine, novibenten, antiplatinum, and pharmaceutically acceptable salts, acids, or derivatives of any of the above.
[0395] In some embodiments, one or more sand virus particles or combinations thereof comprising the following sand virus genome are administered by two or more separate injections over time periods of 1 hour, 2 hours, 3 hours, 6 hours, 12 hours, 24 hours, or 48 hours: the sand virus genome comprises a first heterologous ORF encoding a first fusion protein comprising two or more CTA fragments; and a second heterologous ORF encoding a second fusion protein comprising two or more CTA fragments provided herein.
[0396] In some embodiments, one or more arenavirus particles or compositions thereof comprising the following arenavirus genome are administered by two or more separate injections over time periods of 3 days, 5 days, 1 week, 2 weeks, 3 weeks, 4 weeks or 12 weeks: the arenavirus genome comprises a first heterologous ORF encoding a first fusion protein comprising two or more CTA fragments; and a second heterologous ORF encoding a second fusion protein comprising two or more CTA fragments provided herein.
[0397] In some embodiments, one or more arenavirus particles or combinations thereof comprising the following arenavirus genome are administered by two or more separate injections over a period of 6 months, 12 months, 24 months or 48 months: the arenavirus genome comprises a first heterologous ORF encoding a first fusion protein comprising two or more CTA fragments; and a second heterologous ORF encoding a second fusion protein comprising two or more CTA fragments provided herein.
[0398] In some implementations, the two types of sand virus particles described herein are administered in a treatment regimen at a molar ratio ranging from approximately 1:1 to 1:1000, specifically including ratios of 1:1, 1:2, 1:5, 1:10, 1:20, 1:50, 1:100, 1:200, 1:300, 1:400, 1:500, 1:600, 1:700, 1:800, 1:900, and 1:1000.
[0399] In some embodiments, this document provides a method for treating neoplastic diseases, wherein a first isovirus particle is administered as a “primary immunization” and a second isovirus particle is administered as a “boost.” The first and second isovirus particles may encode the same or different first fusion protein comprising two or more CTA fragments and / or the same or different second fusion protein comprising two or more CTA fragments. Alternatively or in addition, in some specific embodiments, the “primary immunization” and “boost” administration are performed using isovirus particles derived from different isovirus species. In some specific embodiments, the “primary immunization” administration is performed using isovirus particles derived from LCMV, while the “boost” is performed using isovirus particles derived from Pichind virus. In some specific embodiments, the “primary immunization” administration is performed using isovirus particles derived from Pichind virus, while the “boost” is performed using isovirus particles derived from LCMV.
[0400] In some embodiments, administration of a first isovirus particle comprising the following isovirus genome: the isovirus genome comprising a first heterologous ORF encoding a first fusion protein comprising two or more CTA fragments; and a second heterologous ORF encoding a second fusion protein comprising two or more CTA fragments; followed by administration of a second isovirus particle comprising the following isovirus genome: the isovirus genome comprising a first heterologous ORF encoding a first fusion protein comprising two or more CTA fragments; and a second heterologous ORF encoding a second fusion protein comprising two or more CTA fragments, resulting in a greater antigen-specific CD8+ T cell response than administration of a single isovirus particle comprising the following isovirus genome: the isovirus genome comprising a first heterologous ORF encoding a first fusion protein comprising two or more CTA fragments; and a second heterologous ORF encoding a second fusion protein comprising two or more CTA fragments. In some embodiments, the antigen-specific CD8+ T cell count increases by 50%, 100%, 150%, or 200% after the second administration compared to the first administration.
[0401] In some embodiments, administration of a first isovirus particle comprising the following isovirus genome: the isovirus genome comprising a first heterologous ORF encoding a first fusion protein comprising two or more CTA fragments; and a second heterologous ORF encoding a second fusion protein comprising two or more CTA fragments; and administration of a second heterologous isovirus particle comprising the following isovirus genome: the isovirus genome comprising a first heterologous ORF encoding a first fusion protein comprising two or more CTA fragments; and a second heterologous ORF encoding a second fusion protein comprising two or more CTA fragments, elicits a larger CD8+ T cell response than administration of a first isovirus particle comprising the following isovirus genome and a second homologous isovirus particle comprising the following isovirus genome: the isovirus genome of the first isovirus particle comprising a first heterologous ORF encoding a first fusion protein comprising two or more CTA fragments; and a second heterologous ORF encoding a second fusion protein comprising two or more CTA fragments; the isovirus genome of the second homologous isovirus particle comprising a first heterologous ORF encoding a first fusion protein comprising two or more CTA fragments; and a second heterologous ORF encoding a second fusion protein comprising two or more CTA fragments.
[0402] In some embodiments, the first fusion protein and the second fusion protein are selected from the first fusion protein and the second fusion protein described in Section 5.2.4, or the fusion protein described in Section 5.1.
[0403] In some embodiments of the treatment methods disclosed herein, the sand-like virus particles administered to the subject are therapeutically effective amounts. As used herein, the term "therapeuticly effective amount" means an amount of agent sufficient to reduce and / or improve the severity and / or duration of: (i) the subject's disease, condition, or illness, and / or (ii) the subject's symptoms. The term also covers amounts of agent necessary for: (i) reducing or improving the development or progression of a given disease, condition, or illness; (ii) reducing or improving the recurrence, occurrence, or onset of a given disease, condition, or illness; and / or (iii) improving or enhancing the preventive or therapeutic effect of another agent or therapy (e.g., an agent other than the conjugates provided herein).
[0404] 5.4.1 Neoplastic diseases
[0405] In some embodiments, neoplastic diseases that can be treated with the methods and compositions described herein include the neoplastic diseases listed below. Therefore, the expression of PRAME, MAGE-A3, MAGE-A4, and MAGE-A6 may be associated with or may be specific to one of the listed neoplastic diseases. Neoplastic diseases include acute lymphoblastic leukemia; acute lymphoblastic lymphoma; acute lymphoblastic leukemia; acute myeloid leukemia; acute myeloid leukemia (adult / child); adrenocortical carcinoma; AIDS-related cancer; AIDS-related lymphoma; anal cancer; appendiceal cancer; astrocytoma; atypical teratoid / rhabdoid tumor; basal cell carcinoma; extrahepatic bile duct carcinoma (cholangiocarcinoma); bladder cancer; osteosarcoma / malignant fibrous histiocytoma; brain cancer (adult / child); brain tumor, cerebellar astrocytoma (adult / child); brain tumor, cerebral astrocytoma / malignant glioma brain tumor; brain tumor, ependymoma; brain tumor, medulloblastoma; brain tumor Supratentorial primitive neuroectodermal tumors; brain tumors, visual pathway and hypothalamic gliomas; brainstem gliomas; breast cancer; bronchial adenoma / carcinoid; bronchial tumors; Burkitt lymphoma; childhood cancers; gastrointestinal carcinoids; carcinoid tumors; adult cancers of unknown primary site; cancers of unknown primary site; embryonal tumors of the central nervous system; primary central nervous system lymphomas; cervical cancer; childhood adrenocortical carcinoma; childhood cancers; childhood astrocytomas of the brain; chordoma, childhood; chronic lymphocytic leukemia; chronic myeloid leukemia; chronic myeloid leukemia; chronic myeloproliferative disorders; colon cancer; colorectal cancer; craniopharyngioma; cutaneous T-cell lymphoma; fibroblastic tumors. Small round cell tumors; emphysema; endometrial cancer; ependymoblastoma; ependymoma; esophageal cancer; Ewing sarcoma (a member of the Ewing sarcoma family); extracranial germ cell tumors; extragonadal germ cell tumors; extrahepatic bile duct cancer; gallbladder cancer; gastric (stomach) cancer; gastric carcinoid; gastrointestinal carcinoid; gastrointestinal stromal tumor; germ cell tumors: extracranial, extragonadal, or ovarian gestational trophoblastic tumors; gestational trophoblastic tumors of unknown primary location; gliomas; brainstem gliomas; gliomas, visual pathway and hypothalamus in children; hairy cell leukemia; head and neck cancer; cardiac cancer; hepatocellular carcinoma; Hodgkin's lymphoma; hypopharyngeal cancer; hypothalamic and visual pathway gliomas; intraocular melanoma; Pancreatic islet cell carcinoma (endocrine pancreas); Kaposi's sarcoma; Renal cell carcinoma; Langerhans cell histiocytosis; Laryngeal cancer; Lip and oral cancer; Liposarcoma; Hepatocellular carcinoma (primary); Lung cancer, non-small cell; Lung cancer, small cell; Lymphoma, primary central nervous system; Macroglobulinemia, Waldenström; Male breast cancer; Malignant fibrous histiocytoma / osteosarcoma of bone; Medulloblastoma; Medullary epithelioma; Melanoma; Melanoma, intraocular (eye); Merkel cell carcinoma; Merkel cell skin carcinoma; Mesothelioma; Mesothelioma, adult malignant; Metastatic squamous neck carcinoma with occult primary lesion; Oral cancer; Multiple endocrine tumor syndrome; Multiple myeloma / plasma cell tumor;Mycosis fungoides, myelodysplastic syndrome; myelodysplastic / myeloproliferative disorders; myeloid leukemia, chronic; myeloid leukemia, acute in adults; myeloid leukemia, acute in children; multiple myeloma (myeloma); myeloproliferative disorders, chronic; nasal and paranasal sinus carcinoma; nasopharyngeal carcinoma; neuroblastoma, non-small cell lung cancer; non-Hodgkin's lymphoma; oligodendroglioma; oral cancer; oral cavity cancer; oropharyngeal cancer; osteosarcoma / malignant fibrous histiocytoma of bone. Tumors; Ovarian cancer; Ovarian epithelial carcinoma (surface epithelial-stromal tumor); Ovarian germ cell tumors; Low-grade malignant potential ovarian tumors; Pancreatic cancer; Pancreatic cancer, islet cells; Papillomatosis; Paranasal sinus and nasal cavity carcinoma; Parathyroid carcinoma; Penile cancer; Pharyngeal carcinoma; Pheochromocytoma; Pineal astrocytoma; Pineal germ cell tumor; Intermediately differentiated pineal parenchymal tumor; Pineal blastoma and supratentorial primitive neuroectodermal tumor; Pituitary tumors; Pituitary adenoma; Plasma cell tumors / Multiple myeloma; Pleuroblastoma; Primary central nervous system lymphoma; Prostate cancer; Rectal cancer; Renal cell carcinoma (kidney cancer); Transitional cell carcinoma of the renal pelvis and ureter; Respiratory tract cancer involving the NUT gene on chromosome 15; Retinoblastoma; Rhabdomyosarcoma, childhood; Salivary gland cancer; Sarcoma, Ewing sarcoma family; Cézari syndrome; Skin cancer (melanoma); Skin cancer (non-melanoma); Small cell lung cancer; Small bowel cancer; Soft tissue sarcoma. Tumors; soft tissue sarcomas; spinal cord tumors; squamous cell carcinoma; squamous neck carcinoma with occult primary lesions, metastases; gastric (stomach) cancer; supratentorial primitive neuroectodermal tumors; T-cell lymphomas; skin (mycosis fungoides and Cezari syndrome); testicular cancer; pharyngeal cancer; thymoma; thymoma and thymic carcinoma; thyroid cancer; pediatric thyroid cancer; transitional cell carcinoma of the renal pelvis and ureter; urethral cancer; uterine cancer, endometrial cancer; uterine sarcoma; vaginal cancer; vulvar cancer; and nephroblastoma.
[0406] In some embodiments, a method for treating a neoplastic disease in a subject in need includes administering a sand-like virus particle to the subject, wherein the sand-like virus particle encodes a first fusion protein and a second fusion protein, wherein the first fusion protein and the second fusion protein comprise two or more CTA fragments. In some implementations, the expression of these CTAs may be associated with or specific to the following diseases: adrenocortical carcinoma; urothelial carcinoma of the bladder; invasive breast carcinoma; cervical squamous cell carcinoma and cervical endometrial adenocarcinoma; cholangiocarcinoma; colonic adenocarcinoma; lymphoid neoplasms—diffuse large B-cell lymphoma; esophageal cancer; glioblastoma multiforme; head and neck squamous cell carcinoma; chromophobe renal carcinoma; clear cell renal carcinoma; papillary renal carcinoma; acute myeloid leukemia; low-grade glioma of the brain; hepatocellular carcinoma; lung adenocarcinoma; lung squamous cell carcinoma; mesothelioma; ovarian serous cystadenocarcinoma; pancreatic adenocarcinoma; pheochromocytoma and paraganglioma; prostate adenocarcinoma; rectal adenocarcinoma; sarcoma; cutaneous melanoma; gastric adenocarcinoma; testicular germ cell tumor; thyroid cancer; thymoma; endometrial cancer of the uterine corpus; uterine carcinosarcoma; or uveal melanoma. In some embodiments, a method for treating an oncological disease in a subject of need includes administering isoflavone particles to the subject, wherein the isoflavone particles encode a fusion protein comprising two or more fragments of MAGE-A3, MAGE-A4, and / or MAGE-A6, wherein the oncological disease is lung squamous cell carcinoma (LUSC), cutaneous melanoma (SKCM), bladder urothelial carcinoma (BLCA), or esophageal cancer (ESCA). In some embodiments, a method for treating an oncological disease in a subject of need includes administering isoflavone particles to the subject, wherein the isoflavone particles encode a fusion protein comprising two or more fragments of PRAME, wherein the oncological disease is female gonadal cancer, such as ovarian serous cystadenocarcinoma or bladder urothelial carcinoma, endometrial cancer of the uterine body, uterine carcinosarcoma, cervical squamous cell carcinoma, and cervical endometrial adenocarcinoma. In some embodiments, the first and second fusion proteins are selected from the first and second fusion proteins described in Section 5.2.4, or the fusion proteins described in Section 5.1.
[0407] In some embodiments, the method for treating a neoplastic disease in a subject of need further includes administering a second isovirus particle to the subject, wherein the second isovirus particle encodes a first fusion protein and a second fusion protein, wherein the first and second fusion proteins comprise two or more CTA fragments. In some embodiments, the first and second isovirus particles encode the same first fusion protein and the same second fusion protein. In some embodiments, the first and second isovirus particles encode the same first fusion protein but a different second fusion protein. In some embodiments, the first and second isovirus particles encode the same second fusion protein but a different first fusion protein. In some embodiments, the first and second isovirus particles encode different first fusion proteins and different second fusion proteins. In some embodiments, the first and second fusion proteins are selected from the first and second fusion proteins described in Section 5.2.4 or the fusion proteins described in Section 5.1.
[0408] 5.5 Composition, Application and Dosage
[0409] This document also provides vaccines, immunogenic compositions (e.g., vaccine formulations), and pharmaceutical compositions that comprise arenavirus particles (e.g., arenavirus particles disclosed in Section 5.2) provided herein. Such vaccines, immunogenic compositions, and pharmaceutical compositions can be formulated according to standard procedures in the art.
[0410] In some embodiments, this document provides immunogenic compositions comprising arenavirus particles (or combinations of different arenavirus particles) as described herein (e.g., arenavirus particles disclosed in Section 5.2). In some embodiments, such immunogenic compositions also comprise pharmaceutically acceptable excipients.
[0411] In some embodiments, the compositions described herein also contain a preservative, such as the mercury derivative thimerosal. In one specific embodiment, the pharmaceutical composition described herein contains 0.001% to 0.01% thimerosal. In other embodiments, the pharmaceutical compositions described herein do not contain a preservative.
[0412] The pharmaceutical composition contains approximately 10 3 One to about 10 11 Genetically engineered sand-like virus particles forming individual focal units. For parenteral administration, unit dosage forms include ampoules or vials, for example, containing approximately 10... 3 One to 10 10 Each stove forms a unit or 10 5 One to 10 15A vial containing a physical particle of a genetically engineered sand virus particle.
[0413] In another embodiment, the vaccine or immunogenic composition provided herein is administered to the subject via intratumoral injection. In yet another embodiment, the vaccine or immunogenic composition provided herein is administered to the subject via intravenous injection.
[0414] The dosage of the active ingredient depends on the type of vaccination, as well as the subject's age, weight, individual condition, individual pharmacokinetic data, and administration method.
[0415] In some embodiments, the composition is administered to the patient as a single dose, followed by a second dose three to six weeks later. According to these embodiments, booster vaccinations may be administered to the subject at intervals of six to twelve months following the second vaccination. In some embodiments, booster vaccinations may utilize different arenavirus particles or combinations thereof. In some embodiments, administration of the same composition as described herein may be repeated at intervals of at least 1 day, 2 days, 3 days, 4 days, 5 days, 10 days, 15 days, 30 days, 45 days, 2 months, 75 days, 3 months, or at least 6 months.
[0416] In some implementations, a suitable dose of isovirus particles or trisegmental isovirus particles is 10. 2 5×10 2 10 3 5×10 3 10 4 5×10 4 10 5 5×10 5 10 6 5×10 6 10 7 5×10 7 10 8 5×10 8 1×10 9 5×10 9 1×10 10 5×10 10 1×10 11 5×10 11 Or 10 12 PFU can be administered to the subject once, twice, three times or more at intervals as needed.
[0417] This document also provides kits that can be used to perform the methods described herein. In some embodiments, the kits provided herein may include one or more containers. These containers may contain the compositions provided herein (e.g., pharmaceutical compositions, immunogenic compositions, or vaccine compositions) for storage. Instructions for use are also included in the kits. These instructions describe treatment regimens using the compositions contained therein in sufficient detail. For example, the instructions may include dosage and administration instructions for methods of treating neoplastic diseases as provided herein.
[0418] 5.6 Determination of activity
[0419] 5.6.1 Detection and determination of sand virus
[0420] Those skilled in the art can use techniques known in the art to detect arenavirus genomic segments or arenavirus particles as described herein. For example, RT-PCR can be used with primers specific to arenavirus to detect and quantify arenavirus genomic segments or trisegmental arenavirus particles. Western blotting, ELISA, radioimmunoassay, immunoprecipitation, immunocytochemistry, or immunocytochemistry combined with FACS can be used to quantify the gene products of arenavirus genomic segments or arenavirus particles.
[0421] 5.6.2 Measurement of infectivity
[0422] Any assay known to those skilled in the art can be used to measure the infectivity of isopyrvirus vector preparations. For example, the determination of virus / vector titer can be performed using a “foci-forming unit assay” (FFU assay). In short, complementary cells (e.g., HEK293-TVL cells) are plated and inoculated with virus / vector samples at different dilutions. After an incubation period, to allow the cells to form a monolayer and for the virus to attach to the cells, the monolayer is covered with methylcellulose. When the plate is further incubated, the original infected cells release viral progeny. Due to the presence of the methylcellulose covering, the spread of new virus is restricted to adjacent cells. Thus, each infectious particle produces a circular area of infected cells called a “foci.” These foci can be made visible and thus counted using an antibody against LCMV-NP or another protein expressed by the isopyrvirus particle or trisegmental isopyrvirus particle, along with an HRP-based colorimetric reaction. The virus / vector titer can be calculated in units of focus forming per milliliter (FFU / mL). In a similar manner, the proportion of trisegmental, replicating viral particles can be determined. Use non-complementary cell lines (e.g., HEK293) instead of complementary cells. This allows only three-segment viral particles to infect adjacent cells. The titer of replicating virus / vector (RCV) can be calculated in focal-forming units per milliliter (RCV FFU / mL).
[0423] 5.6.3 Growth of Sand-borne Virus Particles
[0424] The growth of arenavirus particles described herein can be assessed by any method known in the art or described herein (e.g., cell culture). Viral growth can be determined by inoculating a specified amount / concentration of arenavirus particles as described herein into a cell culture (e.g., Vero cells or BHK-21 cells). After a specific incubation period, the virus-containing supernatant is collected using standard methods, and infectivity can be measured using the assays described herein.
[0425] 5.6.4 Serum ELISA
[0426] The humoral immune response in animals (e.g., mice, guinea pigs) following vaccination can be measured using an antigen-specific serum ELISA (enzyme-linked immunosorbent assay). In short, an antigen (e.g., histone) is coated onto a plate, blocked to prevent non-specific antibody binding, and incubated with serially diluted serum. After incubation, the bound serum antibodies can be detected, for example, using an enzyme-conjugated species-specific antibody (e.g., mouse, guinea pig) to detect total IgG or IgG subclasses, and a subsequent colorimetric reaction. Antibody titers can be determined, for example, using the endpoint geometric mean titer.
[0427] 5.6.5 Determination of the neutralizing activity of induced antibodies
[0428] The determination of neutralizing antibodies in serum was performed using the following cellular assay, employing ARPE-19 cells from ATCC and GFP-labeled virus. Supplemented guinea pig serum was used as a source of exogenous complement. The assay was initiated one or two days prior to neutralization in 384-well plates at 6.5 × 10⁻⁶ cells / well. 3 Cells were seeded at 50 µl / well. Neutralization was performed in cell-free 96-well sterile tissue culture plates at 37°C for 1 hour. After the neutralization incubation step, the mixture was added to the cells and incubated for another 4 days for GFP detection using a plate reader. Positive neutralized human serum was used as a positive control for each plate to check the reliability of all results. Titers (EC50) were determined using a four-parameter logistic curve fitting. As an additional test, the wells were examined using a fluorescence microscope.
[0429] 5.6.6 Plaque Reduction Assay
[0430] In short, plaque reduction (neutralization) assays of LCMV can be performed using replicable or replication-deficient LCMV encoding a reporter gene (e.g., green fluorescent protein), using 5% rabbit serum as a source of exogenous complement, and plaques can be counted using fluorescence microscopy. The neutralization titer can be defined as the highest serum dilution resulting in a 50%, 75%, 90%, or 95% reduction in plaques compared to a control (pre-immunization) serum sample. qPCR LCMV RNA genomic samples were isolated using the QIAampViral RNA mini Kit (QIAGEN) according to the manufacturer's protocol. LCMV RNA genomic equivalents were determined using the StepOnePlus real-time PCR system (Applied Biosystems) on a SuperScript platform. ® III Platinum ® Detection is achieved using a one-step qRT-PCR kit (Invitrogen) and quantitative PCR with primers and probes (FAM reporter gene and NFQ-MGB quencher) specific to a portion of the LCMV NP coding region or another genomic segment of a arenavirus particle or trisegmental arenavirus particle. The reaction temperature profile can be: 60°C for 30 min, 95°C for 2 min, followed by 45 cycles of 95°C for 15 s and 56°C for 30 s. RNA can be quantified by comparing sample results with a standard curve prepared from a log10 dilution series of in vitro transcribed RNA fragments quantified spectrophotometrically, corresponding to the LCMV NP coding sequence or a fragment containing primer and probe binding sites of another genomic segment of a arenavirus particle or trisegmental arenavirus particle.
[0431] 5.6.7 Protein Blotting
[0432] Infected cells grown in tissue culture flasks or suspensions were lysed using RIPA buffer (Thermo Scientific) at designated time points post-infection, or used directly without cell lysis. Samples were heated to 99°C for 10 minutes in reducing agent and NuPageLDS sample buffer (NOVEX) and cooled to room temperature before loading onto 4% to 12% SDS-PAGE gels for electrophoresis. Proteins were blotted onto membranes using an Invitrogen iBlot gel transfer device and developed by Ponceau S staining. Finally, preparations were probed with a primary antibody against the protein of interest and a secondary antibody conjugated to alkaline phosphatase, followed by staining with 1-Step NBT / BCIP solution (INVITROGEN).
[0433] 5.6.8 MHC-peptide multimer staining assay for detecting antigen-specific CD8+ T cells
[0434] Any assay known to the art can be used to test for antigen-specific CD8+ T cell responses. For example, an MHC-peptide tetramer staining assay can be used (see, for example, Altman JD et al., Science. 1996; 274:94-96; and Murali-Krishna K. et al., Immunity. 1998; 8:177-187). In short, this assay involves the following steps: using a tetramer assay to detect the presence of antigen-specific T cells. To detect antigen-specific T cells, the T cell must simultaneously bind a peptide to a tetramer of an MHC molecule (typically fluorescently labeled) tailored to the specific antigen specificity and MHC haplotype of the T cell. The tetramer is then detected via flow cytometry using the fluorescent label.
[0435] 5.6.9 ELISPOT assay for detecting antigen-specific T cells
[0436] Any assay known to the art can be used to test antigen-specific T cell responses. For example, the ELISPOT assay can be used (see, for example, Czerkinsky CC et al., J Immunol Methods. 1983; 65:109-121; and Hutchings PR et al., J Immunol Methods. 1989; 120:1-8). Cytokines, such as, but not limited to, IFN-γ, can be measured by the ELISPOT assay. Briefly, the assay involves the following steps: coating an immunospot plate with an anti-cytokine antibody; incubating cells with a peptide derived from the antigen of interest in the immunospot plate; secreting cytokines that bind to the coating antibody by antigen-specific cells; washing away the cells; adding a second biotinylated anti-cytokine antibody to the plate; and developing the plate using an avidin-HRP system or other suitable method.
[0437] 5.6.10 Intracellular cytokine assay for detecting CD8+ and CD4+ T cell function
[0438] Any assay known to the technician can be used to test the function of CD8+ and CD4+ T cell responses. For example, an intracellular cytokine assay can be used in conjunction with flow cytometry (see, for example, Suni MA et al., J Immunol Methods. 1998; 212:89-98; Nomura LE et al., Cytometry. 2000; 40:60-68; and Ghanekar S.A. et al., Clinical and Diagnostic Laboratory Immunology. 2001; 8:628-63). In short, the assay involves the following steps: after activating cells via a specific peptide or protein, a protein transport inhibitor (e.g., brefidobacterium A) is added to retain the cytokines within the cells. After a defined incubation period (typically 5 hours), a washing step is performed, and antibodies against other cellular markers may be added to the cells. The cells are then fixed and permeabilized. A fluorescently conjugated anti-cytokine antibody is added, and the cells can be analyzed by flow cytometry.
[0439] 5.6.11 Determination used to confirm viral vector replication defects
[0440] Any assay known to the technician for determining the concentration of viral particles with infectious and replicative capabilities can also be used to measure replication-defective viral particles in a sample. For example, an FFU assay using non-complementary cells can be used for this purpose.
[0441] Furthermore, plaque-based assays are a standard method for determining the viral concentration in plaque-forming units (PFU) within a viral sample. Specifically, a confluent monolayer of non-complementary host cells is infected with different dilutions of virus and covered with a semi-solid culture medium, such as agar, to prevent indiscriminate spread of viral infection. Viral plaques are formed when the virus successfully infects and replicates within the cells of the immobilized monolayer and spreads to surrounding cells (see, for example, Kaufmann, SH; Kabelitz, D. (2002). Methods in Microbiology, Vol. 32: Immunology of Infection. Academic Press. ISBN 0-12-521532-0). Plaque formation can take 2 to 14 days, depending on the virus being analyzed. Plaques are typically counted manually, and the results are combined with the dilution factor used to prepare the plates to calculate the number of plaque-forming units per unit volume of sample (PFU / mL). The PFU / mL result represents the number of infectious and replicating particles within the sample. When using C-cells, the same assay can be used to titrate replication-defective arenavirus particles or trisegmental arenavirus particles.
[0442] 5.6.12 Determination of viral antigen expression
[0443] Any assay known to the technician can be used to measure viral antigen expression. For example, an FFU assay can be performed. For detection, preparations of monoclonal or polyclonal antibodies against the corresponding viral antigen are used (transgenic-specific FFU).
[0444] 5.6.13 Animal Models
[0445] To study the recombination and infectivity of the arenavirus particles described herein in vivo, animal models can be used. In some embodiments, animal models that can be used to study the recombination and infectivity of the three-segmented arenavirus particles include mice, guinea pigs, rabbits, and monkeys. In a preferred embodiment, animal models that can be used to study the recombination and infectivity of arenaviruses include mice. In a more specific embodiment, mice that can be used to study the recombination and infectivity of arenavirus particles are triple-deficient in type I interferon receptor, type II interferon receptor, and recombination activation gene 1 (RAG1).
[0446] In some embodiments, animal models can be used to determine arenavirus infectivity and transgenic stability. In some embodiments, viral RNA can be isolated from the serum of the animal model. These techniques are well known to those skilled in the art. Viral RNA can be reverse transcribed, and cDNA carrying the arenavirus ORF can be amplified by PCR using gene-specific primers. Flow cytometry can also be used to study arenavirus infectivity and transgenic stability.
[0447] In some embodiments, animal models can be used to determine the immunogenicity and efficacy in animals following administration of the arenavirus particles described herein. In some embodiments, animal models that can be used to study the immunogenicity and efficacy in animals following administration of the arenavirus particles described herein include inbred mouse strains (e.g., C57BL / 6, Balb / c, CB6F1). In a preferred embodiment, animal models that can be used to study the immunogenicity and efficacy in animals following administration of the arenavirus particles described herein include HLA (human leukocyte antigen) transgenic mouse strains (e.g., HLA-A). 11:01, HLA-B 07:02, HLA-A 02:01).
[0448] 6. Equivalent scheme
[0449] All patents and publications mentioned in this specification are incorporated herein by reference in their entirety. It will be apparent from the foregoing description that variations and modifications can be made to the invention described herein to adapt it to various uses and conditions. Such embodiments are also within the scope of the following claims.
[0450] 7. Sequence
[0451]
[0452]
[0453]
[0454]
[0455]
[0456]
[0457]
[0458]
[0459]
[0460]
[0461]
[0462]
[0463]
[0464]
[0465]
[0466]
[0467]
[0468]
[0469]
[0470]
[0471]
[0472]
[0473]
[0474]
[0475]
[0476]
[0477]
[0478]
[0479] 8. Examples
[0480] 8.1 Example 1: Design of Sand-like Virus Vector
[0481] (a) LCMV-CTA1_H7 / CTA1_H8, LCMV-CTA1_H9 / CTA1_H10, LCMV-CTA1_H11 / CTA1_H12
[0482] LCMV-CTA1_H7 / CTA1_H8, LCMV-CTA1_H9 / CTA1_H10, and LCMV-CTA1_H11 / CTA1_H12 are attenuated, replication-capable three-segment vectors based on LCMV clone 13 (LCMV cl13), expressing the GP of the LCMV WE strain instead of its endogenous glycoprotein (LCMV cl13 / WE). Figure 1 The NP-S segment contains the nucleotide sequences encoding selected peptides of PRAME, MAGE-A3, MAGE-A4, and MAGE-A6 (corresponding RNA sequences of SEQ ID NO: 1, 3, and 5 (SEQ ID NO: 100, 102, and 104, respectively)), and the GP-S segment contains the nucleotide sequences encoding selected peptides of MAGE-A3, MAGE-A4, and MAGE-A6 (corresponding RNA sequences of SEQ ID NO: 2, 4, and 6 (SEQ ID NO: 101, 103, and 105, respectively)). The peptides were selected based on their genetic distance relative to their respective family members and the human proteome, as well as their predicted binding affinity to MHC I molecules. The identified 9 to 25-mers were arranged according to an “epitope tandem” design. Bioinformatics modeling further optimized the order of the selected epitopes, involving immunogenicity, proteasome cleavage, minimizing interference from linking epitopes, and their genetic distance relative to the human proteome. The nucleotide sequences of CTA1_H7 to CTA1_H12 were modified to lack the CpG dinucleotide motif. This vector was generated de novo by electroporation of production cells using a five-plasmid co-transfection system, as previously described by Kallert et al., Nat Commun 2017; 8:15327.
[0483] (b) LCMV-CTA1_H13 / CTA1_H8, LCMV-CTA1_H14 / CTA1_H12
[0484] LCMV-CTA1_H13 / CTA1_H8 and LCMV-CTA1_H14 / CTA1_H12 are attenuated, replication-capable three-segment vectors based on LCMV clone 13 (LCMVcl13), expressing the GP of the LCMV WE strain instead of its endogenous glycoprotein (LCMVcl13 / WE). Figure 1 The NP-S segment contains nucleotide sequences encoding selected peptides of PRAME, MAGE-A3, MAGE-A4, and MAGE-A6 (corresponding RNA sequences of SEQ ID NO: 13 and 14 (SEQ ID NO: 106 and 107, respectively)), and the GP-S segment contains nucleotide sequences encoding selected peptides of MAGE-A3, MAGE-A4, and MAGE-A6 (corresponding RNA sequences of SEQ ID NO: 2 and 6 (SEQ ID NO: 101 and 105, respectively)). The nucleotide sequences of CTA1_H13 and CTA1_H14 are modified to lack the CpG dinucleotide motif. This vector is generated de novo by electroporation of production cells using a five-plasmid co-transfection system, as previously described by Kallert et al., Nat Commun 2017; 8:15327.
[0485] (c) LCMV-CTA1_H7 / CTA1_H15 and LCMV-CTA1_H7 / CTA1_H21 and LCMV-CTA1_H9 / CTA1_ H16 and LCMV-CTA1_H9 / CTA1_H22
[0486] LCMV-CTA1_H7 / CTA1_H15, LCMV-CTA1_H7 / CTA1_H21, LCMV-CTA1_H9 / CTA1_H16, and LCMV-CTA1_H9 / CTA1_H22 are attenuated, replication-capable three-segment vectors based on LCMV clone 13 (LCMV cl13), expressing the GP of the LCMV WE strain instead of its endogenous glycoprotein (LCMV cl13 / WE). Figure 1The NP-S segment contains nucleotide sequences encoding selected peptides of PRAME, MAGE-A3, MAGE-A4, and MAGE-A6 (corresponding RNA sequences of SEQ ID NO: 1 and 3 (SEQ ID NO: 100 and 102, respectively)), and the GP-S segment contains different versions of nucleotide sequences encoding selected peptides of MAGE-A3, MAGE-A4, and MAGE-A6 (corresponding RNA sequences of SEQ ID NO: 15, 16, 21, and 22 (SEQ ID NO: 108, 109, 114, and 115, respectively)). This vector is de novo generated from production cells via electroporation using a five-plasmid co-transfection system, as previously described by Kallert et al., Nat Commun 2017; 8:15327.
[0487] (d) LCMV-CTA1_H7 / CTA1_H17, LCMV-CTA1_H7 / CTA1_H19, LCMV-CTA1_H9 / CTA1_H18 and LCMV-CTA1_H9 / CTA1_H20
[0488] LCMV-CTA1_H7 / CTA1_H17, LCMV-CTA1_H7 / CTA1_H19, LCMV-CTA1_H9 / CTA1_H18, and LCMV-CTA1_H9 / CTA1_H20 are attenuated, replication-capable three-segment vectors based on LCMV clone 13 (LCMV cl13), expressing the GP of the LCMV WE strain instead of its endogenous glycoprotein (LCMV cl13 / WE). Figure 1 The NP-S segment contains nucleotide sequences encoding selected peptides of PRAME, MAGE-A3, MAGE-A4, and MAGE-A6 (corresponding RNA sequences of SEQ ID NO: 1 and 3 (SEQ ID NO: 100 and 102, respectively)), and the GP-S segment contains nucleotide sequences encoding selected peptides of MAGE-A3, MAGE-A4, and MAGE-A6 (corresponding RNA sequences of SEQ ID NO: 17, 18, 19, and 20 (SEQ ID NO: 110, 111, 112, and 113, respectively)). The nucleotide sequences of CTA1_H17 to CTA1_H20 are modified to lack the CpG dinucleotide motif. This vector is generated de novo by electroporation of production cells using a five-plasmid co-transfection system, as previously described by Kallert et al., NatCommun 2017; 8:15327.
[0489] (e) PICV-CTA1_H7 / CTA1_H8, PICV-CTA1_H9 / CTA1_H10, PICV-CTA1_H11 / CTA1_H12
[0490] PICV-CTA1_H7 / CTA1_H8, PICV-CTA1_H9 / CTA1_H10, and PICV-CTA1-H11 / CTA1_H12 are attenuated, replication-enabled three-segment vectors based on the virulent 18th generation PIC (also known as PICV p18) strain of Pichind virus. Figure 1 The NP-S segments contain nucleotide sequences encoding selected peptides of PRAME, MAGE-A3, MAGE-A4, and MAGE-A6 (corresponding RNA sequences of SEQ ID NO: 1, 3, and 5 (SEQ ID NO: 100, 102, and 104, respectively)), and the GP-S segments contain nucleotide sequences encoding selected peptides of MAGE-A3, MAGE-A4, and MAGE-A6 (corresponding RNA sequences of SEQ ID NO: 2, 4, and 6 (SEQ ID NO: 101, 103, and 105, respectively)). The peptides were selected based on their genetic distance relative to their respective family members and the human proteome, as well as their predicted binding affinity to MHC I molecules. The identified 9 to 25-mers were arranged according to an “epitope tandem” design. Bioinformatics modeling further optimized the order of the selected epitopes, involving immunogenicity, proteasome cleavage, minimizing interference from linking epitopes, and their genetic distance relative to the human proteome. The nucleotide sequences of CTA1_H7 to CTA1_H12 were modified to lack the CpG dinucleotide motif. This vector was generated de novo by electroporation of production cells using a five-plasmid co-transfection system, as previously described by Kallert et al., Nat Commun 2017; 8:15327.
[0491] 8.2 Example 2: In vivo immunogenicity
[0492] To evaluate the ability of different vector combinations encoding specific CTA peptide sequences to stimulate antigen-specific immune responses, a prescribed vector construct was used at a concentration of 1 × 10⁻⁶. 5 The dosage of RCV FFU / drug affects C57BL / 6 inbred lines and C57BL / 6-HLA-A. 11:01 or C57BL / 6 - HLA-B 07:02 Mice of the transgenic strain were immunized intravenously (see the respective study layouts in Tables 2 to 4).
[0493] Table 2
[0494]
[0495] Table 3
[0496]
[0497] Table 4
[0498]
[0499] On day 0, C57BL / 6 inbred mice ( Figure 3A ) and HLA-A 11:01 Transgenic mice (B6NTac.C-Tg(HLA-A)) 1101 / H2-Kb)A11.01; Figure 3B ) or HLA-B 07:02 Transgenic mice (B6; CB2mtm1Unc Tg(HLA-B)) 0702 / H2-Kb)B7.xx Tg(B2M)55Hpl; Figure 3C ) Use PICV-CTA1_H7 / CTA1_H8 (groups 2 and 4 in each experiment) or PICV-CTA1_H9 / CTA1_H10 (groups 3 and 5 in each experiment) at 1×10 5 Intravenous immunization was performed using RCV FFU / dose. Control mice were treated only with formulation buffer (Group 1). After 21 days, mice were immunized with LCMV-CTA1_H7 / CTA1_H8 (Groups 2 and 5 in each experiment) or LCMV-CTA1_H9 / CTA1_H10 (Groups 3 and 4 in each experiment) at a dose of 1×10⁻⁶. 5 Intravenous immunization was administered at a dose of RCV FFU / dose. Control mice were treated only with formulation buffer (Group 1). Another group of mice (Group 6) were immunized with PICV-MAGE-A12-Ctrl vector on day 0 and with LCMV-MAGE-A12-Ctrl vector on day 21, both at a dose of 1×10⁻⁶. 5The dosage of RCV FFU / dose. These vectors encode the full-length MAGE A-12 protein and serve as a control because the experimental CTA1 vector should not induce a T-cell response against MAGE A-12. CTA epitope-specific T-cell responses in immunized animals were analyzed by ELISpot assay (5 days after alternating dual-vector treatment) using freshly isolated spleen cells on day 26. In vitro stimulation was performed using overlapping peptide libraries covering the full length of each specific CTA (i.e., MAGE A3, MAGE A6, MAGE A4, PRAME, and MAGE A12 peptide pools). Each peptide library was designed to contain 15-mers with 11 amino acid overlaps. A minimal epitope mixture based on NPs derived from LCMV and PICV was used as a control. Data were pooled from three independent experiments. The values shown correspond to the values of the treatment group at each stimulation value minus (control mean + 3 × STD).
[0500] Interferon-γ (IFN-γ) response was observed 5 days after alternating dual-vector treatment in C57BL / 6JRj mice ( Figure 3A ) and HLA-A 11:01 Transgenic mice ( Figure 3B ) and HLA-B 07:02 Transgenic mice ( Figure 3C Measurements were performed on freshly isolated spleen cells after stimulation with the indicated overlapping ex vivo vector. For all tested vector combinations, measurements were performed on the inbred mouse strain C57BL / 6 and on human HLA (HLA-A) cells. 11:01 and HLA-B 07:02) Antigen-specific T cell responses were detected in all transgenic mice (groups 2 to 5) (respectively) Figures 3A to 3C The magnitude of the response varied across different animal strains and different combinations of test vectors. Importantly, none of the vector constructs encoding specific CTA peptide sequences induced a detectable T-cell response against MAGE-A12. Conversely, a T-cell response was detectable after restimulation of spleen cells in animals immunized with MAGE-A12-encoded vectors using the MAGE-A12 peptide library.
[0501] To demonstrate the induction of CD8+ T cell responses against minimal epitopes predicted to be presented only by human HLA, ELISpot analysis was performed using spleen cells from groups 2 through 5 (as described in Table 2). This was performed on immunized C57BL / 6 inbred mice and HLA-B... 07:02 Comparison of MAGE A4, the minimal epitope, in transgenic mice. 297-305 CD8+ T cell response ( Figure 4A In immunized C57BL / 6 inbred mice and HLA-A In 11:01 transgenic mice, the minimal epitope MAGE A6 was compared. 176-184 CD8+ T cell response ( Figure 4B The individual comparisons showed that immunization with the indicated vector combination induced MAGE A4. 297-305 and MAGE A6 176-184 HLA-restricted CD8+ T cell responses in humans were respectively affected by HLA-B 07:02 and HLA-A 11:01 has specificity ( Figure 4A and Figure 4B ).
[0502] 8.3 Example 3: Transgenic Stability
[0503] (a) LCMV-CTA1_H7 / CTA1_H8 and LCMV-CTA1_H9 / CTA1_H10
[0504] After generating the LCMV-CTA1_H7 / CTA1_H8 and LCMV-CTA1_H9 / CTA1_H10 vectors, the genetic stability of the encoded transgenes was analyzed by PCR at incremental passage levels. Figure 2 The H7 to H10 transgenes were stable at all tested passage levels.
[0505] (b) PICV-CTA1_H7 / CTA1_H8 and LCMV-CTA1_H9 / CTA1_H10
[0506] After generating the PICV-CTA1_H7 / CTA1_H8 and PICV-CTA1_H9 / CTA1_H10 vectors, the genetic stability of the encoded transgenes was analyzed by PCR at incremental passage levels. Figure 2 The H7 to H10 transgenes were stable at all tested passage levels.
Claims
1. A sand-borne virus particle, said sand-borne virus particle comprising a sand-borne virus genome, said sand-borne virus genome comprising: a. A first heterologous open reading frame (ORF) encoding a first fusion protein comprising two or more cancer-testis antigen (CTA) fragments; and b. A second heterologous ORF encoding a second fusion protein containing two or more CTA fragments. Wherein (i) at least one isovirus ORF is functionally inactivated or deleted, or (ii) at least one isovirus ORF or a fragment thereof is located at a position different from the wild-type position of the at least one isovirus ORF or a fragment thereof.
2. The sand-borne virus particle according to claim 1, wherein the two or more CTA fragments of the first fusion protein and the second fusion protein are selected from the group consisting of: a fragment of a melanoma-preferred antigen (PRAME), a melanoma-associated antigen 3 (MAGE-A3) fragment, a melanoma-associated antigen 4 (MAGE-A4) fragment, and a melanoma-associated antigen 6 (MAGE-A6) fragment.
3. The sand-borne virus particle according to claim 2, wherein the two or more CTA fragments of the first fusion protein comprise at least one PRAME fragment, at least one MAGE-A3 fragment, at least one MAGE-A4 fragment, and at least one MAGE-A6 fragment.
4. The sand-like virus particle according to claim 3, wherein the at least one PRAME fragment is selected from the group consisting of: PRAME 3-13 (SEQ ID NO: 29), PRAME 7-23 (SEQ ID NO: 30), PRAME 73-82 (SEQ ID NO:31), PRAME 84-95 (SEQ ID NO: 32), PRAME 123-141 (SEQ ID NO: 33), PRAME 150-161 (SEQ ID NO:34), PRAME 166-178 (SEQ ID NO: 35), PRAME 210-230 (SEQ ID NO: 36), PRAME 224-232 (SEQ ID NO:37), PRAME 237-250 (SEQ ID NO: 38), PRAME 248-256 (SEQ ID NO: 39), PRAME 267-277 (SEQ ID NO:40), PRAME 278-292 (SEQ ID NO: 41), PRAME 315-327 (SEQ ID NO: 42), PRAME 325-334 (SEQ ID NO:43), PRAME 425-433 (SEQ ID NO: 44), PRAME 435-443 (SEQ ID NO: 45), PRAME 445-458 (SEQ ID NO:46), PRAME 472-491 (SEQ ID NO: 47), PRAME 485-509 (SEQ ID NO: 48), and combinations thereof.
5. The sand-like virus particle according to claim 3 or 4, wherein the at least one MAGE-A3 fragment comprises MAGE-A3. 135-149 (SEQ ID NO: 66).
6. The sand-borne virus particle according to any one of claims 3 to 5, wherein the at least one MAGE-A4 fragment comprises MAGE-A4. 112-121 (SEQ ID NO: 52) and / or MAGE-A4 286-305 (SEQ ID NO: 63).
7. The sand-borne virus particle according to any one of claims 3 to 6, wherein the at least one MAGE-A6 fragment comprises MAGE-A6. 167-184 (SEQ ID NO: 75).
8. The sand-like virus particle according to any one of claims 3 to 7, wherein the two or more CTA fragments of the first fusion protein comprise PRAME. 3-13 (SEQ ID NO: 29), PRAME 7-23 (SEQ ID NO: 30), PRAME 73-82 (SEQ ID NO: 31), PRAME 84-95 (SEQ ID NO: 32), PRAME 123-141 (SEQ ID NO: 33), PRAME 150-161 (SEQ ID NO: 34), PRAME 166-178 (SEQ ID NO: 35), PRAME 210-230 (SEQ ID NO: 36), PRAME 224-232 (SEQ ID NO: 37), PRAME 237-250 (SEQ ID NO: 38), PRAME 248-256 (SEQ ID NO: 39), PRAME 267-277 (SEQ ID NO: 40), PRAME 278-292 (SEQ ID NO: 41), PRAME 315-327 (SEQ ID NO: 42), PRAME 325-334 (SEQ ID NO: 43), PRAME 425-433 (SEQ ID NO: 44), PRAME 435-443 (SEQ ID NO: 45), PRAME 445-458 (SEQ ID NO: 46), PRAME 472-491 (SEQ ID NO: 47), PRAME 485-509 (SEQ ID NO: 48), MAGE-A3 135-149 (SEQ ID NO: 66), MAGE-A4 112-121 (SEQ ID NO: 52), MAGE-A4 286-305 (SEQ ID NO: 63) and MAGE-A6 167-184 (SEQ ID NO: 75).
9. The sand-borne virus particle according to any one of claims 2 to 8, wherein the two or more CTA fragments of the second fusion protein comprise at least one MAGE-A3 fragment, at least one MAGE-A4 fragment, and at least one MAGE-A6 fragment.
10. The sand-borne virus particle of claim 9, wherein the at least one MAGE-A3 fragment is selected from the group consisting of: MAGE-A3 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO: 70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ ID NO:71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A3 160-171 (SEQ ID NO: 68), MAGE-A3 143-151 (SEQ ID NO: 67), and combinations thereof.
11. The sand-borne virus particle according to claim 9 or 10, wherein the at least one MAGE-A4 fragment is selected from the group consisting of: MAGE-A4 136-155 (SEQ ID NO: 53), MAGE-A4 168-179 (SEQ ID NO: 55), MAGE-A4 190-199 (SEQ ID NO: 57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ ID NO: 64), MAGE-A4 175-183 (SEQ ID NO: 56), MAGE-A4 262-272 (SEQ ID NO: 61), MAGE-A4 222-246 (SEQ IDNO: 60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-218 (SEQ ID NO: 59), MAGE-A4 205-217 (SEQ ID NO: 58), MAGE-A4 155-168 (SEQ ID NO: 54), MAGE-A4 266-274 (SEQ ID NO: 62), MAGE-A4 73-83 (SEQ ID NO: 49), and combinations thereof.
12. The sand-borne virus particle according to any one of claims 9 to 11, wherein the at least one MAGE-A6 fragment is selected from the group consisting of: MAGE-A6 196-204 (SEQ ID NO: 77), MAGE-A6 194-202 (SEQ ID NO:76), MAGE-A6 231-241 (SEQ ID NO: 78), MAGE-A6 243-255 (SEQ ID NO: 79), and combinations thereof.
13. The sand-like virus particle according to any one of claims 9 to 12, wherein the two or more CTA fragments of the second fusion protein comprise MAGE-A3. 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO:70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ ID NO: 71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A3 160-171 (SEQ ID NO: 68), MAGE-A3 143-151 (SEQ ID NO: 67), MAGE-A4 136-155 (SEQ ID NO: 53), MAGE-A4 168-179 (SEQ ID NO: 55), MAGE-A4 190-199 (SEQ ID NO: 57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ ID NO: 64), MAGE-A4 175-183 (SEQ ID NO: 56), MAGE-A4 262-272 (SEQ IDNO: 61), MAGE-A4 222-246 (SEQ ID NO: 60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-218 (SEQ ID NO: 59), MAGE-A4 155-168 (SEQ ID NO: 54), MAGE-A4 266-274 (SEQ ID NO: 62), MAGE-A4 73-83 (SEQ ID NO: 49), MAGE-A6 196-204 (SEQ ID NO: 77), MAGE-A6 194-202 (SEQ ID NO: 76), MAGE-A6 231-241 (SEQ ID NO: 78) and MAGE-A6 243-255 (SEQ ID NO: 79).
14. The sand-like virus particle according to any one of claims 9 to 12, wherein the two or more CTA fragments of the second fusion protein comprise MAGE-A3. 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO:70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ ID NO: 71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A3 160-171 (SEQ ID NO: 68), MAGE-A3 143-151 (SEQ ID NO: 67), MAGE-A4 136-155 (SEQ ID NO: 53), MAGE-A4 168-179 (SEQ ID NO: 55), MAGE-A4 190-199 (SEQ ID NO: 57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ ID NO: 64), MAGE-A4 175-183 (SEQ ID NO: 56), MAGE-A4 262-272 (SEQ IDNO: 61), MAGE-A4 222-246 (SEQ ID NO: 60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-217 (SEQ ID NO: 58), MAGE-A4 155-168 (SEQ ID NO: 54), MAGE-A4 266-274 (SEQ ID NO: 62), MAGE-A4 73-83 (SEQ ID NO: 49), MAGE-A6 196-204 (SEQ ID NO: 77), MAGE-A6 194-202 (SEQ ID NO: 76), MAGE-A6 231-241 (SEQ ID NO: 78) and MAGE-A6 243-255 (SEQ ID NO: 79).
15. The sand-borne virus particle according to any one of claims 9 to 12, wherein the two or more CTA fragments of the second fusion protein comprise MAGE-A3. 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO:70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ ID NO: 71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A3 160-171 (SEQ ID NO: 68), MAGE-A3 143-151 (SEQ ID NO: 67), MAGE-A4 168-179 (SEQ ID NO: 55), MAGE-A4 190-199 (SEQ ID NO: 57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ ID NO: 64), MAGE-A4 175-183 (SEQ ID NO: 56), MAGE-A4 262-272 (SEQ ID NO: 61), MAGE-A4 222-246 (SEQ IDNO: 60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-218 (SEQ ID NO: 59), MAGE-A4 155-168 (SEQ ID NO: 54), MAGE-A4 266-274 (SEQ ID NO: 62), MAGE-A4 73-83 (SEQ ID NO: 49), MAGE-A6 196-204 (SEQ ID NO: 77), MAGE-A6 194-202 (SEQ ID NO: 76), MAGE-A6 231-241 (SEQ ID NO: 78) and MAGE-A6 243-255 (SEQ ID NO: 79).
16. The sand-like virus particle according to any one of claims 9 to 12, wherein the two or more CTA fragments of the second fusion protein comprise MAGE-A3. 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO:70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ ID NO: 71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A4 168-179 (SEQ ID NO: 55), MAGE-A4 190-199 (SEQ ID NO: 57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ ID NO: 64), MAGE-A4 175-183 (SEQ ID NO: 56), MAGE-A4 262-272 (SEQ ID NO:61), MAGE-A4 222-246 (SEQ ID NO: 60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-218 (SEQ ID NO: 59), MAGE-A4 155-168 (SEQ ID NO: 54), MAGE-A4 266-274 (SEQ ID NO: 62), MAGE-A4 73-83 (SEQ ID NO: 49), MAGE-A6 196-204 (SEQ ID NO: 77), MAGE-A6 194-202 (SEQ ID NO: 76), MAGE-A6 231-241 (SEQ ID NO: 78) and MAGE-A6 243-255 (SEQ ID NO: 79).
17. The sand-like virus particle according to any one of claims 1 to 16, wherein at least two of the two or more CTA fragments of the first fusion protein and / or the second fusion protein are connected by at least one adapter.
18. The sand-like virus particle of claim 17, wherein the at least one adapter comprises an amino acid sequence of AAY (SEQ ID NO: 80), ALL (SEQ ID NO: 81), SSL (SEQ ID NO: 82), or RKSY (SEQ ID NO: 83).
19. The sand-borne virus particle according to any one of claims 1 to 18, wherein the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 7, SEQ ID NO: 9 or SEQ ID NO:
11.
20. The sand-borne virus particle according to any one of claims 1 to 19, wherein the first fusion protein comprises the amino acid sequence of SEQ ID NO: 7, SEQ ID NO: 9 or SEQ ID NO:
11.
21. The sand-borne virus particle according to any one of claims 1 to 20, wherein the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25 or SEQ ID NO:
26.
22. The sand-borne virus particle according to any one of claims 1 to 21, wherein the second fusion protein comprises the amino acid sequence of SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25 or SEQ ID NO:
26.
23. The sand-borne virus particle according to any one of claims 1 to 13 and 17 to 22, wherein the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 7, and the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO:
8.
24. The sand-borne virus particle of claim 23, wherein the first fusion protein comprises the amino acid sequence of SEQ ID NO: 7, and the second fusion protein comprises the amino acid sequence of SEQ ID NO:
8.
25. The sand-borne virus particle according to any one of claims 1 to 13 and 17 to 22, wherein the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 9, and the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO:
10.
26. The sand-borne virus particle of claim 25, wherein the first fusion protein comprises the amino acid sequence of SEQ ID NO: 9, and the second fusion protein comprises the amino acid sequence of SEQ ID NO:
10.
27. The sand-borne virus particle according to any one of claims 1 to 12, 14 and 17 to 22, wherein the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 11, and the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO:
12.
28. The sand-borne virus particle of claim 27, wherein the first fusion protein comprises the amino acid sequence of SEQ ID NO: 11, and the second fusion protein comprises the amino acid sequence of SEQ ID NO:
12.
29. The sand-borne virus particle according to any one of claims 1 to 12, 15 and 17 to 22, wherein the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 7, and the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO:
23.
30. The sand-borne virus particle of claim 29, wherein the first fusion protein comprises the amino acid sequence of SEQ ID NO: 7, and the second fusion protein comprises the amino acid sequence of SEQ ID NO:
23.
31. The sand-borne virus particle according to any one of claims 1 to 12 and 16 to 22, wherein the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 7, and the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO:
25.
32. The sand-borne virus particle of claim 31, wherein the first fusion protein comprises the amino acid sequence of SEQ ID NO: 7, and the second fusion protein comprises the amino acid sequence of SEQ ID NO:
25.
33. The sand-borne virus particle according to any one of claims 1 to 12, 15 and 17 to 22, wherein the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 9, and the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO:
24.
34. The sand-borne virus particle of claim 33, wherein the first fusion protein comprises the amino acid sequence of SEQ ID NO: 9, and the second fusion protein comprises the amino acid sequence of SEQ ID NO:
24.
35. The sand-borne virus particle according to any one of claims 1 to 12 and 16 to 22, wherein the first fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 9, and the second fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO:
26.
36. The sand-borne virus particle of claim 35, wherein the first fusion protein comprises the amino acid sequence of SEQ ID NO: 9, and the second fusion protein comprises the amino acid sequence of SEQ ID NO:
26.
37. The sand-borne virus particle according to any one of claims 1 to 36, wherein the at least one sand-borne virus ORF encodes the GP, NP, L protein or Z protein of the sand-borne virus particle.
38. The sand-borne virus particle according to any one of claims 1 to 37, wherein the at least one sand-borne virus ORF is located at a position different from the wild-type position of the at least one sand-borne virus ORF.
39. The sand-borne virus particle according to any one of claims 1 to 38, wherein the sand-borne virus particle is three-segmented and has replication capability, and comprises an L segment and two S segments, wherein one of the two S segments is selected from the group consisting of: The aS segment, in which the ORF encoding the nucleoprotein ("NP") is under the control of the 5' UTR of the arenavirus genome; The bS segment, in which the ORF encoding matrix protein Z ("Z protein") is under the control of the 5' UTR of the arenavirus genome; The cS segment, in which the ORF encoding the RNA-dependent RNA polymerase L protein ("L protein") is under the control of the 5'UTR of the arenavirus genome; The dS segment, in which the ORF encoding the glycoprotein ("GP") is under the control of the 3' UTR of the arenavirus genome; The eS segment, wherein the ORF encoding the L protein is under the control of the 3' UTR of the arenavirus genome; and The fS segment, in which the ORF encoding the Z protein is under the control of the 3' UTR of the arenavirus genome.
40. The sand-borne virus particle according to any one of claims 1 to 39, wherein the sand-borne virus genome comprises: a. The first S segment, comprising an ORF encoding an NP located at the 3' UTR of the isopyrvirus genome and a first heterologous ORF encoding the first fusion protein located at the 5' UTR of the isopyrvirus genome; b. The second S segment, comprising an ORF encoding GP located at the 3' UTR control position of the arenavirus genome, and a second heterologous ORF encoding the second fusion protein located at the 5' UTR control position of the arenavirus genome; and cL segment.
41. The sand-like virus particle according to any one of claims 1 to 40, wherein the sand-like virus particle is derived from lymphocytic choriomeningitis virus (LCMV), Piccind virus, Tamiyami virus, or Tacalib virus.
42. The sand-borne virus particle according to any one of claims 1 to 13, 17 to 24, and 37 to 41, wherein the sand-borne virus genome comprises: a. The first S segment, comprising the nucleotide sequence of SEQ ID NO: 92; and b. The second S segment, which contains the nucleotide sequence of SEQ ID NO: 93; and cL segment.
43. The sand-borne virus particle according to any one of claims 1 to 13, 17 to 24, and 37 to 41, wherein the sand-borne virus genome comprises: a. The first S segment, comprising the nucleotide sequence of SEQ ID NO: 96; and b. The second S segment, which contains the nucleotide sequence of SEQ ID NO: 97; and cL segment.
44. The sand-borne virus particle according to any one of claims 1 to 13, 17 to 22, 25, 26 and 37 to 41, wherein the sand-borne virus genome comprises: a. The first S segment, comprising the nucleotide sequence of SEQ ID NO: 94; and b. The second S segment, which contains the nucleotide sequence of SEQ ID NO: 95; and cL segment.
45. The sand-borne virus particle according to any one of claims 1 to 13, 17 to 22, 25, 26 and 37 to 41, wherein the sand-borne virus genome comprises: a. The first S segment, comprising the nucleotide sequence of SEQ ID NO: 98; and b. The second S segment, which contains the nucleotide sequence of SEQ ID NO: 99; and cL segment.
46. A pharmaceutical composition comprising sand-like virus particles according to any one of claims 1 to 45.
47. Multiple nucleic acids, said multiple nucleic acids encoding the isovirus genome of the isovirus particle according to any one of claims 1 to 45.
48. A host cell comprising the various nucleic acids according to claim 47.
49. A method for preparing sand virus particles, wherein the method comprises culturing a host cell according to claim 48 and harvesting the sand virus particles.
50. A method for treating a neoplastic disease in a subject in need, wherein the method comprises administering to the subject a therapeutically effective amount of sand-like virus particles according to any one of claims 1 to 45 or a pharmaceutical composition according to claim 46.
51. The method of claim 50, wherein the neoplastic disease is selected from the group consisting of: adrenocortical carcinoma; urothelial carcinoma of the bladder; invasive breast carcinoma; cervical squamous cell carcinoma and cervical endometrial adenocarcinoma; cholangiocarcinoma; colonic adenocarcinoma; lymphoid tumor—diffuse large B-cell lymphoma; esophageal cancer; glioblastoma multiforme; head and neck squamous cell carcinoma; chromophobe renal carcinoma; clear cell renal carcinoma; papillary renal carcinoma; acute myeloid leukemia; low-grade glioma of the brain; hepatocellular carcinoma; lung adenocarcinoma; lung squamous cell carcinoma; mesothelioma; ovarian serous cystadenocarcinoma; pancreatic adenocarcinoma; pheochromocytoma and paraganglioma; prostate adenocarcinoma; rectal adenocarcinoma; sarcoma; cutaneous melanoma; gastric adenocarcinoma; testicular germ cell tumor; thyroid cancer; thymoma; uterine endometrial cancer; uterine carcinosarcoma; and uveal melanoma.
52. A fusion protein comprising two or more CTA fragments.
53. The fusion protein of claim 52, wherein the two or more CTA fragments are selected from the group consisting of: a melanoma-preferred antigen (PRAME) fragment, a melanoma-associated antigen 3 (MAGE-A3) fragment, a melanoma-associated antigen 4 (MAGE-A4) fragment, and a melanoma-associated antigen 6 (MAGE-A6) fragment.
54. The fusion protein of claim 53, wherein the two or more CTA fragments comprise at least one PRAME fragment, at least one MAGE-A3 fragment, at least one MAGE-A4 fragment, and at least one MAGE-A6 fragment.
55. The fusion protein of claim 54, wherein the at least one PRAME fragment is selected from the group consisting of: PRAME 3-13 (SEQ ID NO: 29), PRAME 7-23 (SEQ ID NO: 30), PRAME 73-82 (SEQ ID NO: 31), PRAME 84-95 (SEQ ID NO: 32), PRAME 123-141 (SEQ ID NO: 33), PRAME 150-161 (SEQ ID NO: 34), PRAME 166-178 (SEQ ID NO: 35), PRAME 210-230 (SEQ ID NO: 36), PRAME 224-232 (SEQ ID NO: 37), PRAME 237-250 (SEQ ID NO: 38), PRAME 248-256 (SEQ ID NO: 39), PRAME 267-277 (SEQ ID NO: 40), PRAME 278-292 (SEQ ID NO: 41), PRAME 315-327 (SEQ ID NO: 42), PRAME 325-334 (SEQ ID NO: 43), PRAME 425-433 (SEQ ID NO: 44), PRAME 435-443 (SEQ ID NO: 45), PRAME 445-458 (SEQ ID NO: 46), PRAME 472-491 (SEQ ID NO: 47), PRAME 485-509 (SEQ ID NO: 48), and combinations thereof.
56. The fusion protein according to claim 54 or 55, wherein the at least one MAGE-A3 fragment comprises MAGE-A3 135-149 (SEQ ID NO: 66).
57. The fusion protein according to any one of claims 54 to 56, wherein the at least one MAGE-A4 fragment comprises MAGE-A4. 112-121 (SEQ ID NO: 52) and / or MAGE-A4 286-305 (SEQ ID NO: 63).
58. The fusion protein according to any one of claims 54 to 57, wherein the at least one MAGE-A6 fragment comprises MAGE-A6. 167-184 (SEQ ID NO: 75).
59. The fusion protein according to any one of claims 54 to 58, wherein the two or more CTA fragments comprise PRAME. 3-13 (SEQ ID NO: 29), PRAME 7-23 (SEQ ID NO: 30), PRAME 73-82 (SEQ ID NO: 31), PRAME 84-95 (SEQ ID NO: 32), PRAME 123-141 (SEQ ID NO: 33), PRAME 150-161 (SEQ ID NO: 34), PRAME 166-178 (SEQ ID NO: 35), PRAME 210-230 (SEQ ID NO: 36), PRAME 224-232 (SEQ ID NO: 37), PRAME 237-250 (SEQ ID NO: 38), PRAME 248-256 (SEQ ID NO: 39), PRAME 267-277 (SEQ ID NO: 40), PRAME 278-292 (SEQ ID NO: 41), PRAME 315-327 (SEQ ID NO: 42), PRAME 325-334 (SEQ ID NO: 43), PRAME 425-433 (SEQ ID NO: 44), PRAME 435-443 (SEQ ID NO: 45), PRAME 445-458 (SEQ ID NO: 46), PRAME 472-491 (SEQ ID NO: 47), PRAME 485-509 (SEQ ID NO: 48), MAGE-A3 135-149 (SEQ ID NO:66), MAGE-A4 112-121 (SEQ ID NO: 52), MAGE-A4 286-305 (SEQ ID NO: 63) and MAGE-A6 167-184 (SEQ ID NO: 75).
60. The fusion protein according to any one of claims 54 to 59, wherein the fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 7, SEQ ID NO: 9 or SEQ ID NO:
11.
61. The fusion protein according to any one of claims 54 to 60, wherein the fusion protein comprises the amino acid sequence of SEQ ID NO: 7, SEQ ID NO: 9 or SEQ ID NO:
11.
62. The fusion protein of claim 53, wherein the two or more CTA fragments comprise at least one MAGE-A3 fragment, at least one MAGE-A4 fragment, and at least one MAGE-A6 fragment.
63. The fusion protein of claim 62, wherein the at least one MAGE-A3 fragment is selected from the group consisting of: MAGE-A3 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO: 70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ ID NO: 71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A3 160-171 (SEQ ID NO: 68), MAGE-A3 143-151 (SEQ ID NO: 67), and combinations thereof.
64. The fusion protein according to claim 62 or 63, wherein the at least one MAGE-A4 fragment is selected from the group consisting of: MAGE-A4 136-155 (SEQ ID NO: 53), MAGE-A4 168-179 (SEQ ID NO: 55), MAGE-A4 190-199 (SEQ ID NO: 57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ ID NO: 64), MAGE-A4 175-183 (SEQ ID NO: 56), MAGE-A4 262-272 (SEQ ID NO: 61), MAGE-A4 222-246 (SEQ IDNO: 60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-218 (SEQ ID NO: 59), MAGE-A4 205-217 (SEQ ID NO: 58), MAGE-A4 155-168 (SEQ ID NO: 54), MAGE-A4 266-274 (SEQ ID NO: 62), MAGE-A4 73-83 (SEQ ID NO: 49), and combinations thereof.
65. The fusion protein according to any one of claims 62 to 64, wherein the at least one MAGE-A6 fragment is selected from the group consisting of: MAGE-A6 196-204 (SEQ ID NO: 77), MAGE-A6 194-202 (SEQ ID NO: 76), MAGE-A6 231-241 (SEQ ID NO: 78), MAGE-A6 243-255 (SEQ ID NO: 79), and combinations thereof.
66. The fusion protein according to any one of claims 62 to 65, wherein the two or more CTA fragments comprise MAGE-A3. 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO: 70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ ID NO: 71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A3 160-171 (SEQ ID NO: 68), MAGE-A3 143-151 (SEQ ID NO: 67), MAGE-A4 136-155 (SEQ ID NO: 53), MAGE-A4 168-179 (SEQ ID NO:55), MAGE-A4 190-199 (SEQ ID NO: 57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ IDNO: 64), MAGE-A4 175-183 (SEQ ID NO: 56), MAGE-A4 262-272 (SEQ ID NO: 61), MAGE-A4 222-246 (SEQ ID NO: 60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-218 (SEQ ID NO: 59), MAGE-A4 155-168 (SEQ ID NO: 54), MAGE-A4 266-274 (SEQ ID NO: 62), MAGE-A4 73-83 (SEQ ID NO: 49), MAGE-A6 196-204 (SEQ ID NO: 77), MAGE-A6 194-202 (SEQ ID NO: 76), MAGE-A6 231-241 (SEQ IDNO: 78) and MAGE-A6 243-255 (SEQ ID NO: 79).
67. The fusion protein according to any one of claims 62 to 65, wherein the two or more CTA fragments comprise MAGE-A3. 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO: 70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ ID NO: 71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A3 160-171 (SEQ ID NO: 68), MAGE-A3 143-151 (SEQ ID NO: 67), MAGE-A4 136-155 (SEQ ID NO: 53), MAGE-A4 168-179 (SEQ ID NO:55), MAGE-A4 190-199 (SEQ ID NO: 57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ IDNO: 64), MAGE-A4 175-183 (SEQ ID NO: 56), MAGE-A4 262-272 (SEQ ID NO: 61), MAGE-A4 222-246 (SEQ ID NO: 60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-217 (SEQ ID NO: 58), MAGE-A4 155-168 (SEQ ID NO: 54), MAGE-A4 266-274 (SEQ ID NO: 62), MAGE-A4 73-83 (SEQ ID NO: 49), MAGE-A6 196-204 (SEQ ID NO: 77), MAGE-A6 194-202 (SEQ ID NO: 76), MAGE-A6 231-241 (SEQ IDNO: 78) and MAGE-A6 243-255 (SEQ ID NO: 79).
68. The fusion protein according to any one of claims 62 to 65, wherein the two or more CTA fragments comprise MAGE-A3. 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO: 70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ ID NO: 71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A3 160-171 (SEQ ID NO: 68), MAGE-A3 143-151 (SEQ ID NO: 67), MAGE-A4 168-179 (SEQ ID NO: 55), MAGE-A4 190-199 (SEQ ID NO:57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ ID NO: 64), MAGE-A4 175-183 (SEQ IDNO: 56), MAGE-A4 262-272 (SEQ ID NO: 61), MAGE-A4 222-246 (SEQ ID NO: 60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-218 (SEQ ID NO: 59), MAGE-A4 155-168 (SEQ ID NO: 54), MAGE-A4 266-274 (SEQ ID NO: 62), MAGE-A4 73-83 (SEQ ID NO: 49), MAGE-A6 196-204 (SEQ ID NO: 77), MAGE-A6 194-202 (SEQ ID NO: 76), MAGE-A6 231-241 (SEQ ID NO: 78) and MAGE-A6 243-255 (SEQ IDNO: 79).
69. The fusion protein according to any one of claims 62 to 65, wherein the two or more CTA fragments comprise MAGE-A3. 243-255 (SEQ ID NO: 72), MAGE-A3 171-184 (SEQ ID NO: 70), MAGE-A3 284-296 (SEQ ID NO: 73), MAGE-A3 167-176 (SEQ ID NO: 69), MAGE-A3 192-202 (SEQ ID NO: 71), MAGE-A3 302-311 (SEQ ID NO: 74), MAGE-A3 70-81 (SEQ ID NO: 65), MAGE-A4 168-179 (SEQ ID NO: 55), MAGE-A4 190-199 (SEQ ID NO: 57), MAGE-A4 77-89 (SEQ ID NO: 50), MAGE-A4 300-308 (SEQ ID NO: 64), MAGE-A4 175-183 (SEQ ID NO: 56), MAGE-A4 262-272 (SEQ ID NO: 61), MAGE-A4 222-246 (SEQ IDNO: 60), MAGE-A4 109-117 (SEQ ID NO: 51), MAGE-A4 205-218 (SEQ ID NO: 59), MAGE-A4 155-168 (SEQ ID NO: 54), MAGE-A4 266-274 (SEQ ID NO: 62), MAGE-A4 73-83 (SEQ ID NO: 49), MAGE-A6 196-204 (SEQ ID NO: 77), MAGE-A6 194-202 (SEQ ID NO: 76), MAGE-A6 231-241 (SEQ ID NO: 78) and MAGE-A6 243-255 (SEQ ID NO: 79).
70. The fusion protein according to any one of claims 62 to 69, wherein the fusion protein comprises an amino acid sequence having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25 or SEQ ID NO:
26.
71. The fusion protein according to any one of claims 62 to 70, wherein the fusion protein comprises the amino acid sequence of SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25 or SEQ ID NO:
26.
72. The fusion protein according to any one of claims 52 to 71, wherein at least two of the two or more CTA fragments of the fusion protein are connected by at least one adapter.
73. The fusion protein of claim 72, wherein the at least one linker comprises the amino acid sequence of AAY (SEQ ID NO: 80), ALL (SEQ ID NO: 81), SSL (SEQ ID NO: 82), or RKSY (SEQ ID NO: 83).
Citation Information
Patent Citations
Replication-defective arenavirus vectors
WO2009083210A1
Tri-segmented arenaviruses as vaccine vectors
WO2016075250A1
Tri-segmented pichinde viruses as vaccine vectors
WO2017198726A1
Arenavirus particles to treat solid tumors
WO2018185307A1
Arenaviruses as vectors
WO2021089853A1
